[
    {
        "Title": "Analyzing the Association of Gene Variants With Increased Risk of Coronary Heart Disease in Women With Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle autoimmune disease predominantly affects younger premenopausal women risk coronary heat disease chd women sle 50 times higher general population.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00563082"
    },
    {
        "Title": "JMKX000189 for Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": " trial evaluate efficacy jmkx000189 versus placebo participants moderately severely active systemic lupus erythematosus sle receiving standard care.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05967520"
    },
    {
        "Title": "Validation of Patient E-tool to Measure Systemic Lupus Activity",
        "Summary": "Lupus is an autoimmune disease that affects the central nervous system. Patients with lupus are more likely to die than those without the disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France, Martinique, Guadeloupe",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05763225"
    },
    {
        "Title": "Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE",
        "Summary": "Study investigate tolerability safety pharmacokinetics efficacy gr1603 subjects systemic lupus erythematosus. Gr1603 injection monoclonal antibody targeting ifnar1 block ifnar binding type interferons ifn",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06015230"
    },
    {
        "Title": "Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud",
        "Summary": " randomized pilot study took place 10 patients secondary rp topical 10 nifedipine one hand 5 sildenafil hand applied thumbs receive cream served control group. Primary outcome improvement blood flow vessel diameter digital arteries measured high frequency color",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Chile",
        "OverallStatus": "COMPLETED",
        "Conditions": "Raynaud Phenomenon Due to Trauma, Raynaud Disease, System; Sclerosis, Lupus Erythematosus, Systemic, Dermatomyositis, Ultrasound Therapy; Complications",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT03027674"
    },
    {
        "Title": "Mediterranean vs. High-Fermented-Food Diet Adherence on Inflammation in Lupus",
        "Summary": " randomized controlled trial evaluate feasibility good adherence mediterranean dietary pattern diet individuals systemic lupus erythematosus slei.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05379725"
    },
    {
        "Title": "A Study of Skin and Systemic Biomarkers In Patients With Active Cutaneous Lupus Erythematosus And In Healthy Volunteers",
        "Summary": "The study was designed to obtain skin blood urine samples from patients with cutaneous lupus lesions.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany, Mexico, United States, Poland, Taiwan, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid, Healthy",
        "Phases": "N/A",
        "IDestudio": "NCT02034344"
    },
    {
        "Title": "Prophylactic Trimethoprim/Sulfamethoxazole to Prevent Severe Infections in Patients With Lupus Erythematous",
        "Summary": "Study to determine whether effective preventing serious infectious complications require hospitalization lead death patients lupus erythematosus receive intermediate high dose steroids.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03042260"
    },
    {
        "Title": "Anti-ficolin-3 Autoantibodies in Lupus Nephritis",
        "Summary": "Systemic lupus erythematosus is a chronic autoimmune disease characterized by production of multiple autoantibodies. antibodies previously identified sera were used to determine prevalence antibodies among sle patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT02625831"
    },
    {
        "Title": "An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": " phase ii multicenter extension ole study evaluate safety efficacy participants systemic lupus erythematosus sle completed study ga30044 nct02908100 48 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Taiwan, Brazil, Spain, Chile, Colombia, Korea, Republic of, Mexico, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03407482"
    },
    {
        "Title": "Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis",
        "Summary": "Human donor corneas carriers boston keratoprosthesis boston kpro patients higher risk corneal melting keratolysis. purpose pilot study test efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Chemical Injuries, Unspecified Complication of Corneal Transplant, Autoimmune Diseases, Ocular Cicatricial Pemphigoid, Stevens Johnson Syndrome, Lupus Erythematosus, Systemic, Rheumatoid Arthritis, Other Autoimmune Diseases",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01582880"
    },
    {
        "Title": "Safety Study of CDP7657 in Patients With Systemic Lupus Erythematosus",
        "Summary": " evaluate safety tolerability pharmacokinetics immunogenicity cdp7657. evaluate safety tolerance for immunogenic effects. evaluate immunogenic activity of drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Romania, Bulgaria, Germany, Spain, Russian Federation, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01764594"
    },
    {
        "Title": "Systemic Lupus Erythematous and Heart Conduction Disorders",
        "Summary": " connective tissue diseases related to heart conduction disorders. antibodies thought pathogenic role prevalent systemic lupus erythematous.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Atrioventricular Block, Sudden Death",
        "Phases": "N/A",
        "IDestudio": "NCT02162992"
    },
    {
        "Title": "A Study to Evaluate the Safety and Efficacy of ATHENA CAR-T in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Athena injection adults moderate severe systemic lupus erythematosus main question aims answer evaluate safety tolerability athena screening participants subjected lymphodepletion regimen recovery participants injected athenan injection followed 24 months",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06373991"
    },
    {
        "Title": "Anti-CD20 in Systemic Lupus Erythematosus",
        "Summary": "Rituximab treating systemic lupus erythematosus sle white blood cells body called b cells give substances active promoting sle disease researchers found block production substances.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00036491"
    },
    {
        "Title": "Study to Evaluate the Natural History of Osteoporosis in Children and Adolescents With Systemic Lupus Erythematosus",
        "Summary": "Study determine people lupus weak bones test better method detecting bone changes. weak bones associated with things like medications amount fat muscle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00582465"
    },
    {
        "Title": "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of E6742 in Systemic Lupus Erythematosus Participants",
        "Summary": "Primary purpose study evaluate safety tolerability multiple oral doses. e6742 participants systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05278663"
    },
    {
        "Title": "A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluated efficacy of ustekinumab against systemic lupus erythematosus. Participants adequately responded to one standard care treatments.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Serbia, Spain, Ukraine, Russian Federation, China, Korea, Republic of, Poland, Bulgaria, South Africa, Lithuania, Canada, Portugal, Taiwan, Japan, Argentina, Germany, Colombia, Hungary",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03517722"
    },
    {
        "Title": "Internet-Based Pain Coping Skills Training for Patients With Lupus",
        "Summary": "Pilot study automated pain coping skills training pcst program paincoach. pilot study automatedPainCoach.com.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03933839"
    },
    {
        "Title": "Trial of Belimumab in Early Lupus",
        "Summary": "Two year study evaluate effects giving belimumab benlysta patients early lupus. two year study evaluates effects on immune system. early lupsus diagnosis l Lupus within 2 years subjects randomized receive belimumabs placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03543839"
    },
    {
        "Title": "Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study compared immunological efficacy two pneumococcal vaccination strategies. Patients treated with systemic lupus erythematosus sle treated corticosteroids associated immunosuppressive drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00611663"
    },
    {
        "Title": "Comparison of Complement Factors and Genetic Polymorphisms of AMD Between Patients With Systemic Lupus Erythematosus (SLE) With and Without Retinal \"Pseudo-drusen-like\" Deposits: Case-control Study (PL-AMD)",
        "Summary": "Study could lead future research could better target treatment patients lupus patients amd age related macular degeneration.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Lupus Erythematosus, Systemic, Age Related Macular Degeneration",
        "Phases": "N/A",
        "IDestudio": "NCT03504540"
    },
    {
        "Title": "Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pain",
        "Summary": "Systemic lupus erythematosus sle chronic autoimmune inflammatory disease musculoskeletal pain one common symptoms study investigate whether transcutaneous stimulation vagus nerve decrease lupsus pain. First clinical study using one body",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic, Musculoskeletal Pain",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02822989"
    },
    {
        "Title": "Exploratory Clinical Study of CNCT19 Anti CD19 Cell Therapy in the Treatment of Refractory Autoimmune Diseases",
        "Summary": "Cnct19 patients are refractory of systemic lupus, nephritis, dermatomyositis and vasculitis. The study aims to evaluate safety and tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06316791"
    },
    {
        "Title": "The Role of Lipids in Immune Cell Function in SLE Patients",
        "Summary": " project investigate different types of immune cells found blood patients systemic lupus erythematosus sle healthy donors know amount fat surface immune cells important factor controlling behaviour immune cells sle patients defective associated changes levels fat cells.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT04361734"
    },
    {
        "Title": "Allogeneic Blood Stem Cell Transplantation for Patients With Life-Threatening Systemic Lupus Erythematosus",
        "Summary": "Stanford medical center division immunology rheumatology division blood marrow transplantation bmt enrolling patients severe systemic lupus erythematosus sle resistant standard treatment prednisone cyclophosphamide cytoxan",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00325741"
    },
    {
        "Title": "Contemplation-Based Intervention and Health Outcomes RCT in Lupus Patients",
        "Summary": "Lupus erythematosus sle compared intervention contemplative techniques meditation mindfulness yoga may impact disease burden.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04032496"
    },
    {
        "Title": "Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sj\u00f6gren's Syndrome",
        "Summary": " purpose study examine whether dehydroepiandrosterone dhea administration improves fatigue. general patients systemic lupus erythematosus primary sj\u00f6gren syndrome.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Sjogren's Syndrome",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00391924"
    },
    {
        "Title": "A Study to Evaluate the Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of TAK-079 in Combination With Standard Background Therapy in Participants With Moderate to Severe Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study evaluated safety tolerability comparison matching placebo administered every 3 weeks dosing period. Participants active sle receiving stable background therapy sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03724916"
    },
    {
        "Title": "Study of VIB7734 for the Treatment of Moderate to Severely Active SLE",
        "Summary": "Vib7734 treatment moderate severely active systemic lupus erythematosus approximately 195 participants study duration 48 weeks safety week 3 parallel arms 2 active treatment 1 placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Taiwan, Greece, Spain, Ukraine, India, Russian Federation, Mexico, Poland, United States, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04925934"
    },
    {
        "Title": "Effect of Cholecalciferol Supplementation on Disease Activity and Quality of Life of Systemic Lupus Erythematosus Patients .",
        "Summary": "Double blind randomized controlled trial conducted female outpatients aged years sle consecutively recruited september december 2021 cipto mangunkusumo hospital sixty subjects met research criteria randomized equally assigned cholecalciferol placebo groups.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Cholecalciferol Supplementation, Disease Activity, Quality of Life",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05326841"
    },
    {
        "Title": "A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus",
        "Summary": "Researchers learn study drug called litifilimab biib059 participants systemic lupus erythematosus sle study focus participants active disease already taking standard care medications. Participants randomized receive either high low dose litfilim",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Philippines, Taiwan, France, Brazil, Greece, Spain, Australia, Russian Federation, Chile, Mexico, Korea, Republic of, Sweden, Peru, United States, Poland",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04895241"
    },
    {
        "Title": "Exploration of Genotype Based Personalized Prescription of Cyclophosphamide in Systemic Lupus Erythematosus Treatment",
        "Summary": " cyclophosphamide treatment systemic lupus erythematosus sle han chinese genetic polymorphisms drug metabolizing enzymes pharmacokinetics. purpose study investigate relationship side effects.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Adverse Effects",
        "Phases": "N/A",
        "IDestudio": "NCT01060410"
    },
    {
        "Title": "A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus",
        "Summary": "Researchers learn study drug called litifilimab biib059 participants systemic lupus erythematosus sle study focus participants active disease already taking standard care medications. Participants randomized receive either high low dose litfilim",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Japan, Romania, Argentina, Germany, Israel, Netherlands, Colombia, Hungary, Canada, China, Italy, United States, Serbia, United Kingdom, Puerto Rico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04961567"
    },
    {
        "Title": "Study of LJP 394 in Lupus Patients With History of Renal Disease",
        "Summary": "Study to determine whether abetimus sodium effective placebo delaying time renal flare up. Patients history renal disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Thailand, Indonesia, Belarus, Spain, Ukraine, Georgia, Hong Kong, Korea, Republic of, Italy, Poland, Sri Lanka, Puerto Rico, Romania, Bulgaria, Philippines, India, Portugal, Taiwan, Argentina, Germany, Lebanon, Czech Republic, Slovakia, Brazil, Hungary, Mexico, Malaysia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00089804"
    },
    {
        "Title": "Mast Cells Are Involved in the Mechanism of NPSLE Epilepsy",
        "Summary": " tryptase tlr4 antibodies measured serum cerebrospinal fluid subjects markers assess relevance of disease activity. find new therapeutic targets timely intervention improve prognosis sle improve quality life patients sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05607368"
    },
    {
        "Title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus",
        "Summary": " rituximab administered scheduled basis every 6 months course 1 year reassessment response 12 months study open participants previously enrolled genentech study u2971g. phase open label multicenter extension study evaluate safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00381810"
    },
    {
        "Title": "Anti-ficolin-2 Autoantibodies in Lupus Nephritis",
        "Summary": "Systemic lupus erythematosus is a chronic autoimmune disease characterized by production of multiple autoantibodies. Antibodies demonstrated higher specificity traditional biomarker results suggest antibodies could useful diagnosis active nephritis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT03063281"
    },
    {
        "Title": "A Complex Contraception Registry",
        "Summary": "Investigators conduct prospective observational cohort study. investigate factors influence contraceptive method utilization among women medical conditions. Investigators also investigate womenMedical conditions access contraception.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Diabetes, Cardiovascular Disease, Epilepsy, Migraine, Neurological Disorders, Cancer, Bariatric Surgery Candidate, Organ or Tissue Transplant; Complications, Lupus Erythematosus, Systemic, Other Hematologic Conditions, Other Venous Embolism and Thrombosis",
        "Phases": "N/A",
        "IDestudio": "NCT02219269"
    },
    {
        "Title": "Effect of Insoles in Patients With Systemic Lupus Erythematosus",
        "Summary": " demonstrate insoles improve painful symptomatology health foot function subjects with podiatric involvement.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Foot Orthoses, Musculoskeletal Pain",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04098055"
    },
    {
        "Title": "Physical Therapy for Systemic Lupus Erythematosus (SLE)",
        "Summary": "Lupus patients focus exercise improvement endurance pain endurance pain overall health. purpose study see improvement patient quality life pain fatigue undergoing supervised exercise program.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic, SLE",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00152555"
    },
    {
        "Title": "Searching for Diagnostic/Prognostic Biomarkers in SLE With Renal Involvement by Proteomic Techniques",
        "Summary": "Systemic lupus erythematosus causing asymptomatic mild proteinuria rapidly progressive glomerulonephritis kidney failure date kidney biopsy invasive medical procedure associated risks complications. Identification biomarkers using biological sample could",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT03687138"
    },
    {
        "Title": "TAB08 in Patients With Systemic Lupus Erythematosus (SLE), Not Adequately Controlled With Current Treatment",
        "Summary": "The study is designed to assess whether tab08 may beneficial compared placebo patients. The aim is to assess efficacy, safety and pharmacokinetic pharmacodynamic parameters. The study population includes patients with systemic lupus erythematosus",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Russian Federation",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02711813"
    },
    {
        "Title": "Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle responder index study evaluate secondary exploratory measures well. evaluate compare efficacy 3 dose levels placebo subjects generalized lupus using measure called systemic lupsus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Argentina, Germany, Taiwan, Colombia, Chile, Hungary, Korea, Republic of, Peru, United States, Poland, Moldova, Republic of, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01405196"
    },
    {
        "Title": "A Study to Learn About the Study Medicine (PF-06823859) in Adults With Active CLE or SLE With Skin Symptoms.",
        "Summary": "48 participants selected receive active study medicine placebo infusion without drug. 16 receive placebo receiving treatments intravenous infusion injected directly veins week 16 participants receiving active study drug since day 1.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Greece, Spain, Canada, United States, Taiwan",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Erythematosus, Cutaneous",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05879718"
    },
    {
        "Title": "Multiple Ascending Dose Study of MHS552 in Adults Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Mhs552 adults mild moderately active systemic lupus erythematosus sle participants treated 4 12 weeks followed period. purpose multiple ascending dose study evaluate safety tolerability multiple doses.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05203419"
    },
    {
        "Title": "Lupus Cohort--Thrombotic Events and Coronary Artery Disease",
        "Summary": "The study looked at patients with systemic lupus erythematosus slem. It also looked at the risk factors for the disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cardiovascular Diseases, Coronary Disease, Thrombosis, Heart Diseases, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00005436"
    },
    {
        "Title": "Acupressure for Fatigue in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle complex autoimmune disease characterized involvement multiple organs female male ratio highest incidence reported women child bearing age years general advances diagnosis management led significant improvements outcomes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Fatigue, Lupus Erythematosus, Systemic, Pain, Chronic, Quality of Life, Sleep",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03200548"
    },
    {
        "Title": "Effects of High-intensity Interval Training in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study evaluate safety effects interval training hiit combined resistance training patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Sweden",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06166199"
    },
    {
        "Title": "Atherosclerosis Prevention in Pediatric Lupus Erythematosus (APPLE)",
        "Summary": "The study was conducted by the research alliance carra. The aim of the study was to establish mechanism conducting clinical trials for rare pediatric rheumatic diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00065806"
    },
    {
        "Title": "Improving the Assessment of SLE Disease Activity",
        "Summary": "Lupus erythematosus disease activity index one commonly used disease activity indices clinical trials experience suggested disease activity instruments function well composite measures developed address issue approach adopted learning clinical trials absence robust sensitive index major flaw designing trial another issue",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic, SLE",
        "Phases": "N/A",
        "IDestudio": "NCT03144063"
    },
    {
        "Title": "Low-dose Interleukin-2 for Treatment of Systemic Lupus Erythematosus",
        "Summary": "Trell cells play important roles dampening overt stimulation effector cells seen in many autoimmune diseases. Treg cells highly dependent application low doses leads markedly increased numbers improved functionality.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03312335"
    },
    {
        "Title": "Lessening the Impact of Fatigue in Inflammatory Rheumatic Diseases",
        "Summary": "Inflammatory rheumatic disease therapies designed improve physical activity treatments positively help patients change way think behave helpful reducing burden fatigue however patients access treatments health services situation results absence standardised programmes limited availability relevant therapists.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Axial Spondyloarthritis, Psoriatic Arthritis, Sjogren's Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03248518"
    },
    {
        "Title": "Six Month Clinical Research Study for Patients With Moderate or Severe Dry Eye Syndrome",
        "Summary": " clinical research trial evaluate effectiveness investigational medication treatment dry eye syndrome. patients diagnosed moderate severe dry eye Syndrome autoimmune disorder females 65 years age older.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Keratoconjunctivitis Sicca, Sjogren's Syndrome, Lupus Erythematosus, Systemic, Arthritis, Rheumatoid, Scleroderma, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00025818"
    },
    {
        "Title": "Assessment of Cognitive Function and Gut Microbiota Analysis in Real World Patients With Lupus Cerebrovascular Disease",
        "Summary": "Systemic lupus erythematosus cerebrovascular disease relationship intestinal microflora analyzed explore possible pathogenesis. based clinical manifestations laboratory data intestinal micro flora detection cognitive function characteristics.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic, Gastrointestinal Microbiome",
        "Phases": "N/A",
        "IDestudio": "NCT05636670"
    },
    {
        "Title": "A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus",
        "Summary": "Primary objective study evaluate safety tolerability litifilimab participants active systemic lupus erythematosus sle secondary objectives study evaluate effect litifilsimab disease activity participants sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Serbia, Spain, China, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Bulgaria, Philippines, France, Taiwan, Czechia, Japan, Argentina, Brazil, Israel, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05352919"
    },
    {
        "Title": "Effect of Qi Gong Training on Quality of Life in Patients With Systemic Lupus Erythematous (LuQi)",
        "Summary": " qi gong ancient chinese practice based relaxation movements posture breathing order harmonize body mind practice improves general state reducing fatigue improving sleep beneficial effect. studied several diseases including cancer diabetes arterial hypertension fibromyalgia.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02732470"
    },
    {
        "Title": "Long-term Safety and Tolerability of Cenerimod in Adults With Systemic Lupus Erythematosus",
        "Summary": " clinical study learn safety tolerability cenerimod adult patients moderate severe symptoms systemic lupus erythematosus main questions aims answer whether ceneriod causes adverse effects effects given top drugs already given systemic l upus",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Spain, Germany, United States",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06475742"
    },
    {
        "Title": "Personalised Pharmacological Approach to the Tapering of Corticosteroid Doses in Systemic Lupus Patients Treated With Prednisone",
        "Summary": "Research period patient 3 months three visits usual care visits needed within 3 months study collecting data blood sampling. glucocorticoid routinely used to treat systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03187743"
    },
    {
        "Title": "Phase II Pilot Study of Cytarabine for Refractory Systemic Lupus Erythematosus",
        "Summary": " evaluate toxicity cytarabine patients refractory systemic lupus erythematosus ii evaluate objective disease parameters including serum complement levels antibody titers and sedimentation rate.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00004643"
    },
    {
        "Title": "Anifrolumab Real-world Treatment Outcomes in Systemic Lupus Erythematosus",
        "Summary": "Anifrolumab administered scope routine clinical practice. polish multicentre observational study aiming collect data characteristic patients systemic lupus erythematosus clinical outcomes.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT06673043"
    },
    {
        "Title": "Comparison of the Clinical Examination and the Joint Ultrasonography in Lupus Patients",
        "Summary": "Sledai composite score calculation 0 105 ultrasonography us validated sensitive tool joint assessment published studies showed us joint abnormalities systemic lupus erythematosus patients without joint pain nevertheless.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02922114"
    },
    {
        "Title": "Pulmonary Disease Among Patients With Systemic Lupus Erythematosus",
        "Summary": "Pulmonary diseases common among patients systemic lupus erythematosus sle associated significantly increased morbidity mortality lower health related quality life investigators aim diagnose categorise sle patients regards pulmonary disease introduce alternative diagnostic tools.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Denmark",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Lupus Erythematosus, Systemic, Pulmonary Disease",
        "Phases": "N/A",
        "IDestudio": "NCT06087523"
    },
    {
        "Title": "Safety and Efficacy of Topical R333 in Patients With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE) Lesions",
        "Summary": "us. purpose study determine safety efficacy tolerability topical r333 ointment discoid lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01597050"
    },
    {
        "Title": "A Crossover Study to Compare RAYOS to IR Prednisone to Improve Fatigue and Morning Symptoms for SLE",
        "Summary": " prednisone fatigue measured functional assessment chronic illness. compare effect versus ir prednisones.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Erythematosus, Fatigue",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03098823"
    },
    {
        "Title": "A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus",
        "Summary": " clinical trial see well cenerimod reduces symptoms systemic lupus erythematosus adult patients moderate severe symptoms. main questions aims answer well cenersimod works top treatment already administered safe. researchers compare one dose c",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Bulgaria, Argentina, Philippines, Taiwan, France, Brazil, Greece, Ukraine, Colombia, Mexico, Korea, Republic of, Poland, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05648500"
    },
    {
        "Title": "Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis",
        "Summary": "Study determine whether adding experimental medication abatacept standard cyclophosphamide therapy effective improving lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00774852"
    },
    {
        "Title": "Evaluation of the Influence of Food Regimen on Oshadi D Absorption",
        "Summary": "Study included one administration placebo, four single administrations oshadi, and two different dose levels administered. Study was open label single dose placebo control.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Israel",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01327352"
    },
    {
        "Title": "Acthar Gel for Active Systemic Lupus Erythematosus (SLE)",
        "Summary": " acthar gel participants active systemic lupus erythematosus sle doctor assign eligible patients one two groups like flipping coin participants receive treatment assigned group 24 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Chile, Mexico, Peru, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02953821"
    },
    {
        "Title": "TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL )",
        "Summary": "Lupus erythematosus sle suffering from\u00a0membraneous form lupus nephritis class v therapeutic options used present include azathioprine small open label safety study. Patients\u00a0experienced therapeutic response",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Germany, Netherlands",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Nephritis",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00368264"
    },
    {
        "Title": "European Society of Cutaneous Lupus Erythematosus (EUSCLE)",
        "Summary": " cutaneous lupus erythematosus cle disease wide spectrum clinical manifestations variable prognosis aim study create standardized evaluation different subtypes disease order receive overview spectrum clinical laboratory features well therapeutic strategies patients cle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00420121"
    },
    {
        "Title": "A Phase II Study to Evaluate Safety and Efficacy of ALX-0061 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle compared placebo. Primary objective assess efficacy safety different dose regimens administered subcutaneously. Secondary objectives assess pharmacokinetics, pharmacodynamics, immunogenicity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Germany, Argentina, Philippines, Taiwan, Spain, Ukraine, Russian Federation, Chile, Hungary, Korea, Republic of, Mexico, Peru, United States, Poland, Portugal, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02437890"
    },
    {
        "Title": "A Safety and Tolerability Study of MEDI-570 in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus slei is a type of systemic lupus. The disease is often fatal. The treatment is known to be effective.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "South Africa, Mexico, Canada, Peru, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01127321"
    },
    {
        "Title": "Pilot Study to Investigate Contemplative Intervention in Lupus Patients",
        "Summary": " meditation mindfulness yoga may impact disease. may decrease psychological distress increase capabilities reduce pain. incorporating patients caregivers may strengthen relationships thereby improve health.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03103243"
    },
    {
        "Title": "Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)",
        "Summary": "Study evaluate efficacy safety atacicept compared placebo preventing new flares. Subjects systemic lupus erythematosus sle confirm optimal dose atacICEpt treatment subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Latvia, Austria, Switzerland, Australia, United States, Serbia, Greece, Spain, Ukraine, Russian Federation, Korea, Republic of, Poland, United Kingdom, Bulgaria, Philippines, South Africa, France, India, Lithuania, Netherlands, Taiwan, Argentina, Germany, Lebanon, Czech Republic, Israel, Croatia, Mexico, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00624338"
    },
    {
        "Title": "Determining the Responses and Impact of Rituximab-instigated Cell Depletion on T Cells in People With SLE",
        "Summary": "Rituximab is being used to treat systemic lupus erythematosus slem. The drug is also being used for other autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01702038"
    },
    {
        "Title": "Synergetic B-cell Immodulation in SLE",
        "Summary": "Study investigates potential new therapeutic approach lupus nephritis combining rituximab and belimumab. Study assess reduction seroconversion pathogenic autoantibodies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02284984"
    },
    {
        "Title": "Osteoporosis and Fragility Fractures Among SLE Patients. (FRAIL Trial)",
        "Summary": " trial designed evaluate prevalence fragility fracture impact quality life sle patients disease treatment variables steroids dosage use specific drugs like hydroxychloroquine dmards belimumab.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05590390"
    },
    {
        "Title": "A Pilot Study to Explore the Role of Gut Flora in Lupus",
        "Summary": "Study seeks to correlate microbiome sequencing data information provided patients medical records. Study seeks to determine if patients' microbiomes are similar to those of other people.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT04213690"
    },
    {
        "Title": "A Study of LY3361237 in Participants With Systemic Lupus Erythematosus",
        "Summary": " ly3361237 administered injections skin study last 26 weeks may include 17 visits study center. main purpose study learn safety ly336 1237 side effects might associated given participants systemic lupus erythematosis sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03933943"
    },
    {
        "Title": "Belimumab In Early Systemic Lupus Erythematosus",
        "Summary": " investigate efficacy belimumab early in patients with disease duration less than 6 months. investigate the effectiveness of the drug in reducing the duration of patients' disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04956484"
    },
    {
        "Title": "Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": " purpose study evaluate safety efficacy. 3 different doses belimumab administered addition standard therapy patients active sle disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00071487"
    },
    {
        "Title": "Role of Altered CD40-Ligand Gene Transcription in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus often devastating autoimmune disease affects 1 women united states recently several research laboratories reported protein named cd154 overexpressed subset white blood cells called lymphocytes.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00008749"
    },
    {
        "Title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus",
        "Summary": " purpose study assess safety tolerability following multiple subcutaneous sc study agent administrations. subjects systemic lupus erythematosus sle determine whether premedication corticosteroids required improve tolerability sc.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02920424"
    },
    {
        "Title": "Study Evaluating The SBI-087 In Subjects With Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus slei is a systemic lupus disease. The disease is caused by a build-up of lymph nodes in the body.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00714116"
    },
    {
        "Title": "MSC2364447C Phase 1b in Systemic Lupus Erythematosus",
        "Summary": "Msc2364447c administered 4 weeks systemic lupus erythematosus subjects sle. primary purpose phase 1b randomized trial evaluate safety tolerability pharmacokinetic pk biological effect.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02537028"
    },
    {
        "Title": "Women Empowered to Live With Lupus Study",
        "Summary": "Research examine whether chronic disease program cdsmp would improve health outcomes reduce health care use. Study focuses on african american women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02988661"
    },
    {
        "Title": "Safety Study of CDP7657 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": " evaluate safety tolerability pharmacokinetics immunogenicity cdp7657. evaluate safety tolerance for immunogenic effects. evaluate immunogenic activity of drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Bulgaria, Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Immune System Diseases, Autoimmune Diseases, Lupus Erythematosus, Systemic, Skin and Connective Tissue Diseases, Connective Tissue Disease",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01093911"
    },
    {
        "Title": "Efficacy and Safety of Telitacicept in Early SLE",
        "Summary": " purpose study evaluate safety efficacy telitacicept adult patients early stage sleet. purpose study evaluates safety efficacy of telitcicept in adult patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05899907"
    },
    {
        "Title": "Engagement in CHildhood-Onset Systemic Lupus",
        "Summary": "Lupus participants systemic lupus ages bronx new york asked complete questionnaires asked participate focus groups help adapt mobile health app participants also invited join pilot study try mobile healthapp 6 months answer questionnaires document experience. goal observational",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic, Depression",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05693571"
    },
    {
        "Title": "Mesenchymal Stromal Cells (MSC\u00b4s) in Renal Lupus",
        "Summary": "Mscs severe renal systemic lupus erythematosus slei. phase ii clinical trial assess efficacy umbilical mesenchymal stromal cells.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Chile",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Glomerulonephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03917797"
    },
    {
        "Title": "Lupus Intervention for Fatigue Trial",
        "Summary": "Study designed evaluate lift intervention decrease fatigue primary outcome improve physical activity secondary outcome dietary behavior exploratory outcome persons sle. Participants chicago lupus database individuals seen northwestern medicine approached.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Fatigue, Physical Activity, Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02653287"
    },
    {
        "Title": "Interactive Digital Technology to Assess and Improve Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus",
        "Summary": ". purpose study evaluate whether short interactive video game device associated performance standard measures attention problem solving patients systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03746197"
    },
    {
        "Title": "Mobile Study to Measure and Predict Lupus Disease Activity Using Digital Signals",
        "Summary": " oasis mobile study measure predict lupus disease activity using digital signals. oasis study exploring patient reported data digital biomarkers like activity level heart rate variability used.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04449653"
    },
    {
        "Title": "Optimization of Glucocorticoid Taper Strategies for SLE-ITP",
        "Summary": " sle associated immune thrombocytopenia one main clinical manifestations sle approximately 70 sle patients follow course similarly often relapses gcs tapering time. maintenance therapy remission inevitable choice sle guidelines recommend gcs immunosuppressive agents is",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Lupus Erythematosus, Systemic, Purpura, Thrombocytopenic, Idiopathic, Glucocorticoids, Adverse Effect of Glucocorticoids",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05506033"
    },
    {
        "Title": "Study of Repeated Administration of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study objective evaluate safety tolerability dose every 4 weeks 24 weeks patients active systemic lupus erythematosus sle participated main study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Germany, France, Mauritius, Hungary, United States, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03427151"
    },
    {
        "Title": "Sirolimus for Autoimmune Disease of Blood Cells",
        "Summary": " autoimmune cytopenias commonly used fraught side effects nevertheless scientific understanding autoimmune diseases improved directed less toxic therapies becoming available number groups studying efficacy medication called sirolimus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Autoimmune Pancytopenia, Autoimmune Lymphoproliferative Syndrome (ALPS), Evans Syndrome, Idiopathic Thrombocytopenic Purpura, Anemia, Hemolytic, Autoimmune, Autoimmune Neutropenia, Lupus Erythematosus, Systemic, Inflammatory Bowel Disease, Rheumatoid Arthritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00392951"
    },
    {
        "Title": "CMR-Lupus Comprehensive Approach by Cardiovascular Magnetic Resonance Tomography",
        "Summary": "Systemic lupus erythematosus sle cardiac manifestations coronary artery disease cad myocarditis leading causes morbidity mortality prevalence subclinical heart disease sle unknown studied whether comprehensive cardiovascular magnetic resonance cmr protocol may useful early diagnosis heart",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic, Coronary Artery Disease, Myocardial Disease",
        "Phases": "N/A",
        "IDestudio": "NCT03488654"
    },
    {
        "Title": "Fatigue, Depression, and Cortical Excitability in Systemic Lupus",
        "Summary": " systemic lupus erythematosus chronic inflammatory autoimmune disease unknown cause many challenges. corticosteroids effective immunosuppressive therapy transformed management patients active.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03165682"
    },
    {
        "Title": "Cyclophosphamide in Lupus Nephritis",
        "Summary": " cyclophosphamide widely used treatment cancer autoimmune diseases lupus nephritis however considerable variability response. Study determine whether response therapy new zealand population can be effective.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "New Zealand",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00441220"
    },
    {
        "Title": "Zostavax in Systemic Lupus Erythematosus",
        "Summary": "Ten healthy people 10 sle patients 50 years age recruited receive single standard dose zostavax blood samples. 12 weeks following vaccination participants receive active vaccine placebo group.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01474720"
    },
    {
        "Title": "Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy",
        "Summary": "Study evaluate safety pharmacokinetics efficacy belimumab intravenous iv pediatric patients 5 17 years age active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Argentina, Spain, Russian Federation, Mexico, Canada, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01649765"
    },
    {
        "Title": "Treatment and Clinical Outcomes Among SLE Patients in Pregnancy",
        "Summary": " systemic lupus erythematosus sle kind systemic autoimmune disease cause multiple organs system damage often occurs women childbearing age compared healthy pregnant women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Pregnancy Related",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04976465"
    },
    {
        "Title": "The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)",
        "Summary": "Lupus erythematosus scle discoid lupus\u00a0erythe Matosus dle systemic lupUS ery thematosUS sle completed 24 week treatment period willow study nct0516",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Greece, Spain, China, Korea, Republic of, Poland, Romania, Bulgaria, Philippines, South Africa, Taiwan, Japan, Argentina, Mauritius, Brazil, Israel, Chile, Colombia, Mexico, Moldova, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05540327"
    },
    {
        "Title": "Development of a Therapeutic Endpoint in Pediatric Rheumatologic Conditions",
        "Summary": "Three distinct rheumatology populations would enable objective assessment pain treatment populations enable much precise approach treatment endpoint stands significantly improve outcomes. Single site observational study aims collect initial pilot data three distinct patient groups observational randomization blinding study patients followed.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Fibromyalgia",
        "Phases": "N/A",
        "IDestudio": "NCT04833465"
    },
    {
        "Title": "Phase II Study of Long-Term Dehydroepiandrosterone for Systemic Lupus Erythematosus",
        "Summary": " gl701 patients systemic lupus erythematosus completed prior gl701 protocol. objectives evaluate safety tolerance synthetic formulation dehydroepiandrosterone.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00004665"
    },
    {
        "Title": "Individualized Patient Decision Making for Treatment Choices Among Minorities With Lupus",
        "Summary": "Study compares efficacy of immunosuppressive therapies with usual education materials. Study compares efficacy with education materials for lupus nephritis patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02319525"
    },
    {
        "Title": "A Study of Telitacicept in Subjects With Childhood-onset Systemic Lupus Erythematosus",
        "Summary": "CNN.com will feature iReporter photos in a weekly Travel Snapshots gallery. Visit CNN.com/Travel each week for a new gallery of snapshots from around the world. Visit iReport.com for more travel snapshots.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05687526"
    },
    {
        "Title": "O-GlcNAcylation Role in the Pathophysiology of Systemic Lupus Erythematosus",
        "Summary": "Study aims defining role physiopathology systemic lupus erythematosus sle metabolic pathway potentially implicated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04440566"
    },
    {
        "Title": "Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With Severe, Refractory Systemic Lupus Erythematosus",
        "Summary": " lupus erythematosus. phase 1 study patients severe refractory systemic lupuses. Patients in the study are in the early stages of treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06544330"
    },
    {
        "Title": "LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus",
        "Summary": " multicenter national controlled trial evaluate effect t2t strategy systemic lupus erythematosus sle 14 centers randomized t2T standard care per arm 303 patients sle remission included receive either tight control visits aim reach remission soc control",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05714930"
    },
    {
        "Title": "Steroid Induced Osteoporosis in Patients With Systemic Lupus Erythematosus",
        "Summary": "Primary aim present study investigate prevalence low bone mineral density bmd vertebral fractures determined standardized assessment. Secondary aim study evaluate following parameters women steroid induced op siop 1 year treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00668330"
    },
    {
        "Title": "A Study Evaluating the Effects of GLPG3667 Administered As Oral Treatment in Adult Participants with Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluating efficacy safety tolerability pharmacokinetics pk pharmacodynamics pd glpg3667 administered orally daily 48 weeks. 180 adult participants active systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Germany, France, Spain, Georgia, Chile, Hungary, Peru, United States, Poland, Puerto Rico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05856448"
    },
    {
        "Title": "Efficacy of Faslodex in Treatment of SLE Clinical, Serologic, and Molecular Studies",
        "Summary": " systemic lupus erythematosus autoimmune disese primarily occurs women. Female gender strongest risk factor sex hormone estrogen proven past enhancer immune response. estrogen serves ligand two specific receptor proteins.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00417430"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",
        "Summary": "Dapirolizumab pegol dzp treatment standard care soc medication achieve clinically relevant long term improvement moderate severe disease activity. purpose study evaluate ability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06617325"
    },
    {
        "Title": "Expression of CXCR4 in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study estimates possible role of cd184 in pathogenesis. Study compares level of CD184 in sle cases to that in healthy controls.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04799730"
    },
    {
        "Title": "Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease",
        "Summary": "Evidence exists immunogenicity safety hpv vaccination patients immune system disorder primary humoral immunodeficiency hypogammaglobulinemia autoimmune diseases concerns exist vaccination may cause aggravation underlying disease addition immune response vaccination may diminished due",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "COMPLETED",
        "Conditions": "Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Juvenile Dermatomyositis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00815282"
    },
    {
        "Title": "Safety of Estrogens in Lupus: Birth Control Pills",
        "Summary": "Lupus erythematosus national assessment selena study test whether women can safely use estrogen determine looking effects oral contraceptives birth control pills.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00000420"
    },
    {
        "Title": "Vitamin D3 Treatment in Pediatric Systemic Lupus Erythematosus",
        "Summary": "18 weeks vitamin d3 supplementation compared with no supplementation. Children with systemic lupus erythematosus sle serum 25 oh levels compared to children with normal levels.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01709474"
    },
    {
        "Title": "In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases",
        "Summary": "Ltreg cytokine dual role immune system stimulates immune responses acting intermediate affinity receptor expressed conventional cells. ltconv activation also contributes inhibition immune responses via ltreg express high affinity receptor difference receptor affinity led development therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia, Systemic Lupus Erythematosus, Multiple Sclerosis, Gvhd, Rheumatoid Arthritis, Autoimmune Thyroiditis, Vitiligo, Alopecia, Atopic Dermatitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05544448"
    },
    {
        "Title": "The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD",
        "Summary": "People aged 18 80 years undergo screening physical exam blood urine tests test heart function chest answer questions sle symptoms participants visit clinic 9 times 8 months screening visits 4 weeks apart visit may take 4 hours participants receive infusions tube attached needle inserted vein arm",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Cardiovascular Disease, Premature Atherosclerosis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05440422"
    },
    {
        "Title": "The WILLOW Study With M5049 in SLE and CLE (SCLE and/or DLE) (WILLOW)",
        "Summary": "Study evaluated efficacy safety orally administered enpatoran. Participants randomized parallel adaptive setting study duration 33 weeks visit frequency every 2 4 weeks enpatorsan available expanded access program. purpose proof concept poc df basket study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Greece, Spain, China, Korea, Republic of, Poland, Romania, Bulgaria, Philippines, South Africa, Taiwan, Japan, Argentina, Mauritius, Brazil, Israel, Chile, Colombia, Mexico, Moldova, Republic of",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05162586"
    },
    {
        "Title": "Clinical Performance of BioCLIA Ro60",
        "Summary": "Study evaluate clinical performance bioclia ro60 measuring autoantibody autoimmune disease patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus, Sjogren's Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT03204448"
    },
    {
        "Title": "SAPHNELO Systemic Lupus Erythematosus Japan Post-Marketing Surveillance (PMS)",
        "Summary": "Anifrolumab is used to treat systemic lupus erythematosus in the U.S.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Japan",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05141201"
    },
    {
        "Title": "Study of Gynecological Follow-up of Patients With Autoimmune Disease or Inflammatory Rheumatism",
        "Summary": " autoimmune diseases consequence abnormality immune system leading attack components body wide variety presentations preferentially affect women often young age systemic lupus erythematosus example often occurs ages 15 40 inflammatory rheumatism spondylo",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Arthritis, Rheumatoid, Spondylitis, Ankylosing, Lupus Erythematosus, Systemic, Scleroderma, Systemic, Sjogren's Syndrome, Mixed Connective Tissue Disease",
        "Phases": "N/A",
        "IDestudio": "NCT05961267"
    },
    {
        "Title": "Phone-Based Based Walk with Ease Program for Adults with Arthritis",
        "Summary": "An objective study examine 6 months 1 year effects of an intervention. An alternative version of the study was designed to ease intervention.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Arthritis, Gout, Fibromyalgia, Rheumatoid Arthritis, Osteoarthritis, Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05289544"
    },
    {
        "Title": "The Impact of Illness Perceptions on Health Related Outcomes in Patients With Lupus and Systemic Sclerosis",
        "Summary": "Research project overall objective investigate direction associations illness perceptions influencing factors outcomes. Investigators want to know whether outcome variables anxiety depression and physical dis functioning influenced illness perceptions vice versa.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Scleroderma, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT02655640"
    },
    {
        "Title": "A Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus",
        "Summary": " clinical trial see well cenerimod reduces symptoms systemic lupus erythematous adult patients moderate severe symptoms. main questions aims answer well cenersimod works top treatment already administered safe. researchers compare one dose cener",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Germany, Philippines, South Africa, Spain, Ukraine, Georgia, Chile, Mexico, Serbia, Portugal, Peru, United States, Poland, United Kingdom, Puerto Rico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05672576"
    },
    {
        "Title": "Role of the Neonatal Fc Receptor for IgG in the Pathophysiology of Lupus",
        "Summary": "Study evaluates expression neonatal fc receptor fcrn white blood cells cells apc active lupus patients compared inactive lupUS patients control investigate upregulated upregulated.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT03896373"
    },
    {
        "Title": "Determination of the RANKL/Osteoprotegerin Ratio in Patients With Systemic Lupus Erythematosus. Role in Osteoporosis and Cardiovascular Calcification",
        "Summary": "Osteoporosis often associated with cardiovascular calcification inflammatory immune factors implicated two processes role system osteoclast differentiation elucidated last ten years rankl induces differentiation osteoclasts inversely opg exerts inhibitory role inactivating",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Osteoporosis, Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02799173"
    },
    {
        "Title": "Evaluation of Patients With Lupus Nephritis Using Kidney MRI (Magnetic Resonance Imaging)",
        "Summary": "Study done find magnetic resonance imaging mri examination kidneys may helpful diagnosing lupus nephritis patients. Participants participation involves kidney mri take 30 60 minutes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus, Systemic, Lupus, SLE, SLE Nephritis, SLE; Glomerulonephritis (Etiology), SLE (Systemic Lupus)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06445127"
    },
    {
        "Title": "JWCAR201 for the Treatment of Hematology Malignancy and Autoimmune Diseases",
        "Summary": " jwcar201 product trial intended evaluate safety efficacy. jw Car201 patients b cell driven hematology malignancy autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "B-cell Tumors, Autoimmune Diseases, Lupus Erythematosus, Systemic, Large B-cell Lymphoma",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06567080"
    },
    {
        "Title": "Treating Systemic Lupus Erythematosus (SLE) Patients With CTLA4-IgG4m (RG2077)",
        "Summary": "us lupus erythematosus sle currently receiving cyclophosphamide. purpose study examine safety single dose rg2077.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00094380"
    },
    {
        "Title": "A Study of the Safety and Pharmacokinetics of CNTO 136 in Patients With Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus",
        "Summary": "Main purpose study evaluate safety pharmacokinetics pk action drug body period time multiple intravenous iv administrations cnto 136 patients. Secondary goal study assess pharmacodynamics biochemical physiological effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01702740"
    },
    {
        "Title": "Effects of an Intervention With EVOO and Physical Activity in Patients With Systemic Lupus Erythematosus",
        "Summary": "Lifestyles could determining role balancing numerous organic processes levels line benefits following healthy dietary pattern mediterranean diet specifically intake extra virgin olive oil evoo well realization regular physical exercise.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05261529"
    },
    {
        "Title": "Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.",
        "Summary": "Cpn10 subjects mild moderate active sle. primary objective study evaluate safety tolerability efficacy 4 weeks intravenous treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01838694"
    },
    {
        "Title": "Establishing Clinical Utility of a New Diagnostic Test for Rheumatology Patients",
        "Summary": "Study collect randomized controlled data nationally representative sample practicing rheumatologists. determine currently manage patients sle systemic lupus erythematosus results.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04266860"
    },
    {
        "Title": "Effect of Green Tea on Treatment of Lupus",
        "Summary": " randomized double blind clinical trial performed 68 patients 32 intervention 36 control group diagnosed sle patients. intervention group given daily dose 1000mg aqueous green tea extract 6 gram dried green tea leaf form two capsules 500 mg. control group patients given daily",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Iran, Islamic Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Autoimmune, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02875691"
    },
    {
        "Title": "Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches",
        "Summary": "Abatacept 125 mg placebo administered weekly subcutaneous doses 3 months. 20 mg prednisone background immune suppressants withdrawn. Two injections screening visit visit 2 months dosing begins.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02270957"
    },
    {
        "Title": "Reducing Disparities in Medication Adherence in SLE",
        "Summary": "Pilot study assess feasibility using surescripts refill data. clinical encounter improve medication adherence patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03738826"
    },
    {
        "Title": "Safety, Tolerability and Pharmacokinetics of KPG-818 in Healthy Subjects",
        "Summary": " phase 1 study investigate safety tolerability pharmacokinetics pk. healthy male female participants effect food pk study assist identifying appropriate well tolerated doses administered subsequent studies. healthy participants participants systemic lupus erythematosus sleus",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03949426"
    },
    {
        "Title": "Anifrolumab Early Access Program",
        "Summary": " marketing authorisation anifrolumab 300 mg iv q4w receiving standard therapy adult patients active sle. provide early access to the drug.",
        "StudyType": "EXPANDED_ACCESS",
        "Countries": "",
        "OverallStatus": "NO_LONGER_AVAILABLE",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04750057"
    },
    {
        "Title": "OPAM-IA: Using Digital Activity Trackers to Improve Physical Activity in Inflammatory Arthritis",
        "Summary": " physically active reduce pain fatigue improve mobility enhance quality life people arthritis adherence active lifestyle poor less half people arthritis active primary goal randomized controlled trial assess efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Joint Diseases, Rheumatoid Arthritis, Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02554474"
    },
    {
        "Title": "Transcutaneous Vagus Nerve Stimulation for the Treatment of Lupus",
        "Summary": "Double blinded randomized controlled study transcutaneous electrical vagus nerve stimulation tvns compared sham stimulation treatment patients active systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02917265"
    },
    {
        "Title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)",
        "Summary": " purpose study evaluate efficacy safety telitacicept treatment moderately severely active sle. purpose study evaluates efficacy safety of telitcicept.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Germany, Philippines, Mauritius, Spain, Australia, Chile, Colombia, Hungary, Mexico, Poland, United States, Guatemala, Puerto Rico",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05306574"
    },
    {
        "Title": "Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus",
        "Summary": "Primary objective study confirm clinical efficacy epratuzumab treatment subjects systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, Russian Federation, Korea, Republic of, Italy, United Kingdom, Puerto Rico, Belgium, Romania, Bulgaria, France, India, Lithuania, Taiwan, Czechia, Germany, Estonia, Brazil, Israel, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01262365"
    },
    {
        "Title": "Umbilical Cord Derived Mesenchymal Stem Cells Transplantation for Active and Refractory Systemic Lupus Erythematosus",
        "Summary": "Study explore safety efficacy allogeneic umbilical cord uc derived mesenchymal stem cells transplantation. Treat patients active refractory systemic lupus erythematosus sle resistant.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01741857"
    },
    {
        "Title": "Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus (MiSLE)",
        "Summary": "Mscs are stem cells obtained from umbilical cords. They are used to treat systemic lupus erythematosus. Study aims to determine if patients receiving msc infusion plus standard care respond better than those receiving",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02633163"
    },
    {
        "Title": "A Study of Obexelimab in Patients with Systemic Lupus Erythematosus",
        "Summary": "Study aims examine efficacy safety obexelimab participants systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Spain, Puerto Rico, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06559163"
    },
    {
        "Title": "A IMMA Master Protocol: A Study of LY3361237 in Participants With at Least Moderately Active Systemic Lupus Erythematosus",
        "Summary": "Main purpose study assess efficacy safety ly3361237 participants least moderately active systemic lupus erythematosus sle study last 34 weeks may include 15 visits.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Argentina, Taiwan, France, Mexico, Poland, United States, Puerto Rico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05123586"
    },
    {
        "Title": "Exercise and Systemic Lupus Erythematosus",
        "Summary": "Aerobic exercise training program positively affect lipid profile, insulin sensitivity, cytokine profile, cardiovascular parameters, muscle strength in patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01515163"
    },
    {
        "Title": "Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases",
        "Summary": "Chinese participants systemic lupus erythematosus sle sj\u00f6gren disease sjd collection intensive pk data chinese population designed ianalumab phase 3 studies. purpose pharmacokinetic pk study describe",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Sjogren Disease, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06411639"
    },
    {
        "Title": "Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus",
        "Summary": "Study determines body absorbs chemically changes single infusion subjects kidney disease caused lupus. purpose study determine body absorbs chemical changes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00479622"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults With Systemic Lupus Erythematosus",
        "Summary": " sifalimumab compared placebo subjects moderately severely active systemic lupus erythematosus sleus. evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Spain, Italy, Poland, United Kingdom, Romania, Bulgaria, Philippines, South Africa, France, India, Netherlands, Canada, Peru, Argentina, Germany, Jamaica, Brazil, Chile, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01283139"
    },
    {
        "Title": "A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluate safety tolerability of dapirolizumab pegol treatment. purpose study evaluates safety tolerable dapirozumab Pegol.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Serbia, Greece, Spain, Korea, Republic of, Italy, Poland, Belgium, Romania, Bulgaria, Philippines, Canada, Peru, Taiwan, Czechia, Argentina, Germany, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04976322"
    },
    {
        "Title": "A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus",
        "Summary": "Study investigated safety tolerability pharmacokinetics pk pharmacodynamics pd ro7507062 participants systemic lupus erythematosus sle study 2 parts part 1 single ascending sad part part 2 dose escalation fractionated dosing",
        "StudyType": "INTERVENTIONAL",
        "Countries": "South Africa, Germany, Spain, Netherlands, Poland, Taiwan, Malaysia, United Kingdom, Thailand",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05835986"
    },
    {
        "Title": "AS-OCT Study of Cornea and Tear Film Parameters in SLE Patients",
        "Summary": "Study assess tear film parameters tear meniscus height, area, depth and corneal pachymetry epithelial thickness maps.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04873739"
    },
    {
        "Title": "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Efavaleukin Alfa in Participants With Systemic Lupus Erythematosus",
        "Summary": " evaluate safety tolerability subcutaneous sc dose administrations efavaleukin alfa participants systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France, Germany, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03451422"
    },
    {
        "Title": "An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "The aim of the trial was to investigate safety tolerability subjects systemic lupus erythematosus sle concomitantly treated stable background therapies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hungary, Serbia, Poland, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Inflammation, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01689025"
    },
    {
        "Title": "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Baricitinib is a treatment for systemic lupus erythematosus sle completed final treatment visit study nct03616912.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Switzerland, Australia, United States, Serbia, Greece, Spain, Russian Federation, China, Italy, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Philippines, South Africa, France, India, Netherlands, Taiwan, Czechia, Japan, Argentina, Germany, Brazil, Israel, Croatia, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03843125"
    },
    {
        "Title": "A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus",
        "Summary": "Primary objective study evaluate safety tolerability multiple doses. Subjects were moderately severely active lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00657189"
    },
    {
        "Title": "Microvascular Ocular Changes of Systemic Lupus Erythematous",
        "Summary": "The study was observational. The aim was to assess ocular microvascular status. The participants were healthy controls matched age sex.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Portugal",
        "OverallStatus": "RECRUITING",
        "Conditions": "Eye Manifestations, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05863689"
    },
    {
        "Title": "Phase Ib Study of SC Milatuzumab in SLE",
        "Summary": " milatuzumab given subcutaneously different dose levels depending dose level 4 weeks determine milatizumab helps control lupus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic, Lupus Vasculitis, Central Nervous System, Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01845740"
    },
    {
        "Title": "Anti-C1s, Anti-HMGB1 and Anti-C1q Autoantibodies in Systemic Lupus Erythematosus (DYSALARM-322)",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune disease characterized production multiple autoantibodies accumulation immune complexes resulting systemic inflammatory response tissue damage dysfunction proteins initially known as classical pathway complement activation.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05193591"
    },
    {
        "Title": "A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus",
        "Summary": " participants given tabalumab blood given two different injection methods traditional syringe spring loaded syringe 12 weeks participants may continue receive study drug 52 weeks. purpose study evaluate amount tabalums given to participants.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of, Puerto Rico, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02041091"
    },
    {
        "Title": "Compassionate Use for Subcutaneous (SC) Belimumab",
        "Summary": " glaxosmithkline gsk submitted biologic license application bla subcutaneous formulation belimumab currently review food drug administration fda goal individual patient compassionate use supply.",
        "StudyType": "EXPANDED_ACCESS",
        "Countries": "United States",
        "OverallStatus": "NO_LONGER_AVAILABLE",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03125486"
    },
    {
        "Title": "Lupus Interval Monitoring to Manage Disease Flare and Enable Treatment Optimization",
        "Summary": "Developed test characterize monitor disease activity status participant home analyzing gene expression participant blood samples using novel fingerstick collection kit.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Lupus, Lupus Erythematosus, Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT03142412"
    },
    {
        "Title": "Meir Medical Center Rheumatologic Biobank",
        "Summary": " serum synovial fluid skin biopsies. patients collected biobank rheumatoid diseases samples later used clinical basic research following approval specific study irb investigators intend extract protein dna rna sample.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Israel",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Lupus Erythematosus, Systemic, Systemic Sclerosis, IgG4-related Disease, Sjogren's Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT03473912"
    },
    {
        "Title": "Ultrasound Evaluation of Hands in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study evaluates ultrasound hands patients systemic lupus erythematosus. purpose study is to evaluate ultrasound hands for patients with\u00a0systemic\u00a0lupus.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Systemic, Arthritis, Rheumatoid",
        "Phases": "N/A",
        "IDestudio": "NCT01471301"
    },
    {
        "Title": "Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus",
        "Summary": " randomized phase 2b trial evaluate efficacy atacicept subjects systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Bulgaria, Argentina, Germany, Philippines, South Africa, Brazil, Spain, Russian Federation, Chile, Mexico, Korea, Republic of, Italy, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01972568"
    },
    {
        "Title": "Memantine for the Treatment of Cognitive Impairment in Systemic Lupus Erythematosus",
        "Summary": "Study phewas identified association variant human gene n2a subunit nmda receptor grin2a systemic lupus erythematosus sle single nucleotide polymorphism snp gene encodes increasednmda receptor activity based",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03527472"
    },
    {
        "Title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus",
        "Summary": " rituximab compared placebo combined single stable background immunosuppressive medication subjects. Subjects moderate severe systemic lupus erythematosus sle primary efficacy endpoint trial evaluated 52 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00137969"
    },
    {
        "Title": "Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.",
        "Summary": "Several autoimmune rheumatologic diseases include systemic lupus erythematosus sle. Vitamin supplementation is considered to play a role in the development of the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01892748"
    },
    {
        "Title": "GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases",
        "Summary": " purpose study determine whether use gonadotropin releasing hormone gnrh acetate cyclophosphamide cyc therapy women rheumatic diseases provide greater ovarian protection placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic, Systemic Vasculitis, Isolated Angiitis of Central Nervous System, Lung Disease With Systemic Sclerosis, Lung Disease Interstitial Diffuse",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01257802"
    },
    {
        "Title": "Vitamin D3 in Systemic Lupus Erythematosus",
        "Summary": "Vitamin d3 expression alpha interferon ifn alpha expression systemic lupus erythematosus sle patients vitamin deficiency. purpose study explore impact of vitamin d3 on vitamin deficiency in patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, SLE, Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00710021"
    },
    {
        "Title": "Comparative Autoantibody and Immunologic Cell Marker Study",
        "Summary": "Study compares immune phenotype function specificity b lymphocytes. Different developmental stages autoimmune patients b cells infectious disease patients healthy controls.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Autoimmune Diseases, Lupus Erythematosus, Systemic, Communicable Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT02422875"
    },
    {
        "Title": "Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus",
        "Summary": "Study examine new approach treating patients severe systemic lupus erythematosus sle involves collecting stem cells cells produced bone marrow develop blood cells. Patients completely shutting patient immune system giving back patient stem cells sle chronic inflammatory disorder immune system",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00076752"
    },
    {
        "Title": "Tacrolimus for the Treatment of Systemic Lupus Erythematosus With Membranous Nephritis",
        "Summary": "Investigators study efficacy safety of tacrolimus treatment for nephritis, systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00125307"
    },
    {
        "Title": "Serologically Active, Clinically Stable Systemic Lupus Erythematosus",
        "Summary": "First part study use database large ongoing lupus study. Second part study add increase prednisone treatment basis abnormalities blood tests c3a dsdna antibodies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00000421"
    },
    {
        "Title": "RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome",
        "Summary": "40 patients randomised ratio receive either rivaroxaban 15mg twice daily orally 24 months warfarin standard care risaps trial maintain target inr range 24 months primary outcome trial rate change brain white matter hyperintensity wmh",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Stroke, Ischemic Stroke, Brain Ischemia",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03684564"
    },
    {
        "Title": "An Investigational Study of Experimental Medication BMS-986165 in Healthy Participants to Study Electrocardiogram Effects",
        "Summary": "Study investigate experimental medication. healthy participants order study effects electrocardiogram results. Study investigated experimental medication healthy participants ordered study effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Healthy Participants",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03541564"
    },
    {
        "Title": "BI 705564 in Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Main objective study assess safety tolerability pharmacokinetics orally administered bi 705564 patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03771885"
    },
    {
        "Title": "Synergetic B-cell Immunomodulation in SLE - 2nd Study.",
        "Summary": "Belimumab followed rituximab lupus nephritis patients. Previous synbiose study present study randomized controlled trial.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03747159"
    },
    {
        "Title": "A Non-drug Study Profiling Cutaneous Lupus",
        "Summary": " purpose study characterize clinical molecular profiles patients cutaneous lupus. purpose study to characterize clinical Molecular profiles of cutaneous Lupus patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid",
        "Phases": "N/A",
        "IDestudio": "NCT01923415"
    },
    {
        "Title": "A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluated efficacy ustekinumab chinese participants active systemic lupus erythematosus sle adequately responded to one treatments.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04060888"
    },
    {
        "Title": "An Open-label Study to Evaluate the Long-term Safety of MEDI-546, for the Treatment of SLE, in Adults",
        "Summary": "Anifrolumab adults moderate severe active systemic lupus erythematosus slei. purpose study evaluate safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Romania, Bulgaria, Taiwan, Brazil, Ukraine, Colombia, Hungary, Korea, Republic of, Mexico, Peru, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01753193"
    },
    {
        "Title": "High-Dose Intravenous (IV) Cyclophosphamide Versus Monthly IV Cyclophosphamide",
        "Summary": "Study compares effectiveness cyclophosphamide treatment gold standard treatment. People moderate severe lupus respond corticosteroid therapy give patients either iv cycloph phosphamide 750 milligrams per square meter body surface area monthly 6 months followed quarterly",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00005778"
    },
    {
        "Title": "Autologous Polyclonal Tregs for Lupus",
        "Summary": "Lupus targeting cutaneous disease offers ability control background therapy readily detect clinical effects perform research analyses blood also skin safety disease activity mechanism.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid, Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02428309"
    },
    {
        "Title": "Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)",
        "Summary": " multicenter phase 2b extension lte address ii core trial emr nct01972568 evaluate safety tolerability atacicept participants systemic lupus erythematosus sle participants completed core study address ii",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Bulgaria, Argentina, Germany, Philippines, South Africa, Brazil, Spain, Russian Federation, Chile, Mexico, Korea, Republic of, Italy, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02070978"
    },
    {
        "Title": "Relationship Between Data Obtained With the LuGENE\u00ae Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE)",
        "Summary": " open label study determine association data obtained ldt standard evaluation patients diagnosed sle including clinical involvement sledai score physician global assessment pga standard laboratory measures including ana complement components c3 c4 well patient reported outcomes capturing pain fatigue quality life test administered",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT05845593"
    },
    {
        "Title": "Pharmacokinetics Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)",
        "Summary": "The study will evaluate epratuzumab processed body pharmacokinetics. The aim is to determine whether 2 dose levels of the drug are safe and effective for patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00113971"
    },
    {
        "Title": "A Study of Rapcabtagene Autoleucel in Systemic Lupus Erythematosus (SLE) Patients With Active, Refractory Lupus Nephritis (LN)",
        "Summary": " purpose study evaluate efficacy safety rapcabtagene autoleucel administered following lymphodepletion versus standard care. soc patients systemic lupus erythematosus sle active refractory lupUS neph",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Singapore, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic, Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06581198"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus",
        "Summary": " phase 2 multicenter randomized study evaluate efficacy safety oral treatment regimen versus placebo adult subjects active systemic lupus erythematosus. approximately 280 subjects documented diagnosis and treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Argentina, Germany, France, Brazil, Spain, Russian Federation, Colombia, Hungary, Canada, Italy, Mexico, United States, Poland, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03161483"
    },
    {
        "Title": "Medication Adherence Patterns in Rheumatic Diseases: A Behavioral Trial",
        "Summary": "Model proposes habit formation three central components behavioral repetition associated context cues rewards model obvious applicability daily repetitive activity tested behavior adapted intervention patients care settings goal pilot study evaluate feasibility effectiveness.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatic Diseases, Gout, Adherence, Medication, Lupus Erythematosus, Systemic",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04776161"
    },
    {
        "Title": "A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus",
        "Summary": "Ustekinumab measured reduction disease activity subjects active active systemic lupus erythematosus sle chronic disorder connective tissue skin rash arthritis kidney problems.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, Argentina, Taiwan, Spain, Australia, Hungary, Mexico, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02349061"
    },
    {
        "Title": "Validation of a Mobile Phone Based on EPRO Tool in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Clinician typically used sle supplement clinical measures standard pros typically used include short form health survey functional assessment chronic illness therapy fatigue. ptga administered paper electronic tablet clinic visits recent development electronic mobile device technology smartphone made possible.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "SLE, Lupus Erythematosus, Systemic, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03142711"
    },
    {
        "Title": "A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus",
        "Summary": "Current phase 3 study evaluate efficacy safety administration subcutaneous sc patients active sle. current phase 3Study evaluate efficacy. safety administration Subcutaneous SC patients active Sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Germany, France, Mauritius, Hungary, Poland, United States, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02504645"
    },
    {
        "Title": "Sirolimus Treatment Of Patients With SLE",
        "Summary": " phase ii randomized treatment trial two arms one sirolimus arm 92 patients one placebo arm 92 Patients safety therapeutic efficacy siroLimus determined within dosage range 1 4 titrated tolerance initial open label period relative placebo sle patients 12 months followed",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04736953"
    },
    {
        "Title": "Employment and Arthritis: Making it Work",
        "Summary": "Investigators plan conduct randomized controlled trial evaluate effectiveness cost effectiveness elearning program entitled employment arthritis making work designed help people inflammatory arthritis stay employed.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Ankylosing Spondylitis, Lupus Erythematosus, Systemic, Psoriatic Arthritis, Other Connective Tissue Diseases, Spondylarthropathy",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01852851"
    },
    {
        "Title": "An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": " phase ii multicenter extension ole study evaluate safety efficacy participants systemic lupus erythematosus sle completed study ga30044 nct02908100 48 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Taiwan, Brazil, Spain, Chile, Colombia, Korea, Republic of, Mexico, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03407482"
    },
    {
        "Title": "Epidemiologic Study of Reproductive Outcome in Women With Systemic Lupus Erythematosus",
        "Summary": " objectives evaluate whether pregnancy independent risk factor affects disease activity women systemic lupus erythematosus ii. evaluate whether maternal disease activity risk factor adverse pregnancy outcome.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00004663"
    },
    {
        "Title": "An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 in Severe, Refractory Systemic Lupus Erythematosus",
        "Summary": "Study intended assess safety efficacy cellular kinetics. ytb323 treatment participants severe refractory systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, Switzerland, France, Spain, Australia, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05798117"
    },
    {
        "Title": "A Phase I Study of ICP-022 in Healthy Subjects",
        "Summary": "The study was conducted by the National Institutes of Health in Washington, D.C. The study was designed to evaluate the safety and pharmacokinetics following oral single multiple escalating dose administration.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Rheumatoid Arthritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03189017"
    },
    {
        "Title": "Validation of the Lupus Low Disease Activity State (LLDAS) in the Asia Pacific Region",
        "Summary": "Lupus erythematosus sle sle lupus archetypal multisystem autoimmune disease estimated incidence cases per people patients sle usually young women suffer marked loss life expectancy severe morbidity due heterogeneous range clinical manifestations caused",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Japan, Philippines, Indonesia, Australia, Hong Kong, China, Korea, Republic of, Singapore, Taiwan, Sri Lanka, Thailand",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03138941"
    },
    {
        "Title": "Phase I Study of Immune Ablation and CD34+ Peripheral Blood Stem Cell Support in Patients With Systemic Lupus Erythematosus",
        "Summary": " erythematosus. objectives determine safety immune ablation cyclophosphamide globulin followed peripheral blood stem cell support.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00017641"
    },
    {
        "Title": "Psychoeducational Approach to Improve Health in Lupus",
        "Summary": "Lupus partners either 1 receive counseling improve partner support problem solving 2 see informational film lupus follow study participants 12 months find physical mental health disease activity beliefs take steps help feel better coping.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00000417"
    },
    {
        "Title": "Belimumab in SLE Synovial Inflammation and Lymph Nodes",
        "Summary": "Systemic lupus erythematosus sle inflammatory disease imids cellular molecular alterations immune system driving diseases still remains largely unknown. lymph nodes also play important role investigating immune compartments body lymph nodes could result.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06327724"
    },
    {
        "Title": "Dehydroepiandrosterone (DHEA) in Systemic Lupus Erythematosus (SLE) for Coronary Artery Disease (CAD) Prevention",
        "Summary": "The study was designed to evaluate the effect of dhea on cardiovascular risk. Patients were enrolled in a randomized crossover trial dhea placebo ten weeks crossed alternate treatment arm.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00189124"
    },
    {
        "Title": "Evaluation of the Discontinuation of Maintenance Corticosteroid Treatment in Quiescent Systemic Lupus",
        "Summary": " systemic lupus sle chronic disease long term treatments warranted aim study study study possibility corticosteroids interruption patients quiescent sle treated since at least one year 5 milligrams predonisone per day.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02558517"
    },
    {
        "Title": "Phase 1b/2a in SLE With Budoputug",
        "Summary": " purpose study determine safety tolerability pharmacokinetics. budoprutug participants sle sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus, SLE, B Cells",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06570434"
    },
    {
        "Title": "Tissue Sodium in Autoimmune Disease",
        "Summary": "Low sodium diet decrease sodium 23na magnetic resonance skin sodium concentrations patients systemic lupus erythematosus sle improve blood pressure inflammation.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02525835"
    },
    {
        "Title": "Efficacy And Safety Of MK-6194 In Adult Participants With Systemic Lupus Erythematosus (MK-6194-006)",
        "Summary": "The study was designed to evaluate efficacy and safety. The study included adult participants with systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Argentina, Philippines, France, Brazil, Spain, Chile, Colombia, Canada, China, Italy, United States, Mexico, Poland, Malaysia, Guatemala",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06161116"
    },
    {
        "Title": "Prevention of Arthritis-Related Work Disability",
        "Summary": " people rheumatic disorders arthritis often trouble keeping jobs study look whether vocational rehabilitation vr improve ability employed people arthritis keep jobs job retention vr services target key factors increase risk job loss aim modify jobs reduce barriers caused functional limitations disease symptoms future",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Knee, Ankylosing Spondylitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00000416"
    },
    {
        "Title": "Treatment of Systemic Lupus Erythematosus With Pooled Allogenic Mesenchymal Stem Cells",
        "Summary": "Systemic lupus erythematosus pooled allogenic mesenchymal stem cells.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belarus",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT04184258"
    },
    {
        "Title": "Efficacy and Immunological Evaluation of Telitacicept and Low Dose IL2 in the Treatment of Systemic Lupus Erythematosus",
        "Summary": " purpose study explore clinical immunological efficacy telitacicept low dose systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05339217"
    },
    {
        "Title": "A Two-part Study to Investigate the Interaction and Pharmacokinetics of GSK2586184",
        "Summary": " study phase study designed evaluate effect repeated doses gsk2586184 pharmacokinetics pk simvastatin rosuVastatin healthy volunteers cohort evaluate pharmacokinetic new tablet formulation. 28 subjects 14 female 14 male subjects enrolled subject",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01953835"
    },
    {
        "Title": "ALPN-101 (Acazicolcept) in Systemic Lupus Erythematosus",
        "Summary": "Acazicolcept adults moderate severe active systemic lupus erythematosus sle. phase 2 multinational randomized blinded study evaluate safety tolerability efficacy immunogenicity pharmacokinetics pharmacodynamics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Taiwan, France, Spain, Hungary, Poland, United States, Puerto Rico",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04835441"
    },
    {
        "Title": "Systemic Lupus and Adverse Pregnancy Outcome",
        "Summary": "Pregnant ladies systemic lupus localities. prospective analytical study pregnant ladies systemic Lupus Localities.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Pregnancy Complications",
        "Phases": "N/A",
        "IDestudio": "NCT03171103"
    },
    {
        "Title": "Centrally Acting ACE Inhibition in SLE",
        "Summary": " autoimmune disease often involves multiple systems organs body autoimmune disease one immune system attacks cells tissues different parts body sle characterized inflammation leads tissue damage many different organ systems lupus cause fever joint pains rashes symptoms also affect organs skin muscles kidneys heart lungs",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04486118"
    },
    {
        "Title": "Effects of Treatment of Chronic Stress in Patients With Lupus",
        "Summary": " daily stress worsens clinical course lupus objective determine efficacy stress management therapy group patients. 45 patients with high daily stress participated clinical trial. Statistical analysis showed significant reduction levels depression anxiety daily stress therapy group compared usual care group.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00483613"
    },
    {
        "Title": "Pregnancy and Medically Assisted Conception in Rare Diseases",
        "Summary": "Rare diseases frequently affect women childbearing age pregnancy women become less rare. High levels complications one obstacle optimal management pregnancy prospective studies pregnancy rare diseases.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Antiphospholipid Syndrome, Sjogren Syndrome, Scleroderma, Myositis, Vasculitis, Mastocytosis, Various Autoimmune and/or Systemic and/or Rare Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT02450396"
    },
    {
        "Title": "Pilot Study - Effect of Omega-3 on Systemic Lupus Erythematosus",
        "Summary": "Single blind pilot study involving systemic lupus erythematosus lupUS nephritis patients propose recruit consent. fish oil supplement placebo contains olive oil baseline metabolomic profile blood test nutritional assessment fatigue severity scale quality life assessment",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02021513"
    },
    {
        "Title": "Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Study evaluated safety efficacy repeated intravenous infusions. Drug bt063 was used to treat systemic lupus erythematosus sle compared people receive placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Georgia, Serbia, Belarus, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02554019"
    },
    {
        "Title": "Electroencephalogram Recording in Patients With Systemic Lupus Erythematosus",
        "Summary": " patients systemic lupus erythematosus sle often experience frustrating decline cognitive skills includes considerable problems attention learning memory cognitive dysfunction termed recognized prevalent nineteen neuropsychiatric sle syndromes affects 80 patients significantly decrease quality life.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06378736"
    },
    {
        "Title": "Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)",
        "Summary": "12 week study observe patients without systemic lupus erythematosus persistent antiphospholipid antibodies. Patients change blood test called annexin a5 resistance assay 12 week period.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Antiphospholipid Syndrome, Thrombophilia Due to Antiphospholipid Antibody, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01475149"
    },
    {
        "Title": "A Study to Evaluate Safety and Tolerability of IV or SC Dose of MEDI-545 in Patients With Systemic Lupus Erythematosus.",
        "Summary": "Study evaluated safety tolerability japanese adult sle patients done collecting data. 3 cohorts iv doses 1 cohort sc doses.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01031836"
    },
    {
        "Title": "Multi-omics Studies on the Efficacy of Telitacicept in Chinese SLE Patients",
        "Summary": " telitacicept approved conditionally china march 2021 biologic agent targeting b lymphocyte stimulator proliferating. systemic lupus erythematosus sle systemic autoimmune disease abnormal activation b lymphocytes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05666336"
    },
    {
        "Title": "Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus",
        "Summary": " clinical trial aims test female patients systemic lupus erythematosus sle main question seeks answer whether etonogestrel implants protect ovarian reserve function patients sle participants randomly divided test group control group test group implanted subcutaneously",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05791799"
    },
    {
        "Title": "Statins and Lupus: Effects of Statins on Clinical Lupus Parameters, Serological Markers and Toll-like Receptors",
        "Summary": "Open label pilot clinical trial cohort 15 lupus patients center rheumatic disease clinical evaluations laboratory tests done eligible patients receive oral atorvastatin fixed dose statins.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00519363"
    },
    {
        "Title": "AntiDFS70 Lupus Nephritis",
        "Summary": " systemic lupus erythematous sle heterogeneous autoimmune disease involve many different organs display variable clinical course prevalence sle varies across gender geographic regions sle demonstrates striking female predominance peak incidence disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06119763"
    },
    {
        "Title": "Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)",
        "Summary": " oral tofacitinib adult patients discoid lupus erythematosus without concurrent slew. evaluate activity safety oral to Facitin ib adult patients without concurrentslew.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Discoid Lupus Erythematosus, Systemic Lupus Erythematosus",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT03159936"
    },
    {
        "Title": "Immunogenicity, Reactogenicity of Shingrix in SLE",
        "Summary": "2 doses adjuvanted herpes zoster subunit vaccine shingrix patients sle randomized trial. investigate immunogenicity reactogenicity safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Zoster, Systemic Lupus Erythematosus, Vaccine Reaction",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06001606"
    },
    {
        "Title": "Regulatory B Cells in Inflammatory Rheumatisms and Biomarkers of Response to Biologic Treatments",
        "Summary": " b cells known play important role diseases activating cells secreting inflammatory cytokines autoreactive antibodies however b cells named regulatory b cells bregs recently shown capacities prevent cure arthritis mouse models bregs also identified humans.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Osteoarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Scleroderma, Spondylitis, Gout, Spinal Disease, Chondrocalcinosis",
        "Phases": "N/A",
        "IDestudio": "NCT01642706"
    },
    {
        "Title": "Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases",
        "Summary": "Transreg assess safety biological efficacy il2 treg inducer set 14 autoimmune diseases aim select diseases therapeutic development performed extensive contribute define common distinct processes responsible breakdown immunological tolerance pathologies ii discover potential biomarkers il2 response.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Psoriasis, Behcet's Disease, Wegener's Granulomatosis, Takayasu's Disease, Crohn's Disease, Ulcerative Colitis, Autoimmune Hepatitis, Sclerosing Cholangitis, Gougerot-sj\u00f6gren, Idiopathic Thrombocytopenic Purpura, Systemic Sclerosis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01988506"
    },
    {
        "Title": "Systemic Lupus Erythematosus Exercise Program",
        "Summary": "Pilot study randomized controlled trial assess effect of supervised exercise program on systemic lupus erythematosus sle compared tau.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03942718"
    },
    {
        "Title": "Study of Epratuzumab in Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluate safety efficacy epratuzumab. standard treatments patients. patients sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Spain, Netherlands, Hungary, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00111306"
    },
    {
        "Title": "Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases",
        "Summary": "Rheumatic diseases may cause joint pain stiffness swelling involve bones muscles tendons ligaments cause abnormalities immune body defense disease. Study explore diverse health beliefs behaviors among minority patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Arthritis",
        "Phases": "N/A",
        "IDestudio": "NCT00069342"
    },
    {
        "Title": "Efficacy and Safety of Sirolimus in Active Systemic Lupus Erythematosus",
        "Summary": " randomized phase 2 study evaluate efficacy safety. sirolimus administered addition standard therapy patients active sle disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04582136"
    },
    {
        "Title": "A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 623 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "623 subjects systemic lupus erythematosus subjects receive 4 weekly doses study drug. 3 week period followed additional 28 weeks total study duration 31 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02411136"
    },
    {
        "Title": "A Study of KZR-616 in Patients With SLE With and Without Lupus Nephritis",
        "Summary": " phase study patients received administered subcutaneous sc injection weekly 13 weeks phase 1b 24 weeks phase 2.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Ukraine, Australia, Russian Federation, Colombia, Mexico, Peru, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT03393013"
    },
    {
        "Title": "Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases",
        "Summary": " autoimmune diseases ads children young adults unresponsive conventional treatments. High dose immunosuppressive therapy followed autologous stem cell transplant asct.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05029336"
    },
    {
        "Title": "Efficacy and Safety of Belimumab in Black Race Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Lupus erythematosus sle lupus is a disease that affects the central nervous system. There are no currently known treatments for the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "South Africa, France, Brazil, Colombia, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01632241"
    },
    {
        "Title": "A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus",
        "Summary": " purpose study explore safety efficacy of cd19 active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06106906"
    },
    {
        "Title": "CD19-CART(Relma-cel) for Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle subjects china. phase multicenter study asess safety tolerability pharmacokinetics pharmacodynamics moderate severe active systemic lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05765006"
    },
    {
        "Title": "Phase 3 Study to Evaluate Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 2)",
        "Summary": "ianalumab compared placebo given monthly subcutaneous injection top soc treatment participants active systemic lupus erythematosus sleus. trial evaluate efficacy safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Argentina, Germany, Taiwan, France, Australia, India, Colombia, Chile, Korea, Republic of, Italy, Mexico, United States, Malaysia, United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05624749"
    },
    {
        "Title": "A Phase II Study of M2951 in SLE",
        "Summary": " m2951 investigational drug evaluation treatment autoimmune inflammatory disorders purpose study assess safety efficacy. Participants systemic lupus erythematosus slem.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Russian Federation, Korea, Republic of, Italy, Poland, Romania, Bulgaria, Philippines, South Africa, Peru, Taiwan, Japan, Argentina, Germany, Mauritius, Colombia, Chile, Mexico, Malaysia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02975336"
    },
    {
        "Title": "Role of PPAR-y Agonists in Immunomodulation and Vascular Prevention in SLE (PPAR-SLE)",
        "Summary": " pioglitazone improves blood vessel function decreases blood vessel inflammation study effect lupus symptoms eligibility adults least 18 years old lupUS design participants screened medical history heart test blood urine tests may bone density test visit 1.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02338999"
    },
    {
        "Title": "Integration of Remote Monitoring in the Management of Chronic Immunosuppressive Therapy",
        "Summary": " systemic autoimmune chronic inflammatory diseases group chronic illnesses whose treatment usually prolonged often lifelong essential keep disease control thus reducing risk complications allowing best possible quality life patients drugs used treating diseases mostly immunosuppressants reduce activity immune system.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Spondyloarthritis, Axial, Ankylosing Spondylitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06544343"
    },
    {
        "Title": "Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus",
        "Summary": " systemic lupus erythematosus sle prototype systemic autoimmune disease neuropsychiatric sle npsle major cause morbidity pathophysiology remains unclear target autoantigens yet identified specific autoantigen expression might correlate imaging abnormalities",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05880121"
    },
    {
        "Title": "Dose Escalation Study of RSLV-132 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "One month study evaluate safety tolerability. 3 intravenous infusions subjects inactive mild sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02194400"
    },
    {
        "Title": "Addressing Disparities in Lupus Care Through an Integrated Care Management Program",
        "Summary": "The study aims to identify lupus patients receiving care brigham women hospital bwh high risk potentially avoidable acute care utilization inconsistent ambulatory care use adverse outcomes. The study also study social determinants contribute acute care use avoidable outcomes",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03915652"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "The study evaluated efficacy 200 micrograms mcg dose compared to placebo. The study also assessed proportion participants achieving combined clinical response using sle responder index sri.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Germany, France, Spain, Ukraine, Hungary, Portugal, Poland, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01135459"
    },
    {
        "Title": "Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis",
        "Summary": " purpose study determine safety tolerability antibody subjects lupus nephritis. purpose study determined safety tolerable antibody subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, New Zealand, Mexico, Canada, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01541670"
    },
    {
        "Title": "Study of Leukocyte Populations in Patients With Chronic Inflammatory",
        "Summary": " exploration pathophysiological mechanisms chronic inflammatory rheumatism rare systemic autoimmune diseases objective identifying therapeutic targets.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Autoimmune Disease, Chronic Inflammatory Rheumatism, Sjogren's Syndrome, Spondyloarthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04749875"
    },
    {
        "Title": "A Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of AMG 557 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "In the study approximately 56 subjects were enrolled. multicenter randomized sequential rising study. Study enrolled 7 dosing cohorts.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02391259"
    },
    {
        "Title": "Evaluation of Belimumab Impact on a BLyS Activity Signature Test in the Absence of Confounding Polypharmacy",
        "Summary": "Open label trial belimumab at least 20 subjects test feasibility. Single agent capitalize simplified background treatment regimens determine immunologic differences.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02270970"
    },
    {
        "Title": "Effectiveness of Belimumab Treatment in a Subpopulation of Systemic Lupus Erythematosus (SLE) Patients: a Pooled Analysis of BLISS-52 and BLISS-76",
        "Summary": "Belimumab registration studies aka. bel110752 aka bel110751 analysis agreed prior unblinding either study primary objective evaluate impact belimumab treatment severe subpopulation systemic lupus erythematosus sle subjects aid physicians",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01914770"
    },
    {
        "Title": "Vaccination Perception in Inflammatory Conditions - Flu, Pneumonia and COVID-19",
        "Summary": "Pneumonia seasonal flu vaccines recommended also prioritised receive vaccines. Early national rollout however uptake pneumonia seasonalflu vaccines among group lower ideal may many reasons seek vaccinated infections belief may cause disease flare.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Inflammatory Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis, Vasculitis, Reactive Arthritis, Inflammatory Bowel Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT05115370"
    },
    {
        "Title": "A Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluate safety efficacy combination standard care therapy. Participants moderate severe active systemic lupus erythematosus slem.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Germany, Taiwan, Brazil, Spain, Chile, Colombia, Korea, Republic of, Mexico, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02908100"
    },
    {
        "Title": "Prevalence and Seroconversion of COVID-19 in Autoimmune Diseases in Europe",
        "Summary": "Pandemic potentially fatal disease represents great global public health concern european countries spain italy germany portugal england france pandemic utmost importance date treatment robustly validated. coronavirus disease 2019 pandemic potentially",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "COVID-19, Systemic Lupus Erythematosus, Sjogren's Syndrome, Axial Spondyloarthritis, Rheumatoid Arthritis, Giant Cell Arteritis",
        "Phases": "N/A",
        "IDestudio": "NCT04397237"
    },
    {
        "Title": "Skin Denervation in Systemic Lupus Erythematosus",
        "Summary": " address issues skin denervation clinical pathological correlations systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00155532"
    },
    {
        "Title": "Intervention to Improve Communication and Medication Adherence in Lupus",
        "Summary": " intervention improve communication medication adherence among patients systemic lupus erythematosus sle purpose study optimize culturally appropriate delivery test effect.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06458075"
    },
    {
        "Title": "The Effect of Vitamin D Supplementation on Disease Activity Markers in Systemic Lupus Erythematosus (SLE)",
        "Summary": "Systemic lupus erythematosus sle chronic inflammatory autoimmune disease vitamin potent immunomodulatory properties promoted potential use treatment autoimmune conditions. 248 sle patients enrolled randomized study patients randomized receive either oral cholecalciferol",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01425775"
    },
    {
        "Title": "Study of Subcutaneous (SC) Belimumab in Pediatric Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "The study evaluated pharmacokinetics, safety, pharmacodynamics and repeat doses of 200 milligrams per milliliter belimumab administered via sc injection. The study was conducted over 68 weeks including open label treatment phase.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Germany, Argentina, Spain, Netherlands, Mexico, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04179032"
    },
    {
        "Title": "Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis",
        "Summary": "Mycophenolate mofetil cellcept safe effective lupus arthritis study patients. Patients randomly assigned to receive mycopenolate or placebo inert pills. 24 patients completed first three months protocol.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Arthritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00594932"
    },
    {
        "Title": "Mon\u0131tor\u0131ng Glucocort\u0131co\u0131d Treatment In Pat\u0131ents Followed In Rheumatology Cl\u0131n\u0131c",
        "Summary": " clinical pharmacist multidisciplinary team patients using glucocorticoids problems patients detected prevented aim study evaluate glucocortsicoid treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Turkey",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Glucocorticoids Toxicity, Rheumatoid Arthritis, Vasculitis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05292456"
    },
    {
        "Title": "Study to Assess Demographic, Pharmacologic, Biomarker, Clinical Features and Quality of Life (QoL) of Participants With Lupus Nephritis",
        "Summary": " multicenter prospective study assess clinical characteristics demographics treatment quality. life hrqol lupus nephritis ln participants across 5 gulf countries united arab emirates uae qatar bahrain kuwait oman",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Arab Emirates",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04971590"
    },
    {
        "Title": "Physical Activity in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study was a randomized controlled blinded trial. 63 patients aged diagnosis systemic lupus erythematosus sle according criteria college american rheumatology 1997 randomization patients allocated 3 groups control group.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00985803"
    },
    {
        "Title": "A Study of AMG 557 in Adults With Systemic Lupus Erythematosus",
        "Summary": "There were 557 adults with systemic lupus erythematosus who took part in the study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00774943"
    },
    {
        "Title": "Study of AC0058TA in Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": " phase 1b double blind randomized study safety tolerability pharmacokinetics pharmacodynamics ac0058ta patients systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03878303"
    },
    {
        "Title": "(Anti-Ribosomal P Protein,Anti-U1 RNP, Anti-Nucleosome and Anti-ds DNA Antibodies) and Relation to Depression and Anxiety in SLE",
        "Summary": "Study determine relation degree depression anxiety systemic lupus erythematosus patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06255743"
    },
    {
        "Title": "Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects",
        "Summary": "Study extension study continue assess safety tolerability epratuzumab moderate severe sle subjects previously participated sl0026 nct01449071 phase trial.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01534403"
    },
    {
        "Title": "Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus",
        "Summary": "Upadacitinib approved drug rheumatoid arthritis psoriatic arthritis axial spondylarthritis developed treatment sle study means neither trial participants study doctors know given upadac itinib given placebo contain treatment drug",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Latvia, Switzerland, Australia, United States, Serbia, Bosnia and Herzegovina, Greece, Spain, China, Italy, Korea, Republic of, Poland, United Kingdom, Puerto Rico, Belgium, Romania, Bulgaria, South Africa, Turkey, France, Lithuania, Canada, Portugal, Taiwan, Japan, Germany, Estonia, Slovakia, Brazil, Israel, Croatia, New Zealand, Chile, Colombia, Hungary, Guatemala",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05843643"
    },
    {
        "Title": "CD19/BCMA HLA-independent TCR-T Cell Therapy for Refractory/Moderate-to-severe Systemic Lupus Erythematosus",
        "Summary": " purpose study explore safety efficacy cluster differentiation 19 cd19 cell maturation antigen bcma human leukocyte antigen hla cell receptor tcr therapy systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06349343"
    },
    {
        "Title": "BAFF and APRIL and RESPONSE TO BELIMUMAB in SLE",
        "Summary": " project intended to identify routes to belimumab treatment among patients diagnosed with cancer. Act order also intended to detect possible future candidates for beliumab treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, BAFF Polymorphism",
        "Phases": "N/A",
        "IDestudio": "NCT03919643"
    },
    {
        "Title": "A Study of RJMty19 in Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "Allogeneic cells rjmty19 infusion preliminary efficacy systemic lupus erythematosus sle subjects. study dose escalation dose expansion study evaluate safety maximum tolerated dose pharmacokinetic characteristics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06340490"
    },
    {
        "Title": "Safety, Tolerability, and Pharmacokinetics of Single Doses of HC022 in Healthy Subjects.",
        "Summary": "Primary objective phase ia study evaluate safety tolerability subcutaneous sc doses. Secondary objectives study follows estimate pk parameters sc doses hc022 healthy evaluate immunogenicity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06657703"
    },
    {
        "Title": "Assessment of Lipid Profile in Juvenile Systemic Lupus Erythematosus",
        "Summary": " determine pattern frequency dyslipoproteinemia patients newly diagnosed juvenile sle assess effect disease activity lipid profile patients juvenile sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06151990"
    },
    {
        "Title": "A Study of the Effect of XmAb\u00ae5871 in Patients With Systemic Lupus Erythematosus",
        "Summary": " purpose study determine ability xmab5871 maintain systemic lupus erythematosus sle disease activity improvement. achieved brief course steroid therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02725515"
    },
    {
        "Title": "Laser Therapy for Patients With Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune disease detrimental effects connective tissue organs musculoskeletal system one affected systems group. temporomandibular joint common symptoms muscle involvement sle muscle atrophy decreased muscle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Muscle Pain, Chewing Function",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04453215"
    },
    {
        "Title": "A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)",
        "Summary": "Belimumab participants autoantibody positive early sle ongoing disease activity despite stable initial sle therapy. prospective single arm clinical study describe efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Germany, Argentina, France, Brazil, Greece, Spain, Mexico, Italy, Portugal, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT06411249"
    },
    {
        "Title": "Type 1 Interferon Induced Changes to Exercise Adaptations in Systemic Lupus Erythematosus Patients",
        "Summary": "55 patients included investigator blinded randomised high intensity aerobic exercise intervention study. Investigators hypothesize pathogenic blockage signalling occurs sle decrease cardiac metabolic adaptations.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Denmark",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Interferon Deficiency",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05478018"
    },
    {
        "Title": "A Study of Belimumab Administered Subcutaneously in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Belimumab administered subcutaneously sc adult subjects systemic lupus erythematosus sle. purpose study evaluate efficacy safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Sweden, United States, Serbia, Thailand, Spain, Ukraine, Russian Federation, Denmark, Italy, Poland, United Kingdom, Belgium, Romania, Bulgaria, Philippines, France, Portugal, Taiwan, Czechia, Japan, Argentina, Germany, Brazil, Croatia, Chile, Colombia, Hungary, Mexico, Singapore, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01484496"
    },
    {
        "Title": "Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST)",
        "Summary": "Lupus erythematosus also known as lupus sle chronic multisystem autoimmune disease body internal system defense attacks normal tissues abnormal autoimmune response result damage many parts body especially skin joints lungs heart brain intestines kidneys.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00230035"
    },
    {
        "Title": "Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
        "Summary": " randomized phase 2 study purpose study initially evaluate safety efficacy. sm934 combined steroids compared placebo adult subjects. active systemic lupus erythematosus sle period period.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03951259"
    },
    {
        "Title": "Pilot Study of Cyclophosphamide in Patients With Life-Threatening Systemic Lupus Erythematosus or Antiphospholipid Antibody Syndrome",
        "Summary": "Systemic lupus erythematosus antiphospholipid antibody syndrome treated cyclophosphamide ii determine toxicity drug patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00010400"
    },
    {
        "Title": "Belimumab Treatment Holiday and Treatment Re-start Study in Lupus Patients",
        "Summary": "Study assess effect withdrawal followed reintroduction belimumab 10 plus standard care medications. Subjects stable low systemic lupus erythematosus sle disease activity rebound phenomenon assessed. Subjects permanently withdrawn belimumdrug treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of, Japan, China, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02119156"
    },
    {
        "Title": "Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "A single-arm, open-label study was conducted to evaluate changes in disease activity biomarkers. The study was designed to examine changes in the skin mouth joints of patients with mild active disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Denmark, Sweden",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00997100"
    },
    {
        "Title": "BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid Arthritis",
        "Summary": "Belimumab rituximab main treatments sle Ra patients respectively detail study aims evaluate condition carrier sle ra patients treated respectively belimumab plus standard care ritUXimab influences immunological molecular clinical variables soluble baff baffs cytok",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Rheumatoid Arthritis, BLyS Polymorphism",
        "Phases": "N/A",
        "IDestudio": "NCT05659407"
    },
    {
        "Title": "PROM Collected Via a WebApp Versus a Touch Screen Solution Among Patients With SLE",
        "Summary": "The trial involved 34 patients with systemic lupus erythematosus. It was conducted via an online webapp and via an outpatient touchscreen.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Denmark",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04411407"
    },
    {
        "Title": "Study of Epratuzumab in Systemic Lupus Erythematosus",
        "Summary": " epratuzumab is an investigational antibody designed help treat sle purpose evaluate safety long term efficacy concert standard sle treatments.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Germany, Czech Republic, France, Slovakia, Brazil, Spain, Netherlands, Hungary, Canada, Italy, United States, United Kingdom",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00382837"
    },
    {
        "Title": "Prediction of Outcome of Lupus Nephritis",
        "Summary": "Lupus erythematosus lupus nephritis may also role predicting disease progression. Antibody patterns may contribute targeted personalized treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02403115"
    },
    {
        "Title": "ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE)",
        "Summary": "Human recombinant interleukin 2 patients moderate severe systemic lupus erythematosus. purpose study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Austria, Germany, Bulgaria, France, Mauritius, Spain, Mexico, Italy, Portugal",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02955615"
    },
    {
        "Title": "Study of Individualized Instruction Versus Pamphlet in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle ii. objectives evaluate educational program pretested cultural appropriateness literacy requirements patients systemic lupus. sle ii assess impact educational program.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00004756"
    },
    {
        "Title": "An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184",
        "Summary": "Gsk2586184 study 3 interim analyses conducted monitor pharmacodynamic effect safety following 2 weeks therapy. 3 subjects meet entry criteria approximately 150 250 randomized ratio receive placebo. 50 milligram mg twice daily 100 mg 200 mg 400 mg placebo",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Romania, Argentina, Germany, South Africa, France, Estonia, Greece, Spain, Chile, Hong Kong, Hungary, Korea, Republic of, Peru, Poland, Sweden",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01777256"
    },
    {
        "Title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 811 in Subjects With Systemic Lupus Erythematosus",
        "Summary": " multicenter study evaluate administration placebo amg 811 single subcutaneous intravenous dose subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02291588"
    },
    {
        "Title": "Assessment of Physician Consideration of ePRO's, From Patients With Gout, Rheumatoid Arthritis, Sjogren's Syndrome or Systemic Lupus, on the Frequency of Therapeutic Adjustments",
        "Summary": " inflammatory rheumatic diseases affect 1 population treatment diseases based disease activity safety issues patient characteristics comorbidities eular 2022 leading higher risk cardiovascular diseases end general approach recommended.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Gout, Rheumatoid Arthritis, Sjogren's Syndrome, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05927688"
    },
    {
        "Title": "Immunogenicity and Safety of HPV Vaccine Gardasil in Young Women",
        "Summary": " purpose study evaluate immunogenicity safety hpv vaccine. vaccine gardasil young women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00786409"
    },
    {
        "Title": "A Study of CM313 Injection in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Study cm313 subjects systemic lupus erythematosus. Study was published in the Journal of Clinical Oncology.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05465707"
    },
    {
        "Title": "A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus",
        "Summary": "Study evaluate pharmacokinetic characteristics safety belimumab subcutaneous sc chinese pediatric participants sle completed 48 weeks. Study nct04908865.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05917288"
    },
    {
        "Title": "Effectiveness Study of Psychotherapy in Systemic Lupus Erythematosus",
        "Summary": " psychosomatic new approach understanding phenomena somatization using knowledge medicine psychology treat human brief group psychanalytic psychotherapy. sle hypothesis study bgpp beside clinical treatment improve quality life coping sle patients aim study evaluate effectiveness.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01840709"
    },
    {
        "Title": "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Baricitinib is a treatment for systemic lupus erythematosus sle completed final treatment visit study nct03616912.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Switzerland, Australia, United States, Serbia, Greece, Spain, Russian Federation, China, Italy, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Philippines, South Africa, France, India, Netherlands, Taiwan, Czechia, Japan, Argentina, Germany, Brazil, Israel, Croatia, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03843125"
    },
    {
        "Title": "Recombinant Zoster Vaccine in Stable SLE Patients",
        "Summary": " risk herpers zoster reactivation higher sle patients general population shown mild even inactive patients could also varicella zoster virus vzv infections account events previous study indicated recent various vzV infection associated increased risk disease flares.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Herpes Zoster, Recombinant Zoster Vaccine, Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04516408"
    },
    {
        "Title": "Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases",
        "Summary": " objectives determine whether prompt engraftment autologous peripheral blood stem cell transplantation using filgrastim mobilization patients life threatening autoimmune diseases. determine kinetics immune reconstitution combination timed plasmapheresis high dose cyclophosph",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00006055"
    },
    {
        "Title": "Safety and Immunogenicity of a Zoster Vaccine in SLE",
        "Summary": "Study finds no evidence that herpes zoster vaccine patients are more likely to develop the disease. Study also found no evidence of a link between the vaccine and herpes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02477150"
    },
    {
        "Title": "Covid-19 in Lupus Patients",
        "Summary": " hydroxychlorquine currently tested several clinical trials evaluate objective study evaluate symptoms related occuring patients systemic lupus erythematosus slem.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Covid-19",
        "Phases": "N/A",
        "IDestudio": "NCT04355702"
    },
    {
        "Title": "The Effectiveness of Walking in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study ought to clarify effectiveness of walking intervention patients. Study should provide reference future nursing strategies to improve disease adaptability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04983784"
    },
    {
        "Title": "Evaluation Of Serum MIF Level in SLE Patients",
        "Summary": "Systemic lupus erythematosis sle chronic autoimmune disease characterized production autoantibodies deposition immune complexes affecting wide range organs clinical onset sle derives interaction genetic predisposition environmental immunological hormonal factors strong predilection women childbearing",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05253638"
    },
    {
        "Title": "Predictors of Mortality in Patients With Autoimmune Diseases Admitted to the Intensive Care Unit",
        "Summary": " autoimmune diseases systemic lupus erythematosus rheumatoid arthritis myositis cytoplasmic antibody anca vasculitis may affect multiple organ systems occasionally patients deteriorate acutely requiring advanced care intensive care unit",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Vasculitis, Systemic Lupus Erythematosus, Myositis",
        "Phases": "N/A",
        "IDestudio": "NCT04022655"
    },
    {
        "Title": "Aspirin Resistance in Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study examine whether patients lupus respond to aspirin related inflammation. Study examine ability aspirin inhibit production thromboxane.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00731302"
    },
    {
        "Title": "The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata",
        "Summary": " study series consists four related studies aims explore describe many important elements alopecia areata. Three key areas are current epidemiology, autoimmune atopic conditions, and common infections.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Alopecia Areata, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorders, Atopic Dermatitis, Allergic Rhinitis, Asthma, Crohn Disease, Ulcerative Colitis, Pernicious Anemia, Type 1 Diabetes, Hashimoto Thyroiditis, Graves Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus, Polymyalgia Rheumatica, Sjogren's Syndrome, Psoriasis, Vitiligo, Multiple Sclerosis, Celiac Disease, Upper Respiratory Tract Infection, Influenza, Lower Resp Tract Infection, Acute Bronchitis, Pneumonia, Gastrointestinal Infection, Skin Infection, Urinary Tract Infections, Genital Infection, Herpes Zoster, Herpes Simplex, Infection, Infection Viral",
        "Phases": "N/A",
        "IDestudio": "NCT04239521"
    },
    {
        "Title": "Utilizing Qualitative and Quantitative Methods to Understand a New Model of Type 1 and 2 Systemic Lupus Erythematosus (SLE)",
        "Summary": "Lupus erythematosus record represents aim 3 study. purpose study pilot test sle duke set tools implement type 1 2 sle model clinical setting well gain understanding providers experiences using intervention clinic visits patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05426902"
    },
    {
        "Title": "Neuron-specific Humoral and Cellular Immune Correlates of Structural and Functional Brain Connectomics in Neuropsychiatric Lupus",
        "Summary": " systemic lupus erythematosus sle prototype systemic autoimmune disease neuropsychiatric sle npsle major cause morbidity pathophysiology remains unclear target autoantigens yet identified specific autoantigen expression might correlate imaging abnormalities",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05880121"
    },
    {
        "Title": "Effect of Pioglitazone on Endothelial Function in Premenopausal Women With Uncomplicated Systemic Lupus Erythematosus",
        "Summary": "Study aims to investigate effect pioglitazone 30 on endothelial function premenopausal women and patients with systemic lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01322308"
    },
    {
        "Title": "Study of M5049 in CLE and SLE Participants",
        "Summary": "Study evaluate safety tolerability pharmacokinetics pk orally administered m5049 participants. systemic lupus erythematosus sle cutaneous luposus cle cle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Germany, Spain, Ukraine, North Macedonia, Moldova, Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04647708"
    },
    {
        "Title": "Maternal Autoimmune Disease Research Alliance (MADRA) Registry",
        "Summary": " registry centered duke university enroll pregnant women autoimmune rheumatologic diseases main goal madra identify ways improve health women rheumatic diseases babies.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Autoimmune Diseases, Pregnancy Related, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma",
        "Phases": "N/A",
        "IDestudio": "NCT03276923"
    },
    {
        "Title": "Prospective Evaluation of Decision and Compliance With Antimalarials in Patients With Systemic Lupus",
        "Summary": "Study evaluated non compliance antimalarials patients systemic lupus nord region france conducted two visits.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02364908"
    },
    {
        "Title": "Role of Antibodies in Cognitive Dysfunction in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study examine possible relationship certain antibodies found patients systemic lupus erythematosus sle cognitive thought processing impairment. antibodies targeting brain may cause cognitive dysfunction many patients sle mild severe cognitive impairment involving example memory thought processing relating objects.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00042523"
    },
    {
        "Title": "Relma-cel for Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle subjects china. assess safety tolerability pharmacokinetics pharmacodynamics moderate severe active systemic lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06297408"
    },
    {
        "Title": "Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus",
        "Summary": "Study evaluate treatment 10 participants systemic lupus erythematosus sle history cutaneous lupsus tofacitinib.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Cutaneous Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05048238"
    },
    {
        "Title": "Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease",
        "Summary": " purpose study determine whether ljp 394 abetimus sodium safe effective delaying reducing renal flares patients lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Germany, France, Spain, Mexico, Canada, Italy, Sweden, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00035308"
    },
    {
        "Title": "Glucocorticoids Withdrawal in Early Systemic Lupus Erythematosus",
        "Summary": "36 months randomized equivalence multicenter trial patients inactive systemic lupus erythematosus evaluate low disease activity sustained withdrawal glucocorticoids.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Glucocorticoids, Therapy Withdrawal",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03804723"
    },
    {
        "Title": "The Predictive and Prognostic Values of the Fibrinogen to Albumin Ratio and C-reactive Protien to Albumin Ratio in Systemic Lupus Erythematosus Patients",
        "Summary": "Study aims to provide new predictive biomarkers disease activity prognosis. aim study study study predictive value far far car order provide new Predictive biomarkers.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06404723"
    },
    {
        "Title": "Humanized LL2IGG to Treat Systemic Lupus Erythematosus",
        "Summary": "Study examine safety new genetically engineered antibody called hll2 epratuzumab patients systemic lupus erythematosus sle. Study also evaluate whether hll 2 lessen overall disease activity sle kidney damage patients lup",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00011908"
    },
    {
        "Title": "Highly Sensitive Serum Cardiac Troponin T and Cardiovascular Events in Patients With Systemic Lupus Erythematosus",
        "Summary": " identification biological markers able better stratify cardiovascular risks systemic lupus erythematosus patients needed aimed determine whether serum cardiac troponin levels measured highly sensitive assay may predict cardiovascular events.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04580108"
    },
    {
        "Title": "A Study to Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN)",
        "Summary": " ocrelizumab compared placebo combined single stable background immunosuppressive medication corticosteroid regimen. patients moderately severely active systemic lupus erythematosus moderate severe glomerulonephritis. phase",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00539838"
    },
    {
        "Title": "Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)",
        "Summary": "i chemoimmunotherapy followed allogeneic stem cell transplantation. Allosct matched family donors matched unrelated cord blood donors well tolerated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00684255"
    },
    {
        "Title": "On Open-Label Study in Participants With Systemic Lupus Erythematosus",
        "Summary": " ly2127399 eligible sle participants completed core studies. purpose sle study evaluate safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01488708"
    },
    {
        "Title": "Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.",
        "Summary": " purpose study assess safety tolerability pharmacokinetics pharmacodynamics japanese patients. purpose study assessed safety tolerable pharmacokinetic pharmacodynamics pharmacodynamics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01559090"
    },
    {
        "Title": "A Study of DS-7011a in Patients With Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle systemic chronic autoimmune disease characterized autoantibody production inflammation tissue damage multiple organs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05638802"
    },
    {
        "Title": "Insulin Resistance and Atherosclerosis in Women With Lupus",
        "Summary": "Study test effects insulin resistance atherosclerosis hardening arteries women systemic lupus erythematosus commonly known. Study consist series tests designed to assess whether association insulin resistance Atherosclerosis. Study participants undergo following procedures outpatient basis",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Insulin Resistance, Atherosclerosis",
        "Phases": "N/A",
        "IDestudio": "NCT00544102"
    },
    {
        "Title": "Immunogenicity and Safety of a Quadrivalent Human Papillomavirus (HPV) Vaccine in Patients With SLE: a Controlled Study",
        "Summary": "Human papillomavirus hpv vaccination elevation antibody titer 4 serotypes hpv patients systemic lupus erythematous compare antibody response equal number healthy women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00911521"
    },
    {
        "Title": "Phase IIb Study of IFN-K in Systemic Lupus Erythematosus",
        "Summary": "Preliminary results showed acceptable safety profile. Patients developped antibodies response. Study confirm neutralization interferon gene signature clinical efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland, United States, Thailand, Georgia, Russian Federation, Korea, Republic of, Italy, Poland, Tunisia, Belgium, Philippines, France, Peru, Taiwan, Argentina, Germany, Croatia, Colombia, Chile, Mexico, Moldova, Republic of",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02665364"
    },
    {
        "Title": "Retrospective Analysis of the Safety and Efficacy of Hydroxychloroquine in Immune Thrombocytopenia",
        "Summary": " hydroxychloroquine among patients immune thrombopenia itp. retrospective study safety efficacy hydroxy chloroquine.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Immune Thrombocytopenia, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01549184"
    },
    {
        "Title": "Progressive Resisted Exercise Plus Aerobic Exercise on Osteoporotic Systemic Lupus Erythmatosus",
        "Summary": "Systemic lupus erythematosus sle common autoimmune disease women childbearing age promoting physical activity major national priority.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05392790"
    },
    {
        "Title": "The Genital Tract Microflora in Women With Systemic Lupus Erythematosus (SLE) and Immunoglobulin A (IgA) Nephropathy.",
        "Summary": "Study hypothesis systemic lupus erythematosus sle chronic autoimmune disease broad spectrum clinical manifestations mechanisms well understood known development influenced genetic factors gender however believed patients specific genetic predisposition certain environmental factors chemicals including drugs toxins smoking infections may initiate",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Poland",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Immunoglobulin A Nephropathy",
        "Phases": "N/A",
        "IDestudio": "NCT05132621"
    },
    {
        "Title": "Individual Patient Exposure and Response in Pediatric Lupus",
        "Summary": "Electronic pill bottle cap help children teens systemic lupus better remember take medicine also gather information best dose hydroxychloroquine children teens. 6 months nurse visit participant 4 times ask questions symptoms draw blood take urine sample.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04358302"
    },
    {
        "Title": "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE-BRAVE II)",
        "Summary": "Study finds baricitinib is effective safe study drug for systemic lupus erythematosus slei.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Romania, Argentina, Philippines, South Africa, France, Spain, India, Colombia, Chile, Korea, Republic of, Italy, Poland, United States, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03616964"
    },
    {
        "Title": "Regulatory BCells in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus archetypal multisystem autoimmune disease presents many diagnostic management challenges one challenge is excess cardiovascular disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03178721"
    },
    {
        "Title": "Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus",
        "Summary": "Study aims investigate feasibility effectiveness remotely delivered psychological intervention. Youth csle intervention aims teach participants skills order cope fatigue pain depressive symptoms symptoms commonly affect adolescents.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04335643"
    },
    {
        "Title": "Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects",
        "Summary": "Study extension study continue assess safety tolerability epratuzumab moderate severe sle subjects previously participated sl0026 nct01449071 phase trial.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01534403"
    },
    {
        "Title": "Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients",
        "Summary": " study evaluate explore efficacy subjects systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02307643"
    },
    {
        "Title": "Low-dose IL-2( Interleukin-2) Treatment in SLE",
        "Summary": " clinical study test efficacy safety low dose treatment systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02084238"
    },
    {
        "Title": "Multicomponent Strategy to Implement a Clinical Practice Guideline and Improve Health Outcomes in People With SLE",
        "Summary": " principal objective produce scientific knowledge effectiveness multicomponent intervention knowledge transfer implementing clinical practice guideline cpg systemic lupus erythematosus sle formed educative intervention computerized clinical decision support system sadc complemented automated feedback built electronic",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03537638"
    },
    {
        "Title": "Safety of IFNa Kinoid in Systemic Lupus Erythematosus",
        "Summary": "Interferon alpha ifna involved pathogenesis systemic lupus erythematosus sle ifna levels associated severity disease blocking ifna could attractive therapeutic strategy. active immunization ifna kinoid induces polyclonal antibody response",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Bulgaria, Germany, Switzerland, France, Croatia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01058343"
    },
    {
        "Title": "Implementing the Decision-Aid for Lupus (IDEAL Strategy)",
        "Summary": "Study attempt put practice shared decision making sDM strategy using individualized computerized aid da systemic lupus erythematosus sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03735238"
    },
    {
        "Title": "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus",
        "Summary": "The study evaluated efficacy safety tolerability two different doses ly2127399 administered addition standard care therapy participants active sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Latvia, Australia, United States, Serbia, Spain, Ecuador, Russian Federation, United Kingdom, Tunisia, Romania, South Africa, France, India, Canada, Taiwan, Brazil, Israel, New Zealand, Hungary, Mexico, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01205438"
    },
    {
        "Title": "An Investigation of NNC 0151-0000-0000 in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": " clinical trial conducted united states america usa aim clinical trial investigate safety tolerability pharmacokinetics signs bioactivity increasing repeated doses. nnc subjects systemic lupus erythematosus slea.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Inflammation, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01018238"
    },
    {
        "Title": "Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE)",
        "Summary": "Study finds best way prevent heart disease stroke people lupus. Study evaluate effectiveness medication education program controlling four risk factors.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00054938"
    },
    {
        "Title": "Efficacy and Safety of Low-dose IL-2 in Patients With SLE: a Multicenter, Randomised, Placebo-controlled Trial",
        "Summary": "Lupus erythematosus is a rare disease with a heterogeneous nature. It is caused by an unbalanced immune system. There are currently no effective treatments for the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04077684"
    },
    {
        "Title": "Memory and Attention Problems in Lupus: New Treatment Trial With Modafinil",
        "Summary": " modafinil currently used treat excessive sleepiness caused certain sleep disorders also shown improve attention concentration people lupus sleep disorders. Study hopes to determine whether drug can be used safely effectively.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00297284"
    },
    {
        "Title": "Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus",
        "Summary": "The U.S. government is funding a study of the effects of climate change on the Great Lakes region of New England. The study is the first of its kind.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05247203"
    },
    {
        "Title": "Allogeneic Stem Cell Transplantation in Systemic Lupus Erythematosus",
        "Summary": " trial designed evaluate safety treating systemic lupus erythematosus participants cyclophosphamide followed allogeneic stem cell transplant.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00278590"
    },
    {
        "Title": "Development and Evaluation of Modified Yoga in Systemic Lupus Erythematosus (SLE)",
        "Summary": " purpose study test effects modified yoga program persons. persons sle. purpose study tests effects modified Yoga program persons on their physical and mental health.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01176643"
    },
    {
        "Title": "Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study designed examine whether treating patients lupus high dose cyclophosphamide together drugs reduce function immune system followed return previously collected stem cells.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00278538"
    },
    {
        "Title": "A Study of Nipocalimab in Adult Participants With Active Systemic Lupus Erythematosus",
        "Summary": "Nipocalimab is a drug used to treat systemic lupus erythematosus sleus. The study was designed to evaluate the drug's efficacy against the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Bulgaria, Germany, Argentina, South Africa, Taiwan, Spain, Ukraine, Colombia, Hungary, Poland, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04882878"
    },
    {
        "Title": "Vitamin D and Curcumin Piperine Attenuates Disease Activity and Cytokine Levels in Systemic Lupus Erythematosus Patients",
        "Summary": "Almost 71 sle patients experience hypovitaminosis serum vitamin 25 levels less 30 several factors contribute low vitamin levels among sle patients less exposure sunlight insufficient vitamin intake contributes sle patients low Vitamin levels studies also revealed vitamin metabolism gene polymorphisms also associated patients",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05430087"
    },
    {
        "Title": "Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone",
        "Summary": " clinical research study learn whether abatacept treat prevent lupus flares specifically patients active lupUS flares. Study participants receive prednisone treatment combination study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Austria, Germany, South Africa, Taiwan, France, Brazil, Australia, Mexico, Canada, Italy, Korea, Republic of, United States, United Kingdom, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00119678"
    },
    {
        "Title": "Omega 3 in LES and APS",
        "Summary": " lupus erythematosus sle antiphospholipid antibody syndrome aas autoimmune diseases characterized chronic inflammatory state associated clinical symptoms. demonstrated epa dha supplementation may properties several chronic diseases namely diabetes obesity rhe",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Primary Antiphospholipid Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01956188"
    },
    {
        "Title": "Serum Levels of Angiotensin Converting Enzyme in Systemic Lupus Erythematous Patients",
        "Summary": "Systemic lupus erythematosus is a heterogeneous autoimmune disease involve many different organs. It has a striking striking female predominance.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05516511"
    },
    {
        "Title": "Study of GL701 in Men With Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle may caused deficiency dehydroepiandrosterone dhea. Gl701 is a new drug meant to enhance dhea levels.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00037128"
    },
    {
        "Title": "The Safety and Efficacy of Zishenqing in Subjects With Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluates safety efficacy traditional chinese medicine zishenqing treatment. Treatment active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT04275193"
    },
    {
        "Title": "FolateScan in Autoimmune Disease",
        "Summary": "Folatescan can detect inflammation joints organs people arthritis rheumatoid arthritis osteoarthritis systemic lupus erythematosus multiple sclerosis interstitial pneumonitis crohn disease well healthy persons without conditions.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Osteoarthritis, Multiple Sclerosis, Crohn's Disease, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00588393"
    },
    {
        "Title": "Objective Measurement Methods for Autoimmune Disease and Dry Eye Syndrome",
        "Summary": " explore association among tcm pattern tcm tongue diagnosis tcm pulse diagnosis autoimmune disease dry eye syndrome.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Sj\u00f6gren's Syndrome, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Systemic Sclerosis, Ankylosing Spondylitis, Dry Eye Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT03937271"
    },
    {
        "Title": "A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases (CALiPSO-1)",
        "Summary": " autoimmune diseases including moderate severe systemic lupus erythematosus sle lupUS nephritis ln idiopathic inflammatory myopathies iim diffuse cutaneous systemic sclerosis dcssc.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies, Diffuse Cutaneous Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06255028"
    },
    {
        "Title": "Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sj\u00f6gren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis",
        "Summary": "Branebrutinib treatment followed abatacept treatment study participants. purpose study evaluate safety effectiveness treatment. participants active systemic lupus erythematosus sle primary sj\u00f6gren syndrome.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Germany, Argentina, France, Spain, Netherlands, Mexico, Poland, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Autoimmune Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Primary Sj\u00f6gren's Syndrome",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04186871"
    },
    {
        "Title": "The Impact of Exercise on Hand Function, Daily Activities Performance and Quality of Life of SLE' Patients",
        "Summary": "240 consecutive sle patients fulfilling slicc classification criteria evaluated sixty two patients met inclusion criteria randomly assigned exercise group control group patients exercise group performed program strengthening stretching resistance upper limbs exercises 30 minutes duration daily 12 weeks performance daily activities evaluated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Greece",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Arthralgia",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03802578"
    },
    {
        "Title": "FT819 in Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": " phase 1 study designed evaluate safety pharmacokinetics pk activity ft819 following treatment without auxiliary medicinal product. Participants moderate severe active systemic lupus erythematosus sle study consist stage followed expansion stage evaluate safety activity ft",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06308978"
    },
    {
        "Title": "Magnetic Resonance Spectroscopy, Perfusion and Diffusion Tensor Imaging in Neuropsychiatric Lupus",
        "Summary": "Study find certain types magnetic resonance mr scanning help better detect markers brain related neuropsychiatric symptoms systemic lupus erythematosus sle small percentage patients experience symptoms may result blood clot.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Fibromyalgia, Acute Neuropsychiatric Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00723671"
    },
    {
        "Title": "Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE)",
        "Summary": "Epratuzumab is a drug that is being tested for its safety and effectiveness in Japan. It is being trialled in patients with severe severe general pain.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01449071"
    },
    {
        "Title": "Safety of the Herpes Zoster Subunit Vaccine in Lupus",
        "Summary": " randomized crossover study evaluate herpes zoster sunbit vaccine sle patients order evaluate safety immunogenicity patients variable baseline clinical activities ages immunosuppressant exposures.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05559671"
    },
    {
        "Title": "Exploratory Study of DHA in Systemic Lupus Erythematosus Patients",
        "Summary": "Primary objective study assess efficacy dha patients sle. secondary objective study assessed efficacy of dha treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03396393"
    },
    {
        "Title": "A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Moderate to Severe Systemic Lupus Erythematosus",
        "Summary": " goal clinical trial assess safety tolerability profile belantamab study also assess levels. participants moderate severe systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06413511"
    },
    {
        "Title": "The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies",
        "Summary": "Study could eventually lead to choice weighting first trimester clinical factors. Study could lead to clinical prediction models.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Pregnancy Complications",
        "Phases": "N/A",
        "IDestudio": "NCT03746028"
    },
    {
        "Title": "GL701 (Prestara\u2122) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids",
        "Summary": "Open label vs. open label safety efficacy is a debate over the effectiveness of drugs on the human body. The debate centers on the safety and efficacy of drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00082511"
    },
    {
        "Title": "A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis",
        "Summary": " sifalimumab adult participants active systemic lupus erythematosus sle active dermatomyositis dm polymyositis pm participated following clinical studies. objective study assess safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Chile, Brazil, Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00979654"
    },
    {
        "Title": "Vitamin D Therapy in Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Vitamin could be used to treat systemic lupus erythematosus, study finds.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00418587"
    },
    {
        "Title": "A Phase 2a Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases",
        "Summary": "Main objective assess safety tolerability inebilizumab subprotocol subcutaneous sc. Adult participants active refractory systemic lupus erythematosus sle nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06570798"
    },
    {
        "Title": "Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)",
        "Summary": "Biib059 litifilimab reducing disease activity was used to evaluate the efficacy of biib059. The study included participants with systemic lupus erythematosus sle and subacute cutaneous lupsus",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Philippines, Taiwan, Israel, Colombia, Mexico, Korea, Republic of, Thailand, Poland, United States, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Active Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02847598"
    },
    {
        "Title": "REACT-01: Reversing Autoimmunity Through Cell Therapy",
        "Summary": " phase 1 study enrolling pediatric young adult research participants systemic lupus erythematosus sle examine safety feasibility efficacy administering cell products derived peripheral blood mononuclear cells pbmc genetically modified express cd19 specific chimeric antigen",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06465147"
    },
    {
        "Title": "Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases",
        "Summary": " autoimmune diseases present special challenge clinicians aim protocol serve effort patients unmanageable disease primary purpose study assess feasibility terms toxicity engraftment less toxic nonablative conditioning regimen moderate dose fludarabine cyclophosphamide patients severe autoimmune diseases",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00849745"
    },
    {
        "Title": "A Phase 2B Open-Label, Single-Arm, Repeat-Dose Study to Evaluate the Reliability of an Autoinjector",
        "Summary": " belimumab administered subcutaneously sc via autoinjector device. 8 weekly doses subjects return visit 4 weeks last sc dose. 118 subjects treated at least one dose.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02124798"
    },
    {
        "Title": "Walk With Ease Program For Patients With Systemic Lupus Erythematosus",
        "Summary": "Walk ease workbook book provides guidance walking safety well start maintain walking program participants complete questionnaires assessing symptoms completing program. purpose study evaluate effects walk ease exercise program.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02631005"
    },
    {
        "Title": "RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus",
        "Summary": " phase study evaluate safety efficacy subjects active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06121297"
    },
    {
        "Title": "The Reduction of Systemic Lupus Erythematosus Flares :Study PLUS",
        "Summary": "Main objective study is to determine potential benefits of individualized hcq dosing schedules aimed at maintaining hCq concentration 1000.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00413361"
    },
    {
        "Title": "Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients",
        "Summary": "Study exploring efficacy safety cs20at04 matched allogenic bone stem cells two subpopulation group systemic lupus erythematosus patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04835883"
    },
    {
        "Title": "Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Diseases.",
        "Summary": "Human papilloma virus hpv cause anogenital warts high risk types strongly related cervical abnormalities cervical cancer hpv vaccines developed prevent conditions human papillomavirus hpv infections prevalent systemic lupus erythematos",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Idiopathic Juvenile Arthritis, Human Papilloma Virus",
        "Phases": "N/A",
        "IDestudio": "NCT04180228"
    },
    {
        "Title": "Early Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases",
        "Summary": "Main purpose evaluate safety. Second purpose evaluate pharmacokinetic pk profile. Third purpose evaluate immunogenicity. Fourth purpose evaluate initial efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, IgG4 Related Disease, Primary Sj\u00f6gren Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06361745"
    },
    {
        "Title": "Assessment of Anxiety, Depression, Sleep Quality and Quality of Life in Systemic Lupus Erythematosus Patients",
        "Summary": "Study asses anxiety sleep depression quality life systemic lupus erythematosus. goal case control observational study.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05971498"
    },
    {
        "Title": "A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Lupus erythematosus slew is a disease that affects the central nervous system. The disease is thought to be linked to an increased risk of death from heart disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT04305197"
    },
    {
        "Title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus",
        "Summary": "Study evaluate safety tolerability pharmacokinetics pharmacodynamics mosunetuzumab participants systemic lupus erythematosus slei.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Moldova, Republic of, Poland, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05155345"
    },
    {
        "Title": "COVID-19 Infection in Vulnerable Patients With Inflammatory Rheumatic Diseases",
        "Summary": "Study aims to identify risk factors serious infection evaluating clinical measures biomarkers inflammation patients inflammatory rheumatic disease hospitalized compared control groups.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Denmark",
        "OverallStatus": "TERMINATED",
        "Conditions": "Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Systemic Lupus Erythematosus, Giant Cell Arteritis",
        "Phases": "N/A",
        "IDestudio": "NCT04335747"
    },
    {
        "Title": "At the Heart of the Matter - Speckle Tracking Echocardiography in Lupus Mothers and Their Offspring",
        "Summary": "Women systemic lupus erythematosus sle high risk complications lead substantial cardiac morbidities affected women offspring. maternal autoantibodies actively transferred across placenta pregnancy affect cardiovascular health. hydroxychloroquine hc",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Placenta-mediated Pregnancy Complications, Hydroxychloroquine, Speckle Tracking Echocardiography, Cardiovascular Morbidity, Cardiovascular Diseases, Cardiovascular Complication, Pregnancy Complications",
        "Phases": "N/A",
        "IDestudio": "NCT05451277"
    },
    {
        "Title": "Belimumab Assessment of Safety in SLE",
        "Summary": "Belimumab given lupus medicines enhances existing knowledge regarding side effects. Study done to help understand treatment belimumab increases risk types events.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland, Australia, United States, Serbia, Thailand, Indonesia, Spain, Ukraine, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, Romania, Bulgaria, Philippines, Lithuania, Canada, Portugal, Peru, Taiwan, Czechia, Argentina, Estonia, Slovakia, Brazil, Croatia, New Zealand, Chile, Colombia, Hungary, Mexico, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01705977"
    },
    {
        "Title": "A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)",
        "Summary": " deucravacitinib compared placebo active moderate severe systemic lupus erythematosus sle population. purpose study evaluate effectiveness safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Hong Kong, China, Italy, Korea, Republic of, Poland, Puerto Rico, Romania, Bulgaria, Turkey, France, India, Lithuania, Ireland, Canada, Portugal, Peru, Argentina, Germany, Slovakia, Brazil, Colombia, Mexico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05617677"
    },
    {
        "Title": "GSK1550188 A 52 Week Study of Belimumab Versus Placebo in the Treatment of Subjects With Systemic Lupus Erythematosus (SLE) Located in Northeast Asia",
        "Summary": "Belimumab addition standard therapy compared placebo subjects northeast asia systemic lupus erythematosus sle 52 week period. purpose study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of, Japan, China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01345253"
    },
    {
        "Title": "A Study in Participants With Mild-to-moderate Systemic Lupus Erythematosus",
        "Summary": "Main purpose study evaluate safety tolerability cug252 following multiple ascending doses. Participants systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, SLE (Systemic Lupus), Autoimmune",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05866861"
    },
    {
        "Title": "Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus",
        "Summary": " trial aimed assessing safety efficacy cells treatment refractory systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, CAR-T Cell Therapy",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06222853"
    },
    {
        "Title": "Estrogen and Gender Biased Autoimmunity",
        "Summary": "Study involves research investigate estrogen affects women childbearing age correlation systemic lupus erythematosus findings. Study might help determine body cells called cells react estrogen.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00519454"
    },
    {
        "Title": "An Open Label Study to Evaluate Daratumumab in Participants With Moderate to Severe Systemic Lupus Erythematosus",
        "Summary": "Daratumumab is an anti- immunosuppressive drug. It is being tested on patients with refractory immune disorders.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04810754"
    },
    {
        "Title": "An Open Labeled Pilot Study of Atorvastatin in Systemic Lupus Erythematosus",
        "Summary": "The study will determine whether atorvastatin 40mg per day effective treatment. The aim of the study is to find out if the drug is effective.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00432354"
    },
    {
        "Title": "The CARRA Registry",
        "Summary": " carra registry study create foundational database rheumatic diseases childhood using novel informatics infrastructure developed as part of larger clinical project. In-house\u00a0informatics infrastructure enable efficient observational data capture across carra sites.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus, Mixed Connective Tissue Disease, Juvenile Ankylosing Spondylitis, Juvenile Dermatomyositis, Localized Scleroderma, Systemic Sclerosis, Vasculitis, Sarcoid, Fibromyalgia, Primary, Auto-inflammatory Disease, Idiopathic Uveitis Idiopathic",
        "Phases": "N/A",
        "IDestudio": "NCT01697254"
    },
    {
        "Title": "The HOP-STEP Intervention: Improving Maternal Health in Women With Lupus sIRB",
        "Summary": "University chicago medical center pilot program demonstrated effective improving provider confidence increasing contraception documentation facilitating equitable pregnancy planning care single clinic duke delivery may need changed increase fit local context.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Contraception",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05818254"
    },
    {
        "Title": "The Effectiveness of Transcranial Direct Current Stimulation as Adjunctive Treatment for Chronic Daily Headache in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is the most common cause of headaches in the U.S. Use of analgesics to treat headaches has been shown to be effective.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Chronic Headache",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05613582"
    },
    {
        "Title": "CHABLIS-SC2: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis",
        "Summary": "Blisibimod measured composite responder index subjects despite corticosteroid use. Autoantibody positive systemic lupus erythematosus sle defined selena sledai score.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02074020"
    },
    {
        "Title": "Efficacy and Tolerance of Abacavir/Lamivudine Treatment in Patients With Systemic Lupus Erythematosus",
        "Summary": " systemic lupus sl rare chronic autoimmune disease characterized production autoantibodies directed nuclear antigens particularly native deoxyribonucleic acid dna excessive production antiviral cytokines type interferons particularly interferon alpha production",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06356740"
    },
    {
        "Title": "Phase 2 Study of Belimumab Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study tested safety tolerability of repeated subcutaneous doses of belimumab. Study participants were given a total of three doses of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00732940"
    },
    {
        "Title": "Levothyroxine in Pregnant SLE Patients",
        "Summary": "New research documenting deleterious impact thyroid disease pregnancy postpartum period relation miscarriage preterm delivery. Approximately 5 pregnant women thyroid disorder spontaneous miscarriage pre-term delivery documented.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01276782"
    },
    {
        "Title": "The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE (WILLOW LTE)",
        "Summary": "Lupus erythematosus scle discoid lupus\u00a0erythe Matosus dle systemic lupUS ery thematosUS sle completed 24 week treatment period willow study nct0516",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Greece, Spain, China, Korea, Republic of, Poland, Romania, Bulgaria, Philippines, South Africa, Taiwan, Japan, Argentina, Mauritius, Brazil, Israel, Chile, Colombia, Mexico, Moldova, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05540327"
    },
    {
        "Title": "Open-label Study of Belimumab Plus Standard Therapy in Chinese Pediatric Participants With Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study conducted evaluate safety efficacy pharmacokinetics. belimumab administered combination background standard therapy pediatric participants active.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04908865"
    },
    {
        "Title": "Feasibility of an Immersive Virtual Reality Based Biofeedback Intervention for Outpatients in Rheumatology",
        "Summary": "Virtual reality clinics help manage chronic pain patients, study finds. Study uses virtual reality vr biofeedback to help treat rheumatologic diseases.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Spondyloarthropathy, Vasculitis",
        "Phases": "N/A",
        "IDestudio": "NCT03459274"
    },
    {
        "Title": "Decoy Receptor 3 (DcR3) Polymorphisms in Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE)",
        "Summary": " autoimmune diseases genetic factors might contributed development dysregulated lymphocyte activation autoimmunity decoy receptor 3 dcr3 secreted protein belonging tumor necrosis factor tnf receptor family binds fas ligand fasl light tl",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00172666"
    },
    {
        "Title": "Study of Duloxetine in the Reduction of Pain in Patient With Systemic Lupus Erythematosus",
        "Summary": " purpose study determine whether duloxetine cymbalta reduce pain severity patient systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01269866"
    },
    {
        "Title": "A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-2)",
        "Summary": " purpose study evaluate efficacy safety telitacicept treatment moderately severely active sle. purpose study evaluates efficacy safety of telitcicept.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06456567"
    },
    {
        "Title": "Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus",
        "Summary": "Rituximab is a monoclonal antibody used to treat proliferative lupus nephritis. The trial compared standard immunosuppressive therapy with cyclophosphamide.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00556192"
    },
    {
        "Title": "Care Coordination Approaches to Learning Lupus Self-management",
        "Summary": "Study designed examine whether modeling reinforcement lay patient coordinator improves disease indicators. Study lasted 12 months recruitment enrollment 6 months intervention delivery 3 months data analysis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04400240"
    },
    {
        "Title": "The Influence of Ketogenic Diet on Lupus Nephritis Patients' Immunity",
        "Summary": "Study investigates dietary habits relation low doses fatty acids subcutaneous adipose tissue disease activity atherosclerosis low intake high intake carbohydrate among patients sle appear associated with worse disease activity adverse serum lipids plaque.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Ketogenic Dieting",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05689580"
    },
    {
        "Title": "Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE)",
        "Summary": "Mycophenolate mofetil mmf risk clinically significant disease reactivation quiescent sle patients mmf therapy. trial seeks to describe effect withdrawal.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, SLE",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01946880"
    },
    {
        "Title": "Web-based CBT for Symptoms of Mild-to-Moderate Anxiety and Depression in Youth With Chronic Illness",
        "Summary": "Online cognitive behavioral therapy (CBT) is a form of cognitive behavioural therapy. Cbt is used to treat chronic illnesses in young adults. Many young patients go untreated with anxiety depression.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Depression, Anxiety, Inflammatory Bowel Disease, Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02453880"
    },
    {
        "Title": "Monitoring the IMmUological TOXicity of Drugs",
        "Summary": "Several drugs chemotherapies seem impact immunological system. International classification disease codes m05 m32 i78 treatments.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Arthritis, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Capillary Leak Syndrome, Hepatitis",
        "Phases": "N/A",
        "IDestudio": "NCT03480529"
    },
    {
        "Title": "A Study to Evaluate the Effect of Belimumab on Vaccine Responses in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Pneumococcal vaccine subjects systemic lupus erythematosus slem. purpose study assess impact belimumab immune response.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01597492"
    },
    {
        "Title": "The Effect of Metformin on Reducing Lupus Flares",
        "Summary": "Metformin conventional immunosuppressants systemic lupus erythematosus sle purpose study evaluate 1 effect metformin reducing disease flares 2 influence met Formin corticosteroid sparing effect 3 influence metform",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02741960"
    },
    {
        "Title": "Pulse Corticosteroid Therapy and Effect on Brain Water Diffusivity",
        "Summary": "High dosis steroid pulse therapy modifies water free diffusion dwi qsi modification diffusivity rapid slow component. Compartment redistribution slow rapid water molecules diffusion decomposition diffusion signal corresponding theorically respectively.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Belgium",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00527176"
    },
    {
        "Title": "Cyclophosphamide and Fludarabine to Treat Lupus Nephritis",
        "Summary": "Study examine whether fludarabine safely given significantly lower doses cyclophosphamide combination controls kidney inflammation patients 18 years age older. Study candidates history physical examination blood urine tests chest electrocardiogram cancer screening may include pap smear mamm",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00001676"
    },
    {
        "Title": "Examining Distinct Immunophenotypes to Validate and Enhance Rational Treatment in Systemic Lupus",
        "Summary": "Study evaluated potential effectiveness 24 weeks mmf within previously discovered immunologically defined subsets of patients. Study also explore compare gene expression patterns among responders mmf mmf plus voclosporin.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05306873"
    },
    {
        "Title": "The Research Registry for Neonatal Lupus",
        "Summary": " neonatal lupus symptoms include abnormally slow heart beat heart block skin rash registry collects information on infants affected. Women become pregnant may pass antibodies.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Neonatal Lupus, Systemic Lupus Erythematosus, Sjogren's Syndrome, Congenital Heart Block",
        "Phases": "N/A",
        "IDestudio": "NCT00074373"
    },
    {
        "Title": "Shotgun Mass Spectrometry-based Lipid Profiling in Chronic Inflammatory Diseases",
        "Summary": "Collection of blood, plasma, and lipotype samples. Blood samples sent to Germany for analysis and analysis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Biomarker, Lipid, Inflammation, Cardiovascular Diseases, Ischemic Stroke, Systemic Lupus Erythematosus, Healthy",
        "Phases": "N/A",
        "IDestudio": "NCT04786431"
    },
    {
        "Title": "A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus",
        "Summary": "Lupus erythematosus sle also called lupus disease causes body immune system attack healthy tissue. Causes swelling inflammation skin skin joints kidneys brain blood vessels organs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06238531"
    },
    {
        "Title": "Different Aspects and Etiologies of Gastointestinal Bleeding in Patients With Systemic Lupus Erythematosus",
        "Summary": "The U.S. association of development gastrointestinal bleeding (G bleed) is a. association for the development of gastrointestinal bleeding. G bleed is a type of bleeding that occurs when a person experiences bleeding.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06641427"
    },
    {
        "Title": "COvid-19 Vaccine Booster in Immunocompromised Rheumatic Diseases",
        "Summary": "People living systemic autoimmune rheumatic diseases sards face new urgent dilemma immunosuppression increases risk worse infection yet immune stimulation vaccination could disease fear disease reactivation. Patients receiving chemotherapy hemodialysis sards disease flare could lead organ",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Systemic Vasculitis, Systemic Sclerosis, Scleroderma, Undifferentiated Connective Tissue Diseases, Overlap Connective Tissue Disease, Immunosuppression",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05236491"
    },
    {
        "Title": "Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluating efficacy safety sc antifrolumab adult patients moderate sle despite receiving standard therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Bulgaria, Argentina, Germany, Philippines, Spain, Ukraine, Colombia, Chile, Hungary, Mexico, Poland, United States, United Kingdom, Thailand",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04877691"
    },
    {
        "Title": "Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)",
        "Summary": "Pilot study to investigate application of proteasome inhibitor bortezomib. Proteasome inhibition lead to reduced antibody titers improved clinical outcome.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "TERMINATED",
        "Conditions": "Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid Arthritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02102594"
    },
    {
        "Title": "Systemic Lupus Erythematosus Within the Framework of the Multidisciplinary Consultation",
        "Summary": "Lupus diagnosis follow lupus cohort multidisciplinary consultation brest france.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04320680"
    },
    {
        "Title": "A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects",
        "Summary": "Study designed evaluate safety pharmacokinetics pk pharmacodynamics pd single ascending doses healthy participants.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05203692"
    },
    {
        "Title": "Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users",
        "Summary": "Anifrolumab users prospective observational cohort study designed to evaluate association anifrolums with adverse effects. primula preg prospective registry investigating maternal infant outcomes. Study fulfil fda requirement.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06659029"
    },
    {
        "Title": "A Study of the Efficacy and Safety of MEDI-546 in Systemic Lupus Erythematosus",
        "Summary": "Study evaluated efficacy safety compared placebo subjects chronic active systemic lupus erythematosus sle inadequate response standard care treatment. purpose study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Bulgaria, Taiwan, Czech Republic, Brazil, Ukraine, India, Colombia, Hungary, Korea, Republic of, Mexico, Peru, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01438489"
    },
    {
        "Title": "Study to Compare Properties of Epratuzumab When Given as an Injection Under the Skin or Directly Into the Blood",
        "Summary": "epratuzumab compared given subcutaneous sc injection given intravenous iv infusion in healthy volunteers. assess absolute bioavailability dose proportionality pharmacokinetics safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02306629"
    },
    {
        "Title": "Study During Pregnancy of Expression of miRNAs in RA or SLE",
        "Summary": " rheumatoid arthritis ra systemic disease mainly targets joints results osteoarticular destruction serious disability clinical symptoms painful swollen joints occur innate adaptive immune responses self antigens already largely amplified might explain even ra patients treated early aggressively remission disease obtained",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02350491"
    },
    {
        "Title": "Study of LJP 394 (Abetimus Sodium) in Lupus Patients",
        "Summary": "Primary purpose study assess safety pharmacodynamic effect ljp 394 doses 100 mg 300 mg 900 mg antibody levels patients sle sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00390091"
    },
    {
        "Title": "Myfortic Versus Azathioprine in Systemic Lupus Erythematosus",
        "Summary": "Study designed explore use myfortic patients active lupus erythematosus similar drugs class increasingly used organ transplantation autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00504244"
    },
    {
        "Title": "Duke Lupus Registry",
        "Summary": " lupus systemic autoimmune disease present many varied symptoms including joint pain fevers, kidney disease and rashes. Lupus affect anyone common younger women.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Cutaneous Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT00512694"
    },
    {
        "Title": "Aerobic Exercise in Women With Systemic Lupus Erythematosus",
        "Summary": "Lupus makes people tired also makes hard people physically active. aerobic exercise training helps people heart lung illnesses less tired active researchers want use exercise training program people lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Lupus, Autoimmune Disease, Rheumatic Disease",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03186794"
    },
    {
        "Title": "A Pilot-Study With Low-dose hrIL-2 for the Treatment of Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus randomized controlled study n 30 versus placebo group n 30. dysfunction regulatory treg cells detected diverse autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02465580"
    },
    {
        "Title": "Cell Surface Marker Expression in Autoimmune Diseases",
        "Summary": "Study designed explore expression markers following seven disease areas systemic lupus erythematosus b sjogren syndrome c multiple sclerosis systemic sclerosis e crohn disease f ulcerative colitis g inflammatory myositis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Sjogren's Syndrome, Multiple Sclerosis, Systemic Sclerosis, Crohn's Disease, Ulcerative Colitis, Inflammatory Myositis",
        "Phases": "N/A",
        "IDestudio": "NCT03757065"
    },
    {
        "Title": "Scrutinizing the Heterogeneity of SLE: Defining Phenotypes",
        "Summary": " sle disease course characterized unpredictable relapses remissions majority patients however small proportion approximately 5 sle presents monophasic pattern meaning patients active disease immediately diagnosis time achieve prolonged remission 12 years average interestingly half patients require medications end clinical spectrum approximately 50 patients",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03348774"
    },
    {
        "Title": "Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease",
        "Summary": "ianalumab exposure following administration one injection 300 ml ai versus two injections 150 ml syringe pfs evaluate safety tolerability. participants rheumatoid arthritis ra sj\u00f6gren disease sjd systemic lupus ",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, Spain, Poland, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Sj\u00f6grens Disease, Systemic Lupus Erythematosus, Rheumatoid Arthritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06293365"
    },
    {
        "Title": "Monoclonal Antibody Treatment for Systemic Lupus Erythematosus",
        "Summary": "Study examine safety effects monoclonal antibody mra patients systemic lupus erythematosus sle antibodies normally fight invading organisms autoimmune diseases. Lupus however antibodies attack body tissues mra antibody manufactured laboratory blocks action",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00046774"
    },
    {
        "Title": "ILD-SARDs Registry and Biorepository",
        "Summary": "Lung disease biobank study aims to identify unique features underlying lung involvement. Biobank may lead to discovery of novel mechanisms, targets and treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Interstitial Lung Disease, Systemic Autoimmune Disease, Rheumatic Diseases, Rheumatic Arthritis, Systemic Sclerosis, Autoimmune Myositis, Systemic Lupus Erythematosus, Usual Interstitial Pneumonia, Nonspecific Interstitial Pneumonia",
        "Phases": "N/A",
        "IDestudio": "NCT05007340"
    },
    {
        "Title": "Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus",
        "Summary": " multinational randomized parallel treatment phase 2 2 arm study evaluating efficacy safety sar441344 comparison placebo treatment participants aged 18 70 years active systemic lupus erythematosus sle study details include study duration 36 weeks treatment duration 24 weeks",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey, Argentina, Switzerland, Mauritius, Brazil, Greece, Spain, Ukraine, Georgia, Russian Federation, Chile, Hungary, Mexico, Italy, United States, Puerto Rico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05039840"
    },
    {
        "Title": "Exercise and Nutrition Recommendations for Patients Using Glucocorticoids (ENRG)",
        "Summary": " randomized controlled clinical trial aims investigate influence exercise training intervention on musculoskeletal health patients. systemic lupus erythematosus undergone glucocorticoid pulse therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05090189"
    },
    {
        "Title": "Follow-up of the Systemic Lupus Erythematosus Cohort as Part of the Multidisciplinary Consultation at Brest CHRU",
        "Summary": " systemic lupus erythematosus complex systemicautoimmune disease affect organs human body although many recommendations diagnosis managment sle diagnosis therapeutic managment still challenging pluridisciplinary consultation grouping rheumatologist nephrologist dermatologist",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06551389"
    },
    {
        "Title": "Drug Therapy in Lupus Nephropathy",
        "Summary": "26 patients systemic lupus erythematoses nephritis may suffer\u00a0membranous\u00a0lupus nephropathy. High levels protein urine may eventually lead kidney failure. Major goal therapy decrease protein losses ultimately",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Nephrotic Syndrome, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00001212"
    },
    {
        "Title": "LUPUS Brain: tACS to Target the Neurophysiology of Depression, Cognitive Deficits, and Pain in Patients With SLE",
        "Summary": "Tacs stimulation montage previously used depression could beneficial patients, according to study. Study investigated effects type transcranial alternating current stimulation tacs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Depression",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04141046"
    },
    {
        "Title": "Belimumab (BENLYSTA\u00ae) Pregnancy Registry",
        "Summary": "Belimumab pregnancy registry collect prospective data pregnancies pregnancy outcomes voluntary basis women systemic lupus erythematosus sle received commercially supplied belimumab within 4 months prior pregnancy registry.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Belgium, Austria, Argentina, Germany, Switzerland, France, Spain, Israel, Canada, Italy, Portugal, United States, Sweden",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01532310"
    },
    {
        "Title": "Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular Diseases",
        "Summary": " accelerated atherosclerosis established complication systemic autoimmune diseases particularly sle young female patients sle likely develop myocardial infarction matched healthy controls cvd nowadays one common causes death 27 lupus patients traditional cv risk factors explain increased cv",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France, Germany",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04276701"
    },
    {
        "Title": "Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus",
        "Summary": "Aspirin statins agents reduce progression subclinical atherosclerosis patients systemic lupus erythematosus slem.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "COMPLETED",
        "Conditions": "Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00371501"
    },
    {
        "Title": "Cardiac and Laboratory Findings in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study designed investigate association clinical laboratory parameters data. cardiac structural functional abnormalities systemic lupus erythematosus sle patients least four acr classification criteria sle stable clinical condition need immunosuppressive therapy intensification.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03179046"
    },
    {
        "Title": "Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).",
        "Summary": "ianalumab participants systemic lupus erythematosus previously completed treatment period one two core studies cvay736f12301 cvays736f12302. purpose study evaluate safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Germany, Taiwan, Spain, Australia, Hungary, Canada, China, Poland, United States, Malaysia, Thailand",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06133972"
    },
    {
        "Title": "Development of a Novel Glutamate Receptor Ligand for PET Scans in Neuropsychiatric Systemic Lupus Erythematosus",
        "Summary": "Cognitive impairment occurs many 80 lupus patients affective disorders depression depression anxiety also common problems contribute significantly disease burden disability associations serum aab cognitive behavioral changes human sle remained controversial however elevated titers aabs cerebrospinal fluid c",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02456168"
    },
    {
        "Title": "Treatment of Periodontal Disease in Systemic Lupus Erythematosus",
        "Summary": "Primary objective study part 1 baseline comparisons primary objective part 1 investigate association sle measures vascular health brachial artery dilatyation patients systemic lupus erythematosus sle healthy periodontium compared patients sle periodontitis",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Periodontitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04046172"
    },
    {
        "Title": "Spine Quantitative Computed Tomography (QCT) for the Assessment of Osteoporosis on Children",
        "Summary": "Study compares healthy children children with systemic lupus erythematosus sle sle childhood disease high risk low bone mass.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01330368"
    },
    {
        "Title": "A Prospective, Single Arm, Open Label, Proof of Concept Clinical Study of Sulfasalazine in the Treatment of Active Systemic Lupus Erythematosus",
        "Summary": " clinical trial learn sulfasalazine safe feasible treatment. active lupus erythematosus sle main questions aims answer drug sulf asalazine stable background treatment help lower disease activity sledai.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06360068"
    },
    {
        "Title": "Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis",
        "Summary": " systemic sclerosis ssc systemic disease characterized limited diffuse cutaneous sclerosis microangiopathy overproduction autoantibodies variable organ damage due vasculopathy fibrosis loss believed caused dysregulation innate adaptive immune systems.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Sclerosis, Other Connective Tissue Disease, Systemic Lupus Erythematosus, Dermatomyositis, ANCA Associated Vasculitis",
        "Phases": "N/A",
        "IDestudio": "NCT06462768"
    },
    {
        "Title": "An Clinical Study of YTS109 Cell Injection in Subjects With Recurrent/Refractory Autoimmune Disease",
        "Summary": "Yts109 cell injection subjects autoimmune disease. Yts109 cells injected into subjects with autoimmune disease in a clinical study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis, Inflammatory Myopathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Antiphospholipid Syndrome, Sjogren's Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06379646"
    },
    {
        "Title": "Study to Determine if Gardasil Vaccine is Safe and Effective in Lupus Patients",
        "Summary": "Gardasil vaccine prevents cervical infection. cervical neoplasia increased women sle likely due cervical infection human papilloma virus hpv 70 cervical cancer caused hpv types 16 18. thus lupus patients susceptible cervical cancer may benefit",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01741012"
    },
    {
        "Title": "CHABLIS7.5: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus With or Without Nephritis",
        "Summary": "Blisibimod measured composite responder index subjects despite corticosteroid use. Study evaluated clinical efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Georgia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02514967"
    },
    {
        "Title": "Long-Term Safety and Efficacy Study of Deucravacitinib in Participants With Systemic Lupus Erythematosus",
        "Summary": "Main objective trial characterize safety tolerability subjects systemic lupus erythematosus slei. main objective trial characterized safety tolerable subjects systemic. lupUS ery thematosum slei main objective study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Romania, Argentina, Taiwan, Brazil, Spain, Russian Federation, Colombia, Hungary, Canada, Korea, Republic of, Mexico, United States, Poland",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03920267"
    },
    {
        "Title": "Single Ascending Dose Study of AMG 570 in Healthy Subjects",
        "Summary": "The study was conducted to determine the safety and tolerability of amg 570. The study was designed to obtain initial information about the drug's safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02618967"
    },
    {
        "Title": "A Continuation Trial for Subjects With Lupus Who Completed Protocol HGS1006-C1056 in the United States",
        "Summary": "Study provides continuing treatment subjects completed study united states evaluate safety efficacy belimumab subjects sle disease. continuation study provide continuing treatment Subjects completed study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00724867"
    },
    {
        "Title": "Healthy Lifestyle Intervention in Patients With Systemic Lupus Erythematosus: The Living Well With Lupus Study",
        "Summary": "Research program aims investigate clinical physiological metabolic molecular effects lifestyle change patients systemic lupus erythematosus high cardiovascular risk randomized controlled trial aims investigate feasibility efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04431167"
    },
    {
        "Title": "Molecular Mechanisms Characteristics in Systemic Lupus Erythematous Autoimmune Disease",
        "Summary": "Deregulation immune responses plays major role many autoimmune diseases systemic lupus erythematosus sle main objective protocol determine whether expression function specific molecules deregulated immune cells patients sle examining irf4 irf5 rock1",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02270710"
    },
    {
        "Title": "Accuracy, Feasibility and Acceptance of CGM Lupus",
        "Summary": "Continuous glucose monitoring system critically systemic lupus erythematosus sle newly developed technologies continuous glucose monitoring critically sle patients may improve glycemic control. Subcutaneous glucose continuously monitored critical sle patients freestyle libre glucose monitoring",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Critical Illness, Diabetic Blood Glucose Monitoring",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03296995"
    },
    {
        "Title": "Motivating Individuals With Lupus to Exercise",
        "Summary": " physical activity exercise helpful managing symptoms like fatigue people living systemic lupus erythematosus lupUS often inactive report afraid exercise.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05287581"
    },
    {
        "Title": "Effectiveness of Mycophenolate Mofetil Combined With Tacrolimus for Steroid Tapering in Systemic Lupus Erythematosus",
        "Summary": " clinical trial determine whether mycophenolate mofetil mmf combined tacrolimus tac maintain remission patients lupus nephritis ln reached treatment targets steroid tapering main question aims answer efficacy safety tolerability mmf",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05916781"
    },
    {
        "Title": "Evaluation of Janus Kinase_3 in Juvenile Onset Systemic Lupus Erythematosus",
        "Summary": " cytokines activate signals thus eliciting specific responses target cells involves enzymes janus kinases jaks transcriptional factors signal transducers activators transcription stats immune mediated diseases activating inactivating mutations jaks stats may cause abnormalities immune homeostasis",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04293510"
    },
    {
        "Title": "Vitamin D to Improve Endothelial Function in SLE",
        "Summary": "Vitamin deficient systemic lupus erythematosus sle patients investigators enroll vitamin deficient sle patients randomize receive either 400 iu iu cholecalciferol d3 daily measure change fmd measure ec function baseline",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Atherosclerosis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01911169"
    },
    {
        "Title": "Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS)",
        "Summary": "Study enrolled 700 pregnant patients enrolled nine major clinical centers. The aim of the study was to determine whether certain proteins called complement split products injure healthy organs used predict poor pregnancy outcome.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada, United Kingdom, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Antiphospholipid Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT00198068"
    },
    {
        "Title": "Prospective Registry Investigating Maternal, Infant, and Lactation Outcomes in Anifrolumab Users",
        "Summary": "Anifrolumab is a drug used to treat lactation. The drug is approved by the FDA for use in humans.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT06594068"
    },
    {
        "Title": "CArdiovascular Risk Assessment STudy in Lupus Erythemathodes (CASTLE)",
        "Summary": "Key prospective study identify potentially increased cardiovascular risk patients systemic lupus erythematodes without renal affection. Three groups patients compared.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01520155"
    },
    {
        "Title": "Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry",
        "Summary": "Aesi is a prospective observational cohort study evaluating incidence adverse events. Study participants assessed aesi including serious infections, opportunistic infections, malignancies, and serious psychiatric events.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Belgium, Austria, Argentina, Germany, France, Slovakia, Spain, Israel, Canada, Italy, Portugal, United States, Sweden",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01729455"
    },
    {
        "Title": "Clinical Characteristics and Outcomes of SLE Patients Admitted to Critical Care Unit",
        "Summary": "Study aims to determine frequency of critical complications in patients admitted to intensive care unit. Study also aims to identify risk factors for these complications.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05418855"
    },
    {
        "Title": "A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)",
        "Summary": "Lupus nephritis systemic lupus erythematosus treatment consists single infusion autologous cells administered intravenously lymphodepleting therapy regimen consisting fludarabine cyclophosphamide. phase study",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06153095"
    },
    {
        "Title": "Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)",
        "Summary": " purpose study evaluate safety efficacy epratuzumab. standard treatments patients. patients sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Germany, Czech Republic, France, Brazil, Spain, Netherlands, Canada, Italy, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00383214"
    },
    {
        "Title": "Practice of Treat-to-target on Pediatric Systemic Lupus Erythematosus: a Two-center Retrospective Study",
        "Summary": "T2t strategies proved useful several chronic disorders including rheumatoid arthritis systemic lupus erythematosus sle t2t strategy proposed order control disease activity improve quality life reduce morbidity mortality remission.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04942314"
    },
    {
        "Title": "Triptorelin for Ovary Protection in Childhood Onset Lupus",
        "Summary": "Female patients diagnosed systemic lupus erythematosus younger 21 years age require intravenous cyclophosphamide control disease patient study approximately 23 months. 50 patients participate study patient randomized assigned one 5 groups randomization means patients put",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00124514"
    },
    {
        "Title": "Phase II/III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Mild to Moderate Systemic Lupus Erythematosus",
        "Summary": "Women systemic lupus erythematosus ii describe pharmacokinetics gl701. objectives evaluate safety efficacy synthetic dehydroepiandrosterone gl701 women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00004795"
    },
    {
        "Title": "Japanese phase1 Study of Belimumab (IV vs SC)",
        "Summary": " study randomized 2 parallel group single dose study healthy japanese males assess pharmacokinetics. single intravenous administration single subcutaneous administration gsk1550188 serial blood samples determination.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01516450"
    },
    {
        "Title": "Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED)",
        "Summary": " lupus erythematosus sle prone cardiovascular disease early detection improvement endothelial function simvastatin could clue future intervention trials.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00739050"
    },
    {
        "Title": "Effectiveness of Pharmaceutical Care in the Adherence of Systemic Lupus Erythematosus Treatment",
        "Summary": " project aims improve adherence rate pharmaceutical care patients systemic lupus erythematosus sle help achieving therapeutic goals finally improve quality life patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Medication Adherence",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02330250"
    },
    {
        "Title": "Dissemination of the Lupus Interactive Navigator",
        "Summary": "Lupus erythematosus incurable chronic inflammatory disease affects preferentially young women. unmet needs include 15 excess mortality high morbidity poor work outcomes despite prevalence. lupus mostly unknown public access specialized care remains",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02950714"
    },
    {
        "Title": "Telangiectatic Palmoplantar Keratoderma in Systemic and Subacute Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle subacute is a rare phenomenon seldom reported literature.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Lichen Planus",
        "Phases": "N/A",
        "IDestudio": "NCT04356014"
    },
    {
        "Title": "Clonal Hematopoiesis of Indeterminate Potential and Accelerated Atherosclerosis in Systemic Lupus Erythematosus",
        "Summary": " chip predisposes cardiovascular events cve general population aimed determine whether chip associated cve sle. accelerated atherosclerosis patients systemic lupus erythematosus sle fully explained framingham risk factors detection.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05146414"
    },
    {
        "Title": "Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)",
        "Summary": "ianalumab compared placebo given monthly quarterly subcutaneous injection top soc treatment participants active systemic lupus erythematosus sleus. trial evaluate efficacy safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Bulgaria, South Africa, Turkey, Slovakia, Brazil, Spain, Israel, Hungary, Canada, China, Poland, United States, Portugal, Singapore, Guatemala, Thailand",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05639114"
    },
    {
        "Title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Baricitinib is a drug used to treat systemic lupus erythematosus. The study was designed to evaluate the drug's efficacy and safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Austria, Argentina, Romania, Taiwan, France, Spain, Mexico, Korea, Republic of, Poland, United States, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02708095"
    },
    {
        "Title": "Evaluation of Serum Galectin-9 Level in Systemic Lupus Erythematosus Patients and it's Association With Disease Activity and Organ Damage",
        "Summary": "Study aims evaluate serum systemic lupus erythematosus patients to determine correlation overall disease process.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04558814"
    },
    {
        "Title": "BAFF CAR-T Cells (LMY-920) for Systemic Lupus Erythematosus",
        "Summary": " phase 1 study seeks examine safety recommended phase 2 dose rp2d cells adult patients refractory systemic lupus erythematosus sle hypothesized baff cells safe improve sle disease activity scores.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06340750"
    },
    {
        "Title": "A Prospective Study of Cyclophosphamide in Systemic Lupus Erythematosus Treatment",
        "Summary": "Study compares personal prescription cyclophosphamide with traditional prescription. Purpose of study was to compare personal prescription and traditional prescription drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01689350"
    },
    {
        "Title": "A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases",
        "Summary": " purpose study establish tolerability preliminary efficacy pharmacokinetics participants severe refractory autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Germany, France, Spain, Italy, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05869955"
    },
    {
        "Title": "Study of Families With Twins or Siblings Discordant for Rheumatic Disorders",
        "Summary": "Study examine families one sibling sibling pair twin pair developed systemic rheumatic disease one see two differ following blood cell metabolism types cells blood environmental exposures genetic factors might explain one developed disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies",
        "Phases": "N/A",
        "IDestudio": "NCT00055055"
    },
    {
        "Title": "Peer Approaches to Lupus Self-management",
        "Summary": "Lupus recruited musc sle database 60 mentors 300 mentees peer mentoring intervention patients matched peer mentors considered competent management condition provide modeling reinforcement participants occur telephone approximately 60 minutes every two weeks 24 weeks participants assessed baseline 12 weeks immediately following intervention",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Quality of Life, Behavior, Health",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03734055"
    },
    {
        "Title": "Prediction of Relapse Risk in Stable Systemic Lupus Erythematosus",
        "Summary": "Whether systemic lupus erythematosus sle patients stable disease withdraw glucocorticoid gc relapse risk risk factors disease flare unclear gc treatment lot even sustaining low dose aim study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02842814"
    },
    {
        "Title": "Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of ACT-334441 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "International trial evaluate biological activity safety cenerimod systemic lupus erythematosus sle patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Belarus, Ukraine, Georgia, Russian Federation, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02472795"
    },
    {
        "Title": "A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Systemic Lupus Erythematosus",
        "Summary": " lupus erythematosus patients refractory to systemic lupUS. Study is first of its kind.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Autoimmune Diseases",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT05030779"
    },
    {
        "Title": "A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus",
        "Summary": "Study evaluate pharmacokinetic characteristics safety belimumab subcutaneous sc chinese pediatric participants sle completed 48 weeks. Study nct04908865.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05917288"
    },
    {
        "Title": "A Phase Ia Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneously Administered CUG252 in Normal Healthy Volunteers",
        "Summary": "252 healthy adult subjects. intent study evaluate safety tolerability single escalating subcutaneous doses cug252 healthy adults subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05328557"
    },
    {
        "Title": "The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients",
        "Summary": " milnacipran shown effective treatment pain fatigue physical function fms patients date clinical trials demonstrated efficacy treatment fatigue sle patients concomitant wsp fms investigators hypothesize based on fms studies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus, Widespread Pain, Fibromyalgia",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01359826"
    },
    {
        "Title": "Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis",
        "Summary": " randomized multiple dose escalation study enrolling approximately 48 subjects. Study enrolls subjects systemic lupus erythematosus sle without glomerulonephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France, Hong Kong, Mexico, United States, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Nephritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00818948"
    },
    {
        "Title": "Exploring the Therapeutic Effect of Telitacicept on Lupus Erythematosus Complicated With Thrombocytopenia",
        "Summary": " purpose study evaluate efficacy telitacicept patients systemic lupus erythematosus refractory thrombocytopenia.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05929248"
    },
    {
        "Title": "Probiotics in Systemic Lupus Erythematosus",
        "Summary": "Lactobacilli immunoregulatory properties may viable strategy controlling disease development progression patients lupus increasing remission period decreasing flare frequency. dysbiosis disruption gut microbiota leads onset autoimmunity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05433857"
    },
    {
        "Title": "Rheumatology Patient Registry and Biorepository",
        "Summary": " facilitate clinical basic science translational research projects involving study rheumatic diseases. facilitate clinicalbasic science translatory research projects in the U.S. and abroad.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatic Diseases, Adult Onset Still Disease, Ankylosing Spondylitis, Psoriatic Arthritis, Reactive Arthritis, Antiphospholipid Syndrome, Systemic Lupus Erythematosus, Behcet Disease, Dermatomyositis, Polymyositis, Giant Cell Arteritis, Lyme Disease, Mixed Connective Tissue Disease, Polymyalgia Rheumatica, Rheumatoid Arthritis, Sarcoidosis, Systemic Sclerosis, Scleroderma, Sjogren's Syndrome, Undifferentiated Connective Tissue Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT04402086"
    },
    {
        "Title": "Breaking Implicit Bias Habits: An Individuation Pilot Study In Rheumatology",
        "Summary": "First aim study test efficacy individuation intervention improve receipt rheumatic disease care among american lower socioeconomic status ses individuals. Second aim determine effect individuated intervention communication adherence provider trust care satisfaction.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Rheumatoid Arthritis, Inflammatory Arthritis, Osteoarthritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05116163"
    },
    {
        "Title": "Efficacy and Safety of Telitacicept for Prevention of Flares in SLE Patients",
        "Summary": " telitacicept prevention flares sle patients low disease activity. study randomized clinical trial aim study investigate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06394063"
    },
    {
        "Title": "Study of Methotrexate in Lupus Erythematosus",
        "Summary": "Methotrexate folic acid is used to treat systemic lupus erythematosus. The treatment aims to decreasing mortality and morbidity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00470522"
    },
    {
        "Title": "BEL114333, a Continuation Study of BEL113750 in Subjects With Systemic Lupus Erythematosus (SLE) in Northeast Asia, and in Japan Subjects Completing the Open-label Extension of HGS1006-C1115",
        "Summary": "Study provides subjects complete bel113750 study subjects complete extension referred c1115 study japan option continuing treatment belimumab 10 intravenously every 4 weeks randomized.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Korea, Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01597622"
    },
    {
        "Title": "Vagus Nerve Stimulation for Systemic Lupus Erythematous",
        "Summary": " trial uses double blinded randomized active sham placebo controlled parallel group design. investigating effects transcutaneous vagus nerve stimulation tvns patients systemic lupus erythematosus sle main objective evaluate whether adjuvant treatment tvns sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Autonomic Dysfunction, Autonomic Neuropathy, Fatigue",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05315739"
    },
    {
        "Title": "Pulmonary Hypertension Screening for Rheumatology Patients (SOPHIE)",
        "Summary": "Pulmonary arterial hypertension pah serious often fatal complication connective tissue diseases including systemic sclerosis systemic lupus erythematosus reported primarily european series prevalence. pulmonary hypertension screening patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Connective Tissue Diseases, Systemic Sclerosis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03446339"
    },
    {
        "Title": "Predictors of Remission and Renal Outcomes in Lupus Nephritis in Assuit University Hospitals.",
        "Summary": "Study aims to identify predictors of remission renal outcomes in patients with lupus nephritis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06228222"
    },
    {
        "Title": "Immune Ablation and Hematopoietic Stem Cell Support in Patients With Systemic Lupus Erythematosus: A Phase II Study",
        "Summary": " lupus erythematosus immunosuppressive therapy point complete immune ablation hematopoietic stem cell recovery.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00271934"
    },
    {
        "Title": "Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus",
        "Summary": "About 20 subjects discoid lupus erythematosus enrolled receive amg 811 placebo one two sequences. randomized crossover study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus, Discoid Lupus, Lupus, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01164917"
    },
    {
        "Title": "A DOSE-RANGING STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-06700841 IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)",
        "Summary": " assessment participants moderate severe active generalized systemic lupus erythematosus sle inadequate response standard care.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Greece, Spain, Ukraine, Hong Kong, China, Italy, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Bulgaria, France, Canada, Portugal, Taiwan, Czechia, Japan, Argentina, Germany, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03845517"
    },
    {
        "Title": "Monogenic Lupus in Childhood Onset Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is a rare form of systemic lupus. It is the most common form of Lupus.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Monogenic Lupus, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04532541"
    },
    {
        "Title": "Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults With Chronic Conditions",
        "Summary": "Study tested efficacy peer support coaching intervention to improve activated chronic illness versus attention control group. 225 adolescents young adults childhood onset chronic conditions.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Sickle Cell Disease, Chronic Kidney Diseases, Systemic Lupus Erythematosus, Childhood Cancer, Inflammatory Bowel Diseases, Stem Cell Transplant, Organ Transplant, Diabetes Mellitus, Type 1, Cystic Fibrosis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03938324"
    },
    {
        "Title": "Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus",
        "Summary": " phase study intended evaluate pharmacological properties. pharmacokinetics pharmacodynamics safety tolerability preliminary effectiveness tofa administrated young adults years moderately severely active subjects studied.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT03288324"
    },
    {
        "Title": "The Effect of Deep Breathing and Transcutaneus Electrical Nerve Stimulation on Heart Rate Variability",
        "Summary": "Interventional study aims to investigate effect of deep breathing. Study consists of three sessions to compare effect and hypothesise effect.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Denmark",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Healthy Participants",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05157334"
    },
    {
        "Title": "Study of the Predictors of the Course and Early Outcome of Patients With Systemic Lupus Erythematosus: Nature Versus Nurture",
        "Summary": "Lumina study cohort ii recruit lumina cohort newly diagnosed patients systemic lupus erythematosus sle ii determine impact additional major histocompatibility complex mhc genetic factors previously examined specifically tumor necrosis factor man",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00006134"
    },
    {
        "Title": "Retrospective Medical Chart Review Study to Describe the Experience of SLE Patients Treated With Anifrolumab in the Early Access Programs.",
        "Summary": "erythro study retrospective medical chart review study patients amana atuc early access programs eaps across number countries assess anifrolumab usage patient experience treating sle setting.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France, Greece, Spain, Israel, Portugal, Italy, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06046534"
    },
    {
        "Title": "The Study of Comparing the Efficacy and Safety of Human Umbilical Cord MSCs and Low-dose IL-2 in the Treatment of LN",
        "Summary": "Human umbilical cord mesenchymal stem cells treatment ln. purpose study compare efficacy and safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05631717"
    },
    {
        "Title": "Study of Recombinant Human B Lymphocyte(RC18) Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)",
        "Summary": "The study was designed to access safety effectivity. The aim of the study was to assess the safety and effectiveness of a combination of standard treatment and placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04082416"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus",
        "Summary": "Study evaluate efficacy safety obinutuzumab versus placebo participants active systemic lupus erythematosus sle treated therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Argentina, South Africa, France, Brazil, Spain, Russian Federation, New Zealand, Mexico, Italy, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04963296"
    },
    {
        "Title": "Clinical Risk Assessment of Cognitive Function in Systemic Autoimmune Diseases",
        "Summary": "Mild cognitive impairment affecting attention memory complicated solution tasks. Symptoms significantly impact patients routines and quality of life. Clinical parameters regarding systemic autoimmune diseases.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Hungary",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Sclerosis, Systemic Lupus Erythematosus, Myopathies, Inflammatory, Rheumatoid Arthritis, Healthy",
        "Phases": "N/A",
        "IDestudio": "NCT06029335"
    },
    {
        "Title": "IL17 in Systemic Lupus Erythematosus Patients: Association With Disease Activity and Organ Damage",
        "Summary": "Many laboratory markers measured assessment lupus activity aberrant manufacturing imbalance cytokines cell already implicated within autoimmunity pathogenesis levels usually elevated. sledai score linked organ damage several autoimmune diseases recently linked pathogenesis murine model lup",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05045417"
    },
    {
        "Title": "fMRI Study of Early Brain Injury in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune disease involving multiple organs systems central nervous system one commonly involved parts involvement nervous system called neuropsychiatric lupUS one common complications sle main cause death cognitive impairment emotional disorders common",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06226324"
    },
    {
        "Title": "A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis",
        "Summary": "Vib7734 participants systemic lupus erythematosus sle cutaneous luposus cle sjogren syndrome systemic sclerosis polymyositis dermatomyositis. purpose study evaluate safety tolerability escalating multiple",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, Dermatomyositis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03817424"
    },
    {
        "Title": "Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders",
        "Summary": "Total body irradiation combination cyclophosphamide globulin autologous peripheral blood stem cell pbsc transplantation children refractory autoimmune disorders. objectives determine safety long term complications.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Sclerosis, Systemic Lupus Erythematosus, Dermatomyositis, Juvenile Rheumatoid Arthritis, Autoimmune Diseases",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00010335"
    },
    {
        "Title": "ROLE of PLATELETS in the PATHOPHYSIOLOGY of SYSTEMIC LUPUS",
        "Summary": " blood platelets well known role hemostasis abnormally activated patients suffering systemic lupus erythematosus sle also immunomediated diseases scleroderma vasculitis myositis rheumatoid arthritis cases high",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Scleroderma Meeting, ANCA Vasculitis, Inflammatory Myositis, Gougerot-Sj\u00f6gren Syndrome, Rheumatoid Arthritis",
        "Phases": "N/A",
        "IDestudio": "NCT06593041"
    },
    {
        "Title": "The Effect of Calcitriol on Progress and Activity of Lupus Nephritis",
        "Summary": "purpose study determine whether calcitriol effective treatment lupus nephritis. purpose study determine if calcitriols effective treatment for lupUS neph arthritis. purpose Study determine whether calcium is effective treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Iran, Islamic Republic of",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01863641"
    },
    {
        "Title": "Pharmacodynamics Assessment Study After Single Subcutaneous Dose Of SAR113244 Versus Placebo In Lupus Male And Female Patients",
        "Summary": "Primary objective assess systemic lupus erythematosus sle patients effect sar113244 subsets compared placebo. Secondary objectives assess male female lupsus patients sc single dose sar 113244 tolerability safety. Assess male",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02331810"
    },
    {
        "Title": "Study of RC18 Administered Subcutaneously to Subjects With Systemic Lupus Erythematosus(SLE)",
        "Summary": "rc18 combined standard treatment placebo combined standard therapy subjects moderate severe sle besides provide dose basis clinical trials. purpose study initially access safety effectivity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02885610"
    },
    {
        "Title": "Reappraisal of the Therapies of Refractory Autoimmune Hemolytic Anemia in Systemic Lupus Erythematosus",
        "Summary": "Mycophenolate mofetil mmf showed promising results patients still data available form case reports investigators investigate efficiency mmf.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Autoimmune Hemolytic Anemia, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05057481"
    },
    {
        "Title": "An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants",
        "Summary": "Study evaluate pk pd efficacy safety. anifrolumab children moderate severe active sle sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Turkey, Argentina, Germany, South Africa, France, Brazil, Spain, Colombia, Mexico, Canada, China, Italy, United States, Poland, Portugal, United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05835310"
    },
    {
        "Title": "Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "The study was designed to identify the highest dose bh002 injection cells patients suffering resistant systemic lupus erythematosus tolerate.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis, Autoimmune Diseases, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06350110"
    },
    {
        "Title": "Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease",
        "Summary": "Primary objective study assess safety epratuzumab patients sle sle. secondary objective study assessed safety of the drug in patients with cancer.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Brazil, Spain, Ukraine, India, Lithuania, Hungary, Hong Kong, Poland, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00660881"
    },
    {
        "Title": "Study of Epratuzumab in Systemic Lupus Erythematosus",
        "Summary": " epratuzumab investigational antibody designed help treat systemic lupus erythematosus sle purpose study obtain additional information regarding safety efficacy continued administrations.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00383513"
    },
    {
        "Title": "Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors",
        "Summary": "Researchers use information collected to improve educational materials help patients make future decisions treatment. Study learn easily patients use educational tool created.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Ankylosing Spondylitis, Autoimmune Disease, Crohn Disease, Enteropathic Arthritis, Enteropathic Spondylitis, Inflammatory Bowel Disease, Melanoma, Psoriasis, Psoriatic Arthritis, Reactive Arthritis, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ulcerative Colitis",
        "Phases": "N/A",
        "IDestudio": "NCT04751396"
    },
    {
        "Title": "A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "Afimetoran is a treatment for systemic lupus erythematosus. The study was designed to evaluate the effectiveness and safety tolerability of the treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, China, Poland, United Kingdom, Puerto Rico, Romania, France, India, Ireland, Taiwan, Japan, Argentina, Germany, Brazil, Chile, Colombia, Mexico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04895696"
    },
    {
        "Title": "Periodontal Status in Patients With Chronic Skin Diseases",
        "Summary": "The study aimed to evaluate compare periodontal status chronic skin disease csd patients healthy controls material method 109 patients 109 patients 37 healthy subjects included study parameters evaluated included bleeding probing index bopperiodontal pocket depths ppd clinical attachment level",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Vietnam",
        "OverallStatus": "COMPLETED",
        "Conditions": "Periodontal Diseases, Psoriasis, Atopic Dermatitis, Autoimmune Bullous Dermatosis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06073613"
    },
    {
        "Title": "REACH (Restore Energy, Activity Can Help) Lupus Study",
        "Summary": "Goal clinical trial pilot test reach peer coaching program fatigue people systemic lupus erythematosus main questions aims answer 1 reach program feasible acceptable participants 2 impact reach program fatigue researchers compare reachpeer coaching program to reach mobile health application",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Fatigue",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06479213"
    },
    {
        "Title": "Activity and Nutrition Trial in Lupus to Energize and Renew",
        "Summary": "Study participants fatigue lifestyle physical activity sle study approached enroll 6 week pilot intervention study look barriers facilitators increasing physical activity improving intake improving study offer support information.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Physical Activity, Sleep",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02281513"
    },
    {
        "Title": "Study of Anti-Malarials in Incomplete Lupus Erythematosus",
        "Summary": " project multicenter randomized clinical trial designed test whether treating patients risk development. lupus hydroxychloroquine slow accumulation disease features effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03030118"
    },
    {
        "Title": "Neutrophil Extracellular Traps in Systemic Sclerosis",
        "Summary": " systemic sclerosis ssc systemic disease characterized limited diffuse cutaneous sclerosis microangiopathy overproduction autoantibodies variable organ damage due vasculopathy fibrosis loss believed caused dysregulation innate adaptive immune systems may involve reactive oxygen species ros",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03374618"
    },
    {
        "Title": "CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease",
        "Summary": "B cells are a type of white blood cell. They are used to treat autoimmune diseases. B cells are genetically engineered using lentiviral vector express.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis, Dermatomyositis, Polymyositis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06347718"
    },
    {
        "Title": "Clinical and Diagnostic Value of Ribosomal p2 Autoantibodies in Systemic Lupus Erythematosus",
        "Summary": "Systemic lupus erythematosus is a chronic autoimmune disorder characterized by periods of remission and relapse. 180 autoantibodies have been identified.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05179018"
    },
    {
        "Title": "Evaluation of Slit2 in Systemic Lupus Erythematosus and Systemic Sclerosis Patients",
        "Summary": "Slate2 level sle patients correlation disease activity slit2 level ssc patients correlation diseases activity.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05105217"
    },
    {
        "Title": "Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study evaluated safety tolerability pharmacokinetics pk pharmacodynamics pd gsk1550188 japanese subjects systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01381536"
    },
    {
        "Title": "HIPP Learning to Live Better With Lupus: The Health Improvement and Prevention Program in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle poor general health higher risk heart attack bone loss osteoporosis compared general population risks associated heart attacks bone loss modifiable changed. diet low calcium smoking lack exercise modifiable risk factors",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00188357"
    },
    {
        "Title": "BENLYSTA\u00ae Special Drug Use Investigation",
        "Summary": "About 600 subjects enrolled study observation period per subject 52 weeks start benlysta administration.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Japan",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03370263"
    },
    {
        "Title": "Efficacy and Immunological Evaluation of Belimumab Plus Low Dose IL-2 in the Treatment of Systemic Lupus Erythematosus",
        "Summary": " purpose study explore clinical immunological efficacy belimumab plus low dose systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05262686"
    },
    {
        "Title": "Safety of Estrogens in Lupus: Hormone Replacement Therapy",
        "Summary": "Lupus erythematosus national assessment selena study test whether postmenopausal women can safely use hormone estrogen part study look effects estrogen replacement therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00000419"
    },
    {
        "Title": "Study Evaluating SC291 in Subjects with Severe R/r B-cell Mediated Autoimmune Diseases (GLEAM)",
        "Summary": " phase 1 study evaluate sc291 safety tolerability. preliminary clinical response cellular kinetics. exploratory assessments subjects severe autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Systemic Lupus Erythematosus, SLE (Systemic Lupus), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Granulomatous Polyangiitis, Microscopic Polyangiitis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06294236"
    },
    {
        "Title": "A Study of rhuMAb IFNalpha in Adults With Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is the most common form of systemic lupus. Patients with the disease are often hospitalized.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00541749"
    },
    {
        "Title": "Recombinant Herpes Zoster Vaccine in Patients With Autoimmune Rheumatic Diseases",
        "Summary": "Immunosuppressive treatments impair response including conventional unconventional synthetic drugs dmards biological agents context recent availability recombinant vaccine hz rzv composed recombinant vzv glycoprotein e ge as01b adjuvant system",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Spondylitis, Ankylosing, Spondyloarthritis, Systemic Lupus Erythematosus, Sjogren's Syndrome, Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Vasculitis, Systemic, Juvenile Idiopathic Arthritis, Dermatomyositis, Juvenile, Beh\u00e7et Disease",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05879419"
    },
    {
        "Title": "Abnormalities of B Lymphocytes During Systemic Lupus",
        "Summary": "Previous experimental data strongly suggest b lymphocytes intrinsic abnormalities lupus mice spontaneously affected disease. Study tries to define abnormalities looking gene expression profile purified b lymphocyte patients non active systemic l Lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00401141"
    },
    {
        "Title": "Efficacy and Safety of Belimumab in SLE Patients",
        "Summary": " systemic lupus erythematosus sle chronic inflammatory systemic autoimmune disease recurrent relapses disease development organ damage two key unsolved clinical problems belimumab biological agent sle data showed treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04515719"
    },
    {
        "Title": "A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of Single Dose of AMG 623 in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Study evaluated safety amg 623 subjects systemic lupus erythematosus study consists 21 day screening period followed administration investigational product 70 day follow period.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02443506"
    },
    {
        "Title": "Transcriptional and Immune Parameters of Response to Belimumab",
        "Summary": "Investigators propose perform whole blood initially cohort 80 sle patients receive belimumab therapy sle patients. Investigators deconvolute data define pertinent molecular alterations specific immune cell types.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Greece",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04570306"
    },
    {
        "Title": "A Clinical Study of MIL62 in Systemic Lupus Erythematosus",
        "Summary": "Study evaluate efficacy safety pharmacokinetics pk pd ada mil62 compared placebo participants systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05796206"
    },
    {
        "Title": "Belimumab in Patients With Systemic Lupus Erythematosus",
        "Summary": " project pretends obtain extensive data registry patients systemic lupus erythematosus sle main objective create national patients registry treated belimumab.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Spain",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04671706"
    },
    {
        "Title": "Exercise and Arterial Stiffness in Systemic Lupus Erythematosus",
        "Summary": " increased arterial stiffness leads cardiovascular diseases cvd arteriosclerotic origin main cause mortality. Exercise modifiable factor reduces cardiovascular mortality associated risk factors.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03107442"
    },
    {
        "Title": "Efficacy and Safety Study of R935788 Tablets to Treat Systemic Lupus Erythematosus",
        "Summary": "About 225 patients meeting study entry requirements enrolled randomized active versus placebo superimposed background treatment r788 placebo patients followed efficacy safety parameters 6 months investigator taper corticosteroids clinically warranted.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00752999"
    },
    {
        "Title": "Omega 3 Fatty Acids and Systemic Lupus Erythematosus",
        "Summary": " fatty acids considered lipids based data epidemiological studies greenland eskimos whose diet rich fish sources polyunsaturated fatty acids fatty acids family mainly acid eicosapentaenoic epa docosahexaenoic d",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02524795"
    },
    {
        "Title": "PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluate efficacy safety tolerability three different doses administered addition standard therapy subjects active in disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Philippines, Taiwan, Brazil, India, Colombia, Chile, Hong Kong, Mexico, Peru, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01162681"
    },
    {
        "Title": "Hormonal and Environmental Risk Factors for Developing Systemic Lupus Erythematosus: The Carolina Lupus (CLU) Study",
        "Summary": " systemic lupus erythematosus sle severe chronic disabling autoimmune disease significantly affects health status quality life since disease occurs often young adults sle also affect work disability however currently little information disability longitudinal studies sle participants enrolled carolina lup",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00342095"
    },
    {
        "Title": "Utility of a Measure of Lupus Low Disease Activity State (LLDAS) in SLE",
        "Summary": " belimumab hgs1006 fully human monoclonal antibody subjects systemic lupus erythematosus sle ii phase 3 randomized study evaluate efficacy safety. study secondary pooled analysis two completed phase 3 clinical trials phase 3",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02769195"
    },
    {
        "Title": "Belimumab Phase I Study in Chinese Subjects With Systemic Lupus Erythematosus",
        "Summary": "Belimumab gsk1550188 developed dosing regimen intravenous iv infusion treatment sle single dose study evaluate safety tolerability pharmacokinetics pk pharmacodynamics pd belimumab chinese sle subjects total approximately 20 subjects enrolled receive",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02880852"
    },
    {
        "Title": "Reducing Depressive Symptoms in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus sle comorbid depressive symptoms. purpose randomized controlled trial evaluate efficacy skills training intervention.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01120652"
    },
    {
        "Title": "Intervention to Improve Quality of Life in African American Lupus Patients",
        "Summary": "iqan project designed examine whether uniquely tailored intervention program improve quality life decrease indicators depression reduce perceived biological indicators stress. goal proposed project enhance principal investigator research ability conduct behavioral interventions people lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Depression, Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01837875"
    },
    {
        "Title": "Effect of Applying Ujjayi Pranayama on Cortisol in Lupus Patients",
        "Summary": "Lupus rates depression insomnia easy fatigue perception anxiety high women pranayama yogic intervention may treat problems. stress vulnerability common lupus patients specifically women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05748899"
    },
    {
        "Title": "Fatigue in Lupus Intervention Programmes (FLIP)",
        "Summary": "Group cognitive behavioural approach effective helping patients manage fatigue pandemic changed way healthcare delivered nhs healthcare professionals find alternate solutions virtual appointments study aims establish whether virtual group fatigue management programme is effective.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06308770"
    },
    {
        "Title": "A Study of the Metabolic Syndrome in Patients With Systemic Lupus Erythematosus",
        "Summary": " metabolic syndrome found in patients with systemic lupus erythematosus recent years.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Metabolic Syndrome, Cardiovascular Risk Factors, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00982670"
    },
    {
        "Title": "Dose Ranging Study of Brentuximab Vedotin in Adults With Lupus",
        "Summary": "Brentuximab vedotin adults active systemic lupus erythematosus sleus. purpose study evaluate safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02533570"
    },
    {
        "Title": "Anti KU Antibodies and Its Relationship With Systemic Lupus Erythematosus",
        "Summary": "Systemic lupus erythematosus sle multi system autoimmune disorder abroad spectrum clinical presentations diagnosis sle depending systemic lupsus international collaborating clinics slicc criteria. requires either patient satisfy at least 4 17 criteria including least 1 11",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05900232"
    },
    {
        "Title": "Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
        "Summary": "Cenerimod is used to treat systemic lupus erythematosus sleus. The study was designed to assess efficacy and safety of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Greece, Spain, Ukraine, Georgia, Russian Federation, Italy, Poland, United Kingdom, Puerto Rico, Romania, Bulgaria, Philippines, Turkey, France, Taiwan, Czechia, Japan, Germany, Israel, Chile, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03742037"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus",
        "Summary": "Rontalizumab compared placebo patients moderately severely active systemic lupus erythematosus sleus. phase ii randomized multicenter study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Russian Federation, Colombia, Mexico, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00962832"
    },
    {
        "Title": "Precision Medicine in LN: A Multicenter Proof-of-concept Study for Histopathological Biomarkers Analysis in Renal Biopsy",
        "Summary": "Lupus nephritis ln may affect approximately half patients systemic lupus erythematosus sle ln major cause morbidity important predictor mortality patients sle patients may develop renal disease within 10 years time diagnosis studies described",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Spain",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05358652"
    },
    {
        "Title": "Ultraviolet Light Therapy for Systemic Lupus Erythematosus",
        "Summary": " objectives evaluate mechanisms ultraviolet light therapy patients systemic lupus erythematosus normal controls.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00004375"
    },
    {
        "Title": "Lupus Education Alliance Program",
        "Summary": "Study evaluated effect navigation interventions testing vaccination people systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, COVID-19",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05243875"
    },
    {
        "Title": "Systemic Lupus Erythematosus (SLE) Prospective Observational Cohort Study (SPOCS)",
        "Summary": "Spocs is an international multicenter prospective observational cohort study study. Study visits are designed to systematically describe comprehensive clinical features.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany, France, Spain, Australia, Canada, Italy, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03189875"
    },
    {
        "Title": "Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus",
        "Summary": " purpose study explore safety efficacy recombinant cd19xcd3 double antibody systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06400537"
    },
    {
        "Title": "A Study of GC012F Injection in Subjects With Refractory Systemic Lupus Erythematosus",
        "Summary": " multicenter phase clinical study assess safety efficacy gc012f injection subjects refractory systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06530849"
    },
    {
        "Title": "A Trial of Rosuvastatin in Systemic Lupus Erythematosus",
        "Summary": "Study examine effects rosuvastatin cholesterol lowering drug given patients degree thickening arteries course two years. Participants randomly assigned two groups one group given active drug whereas placebo subjects study cardiac magnetic resonance.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Atherosclerosis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01170585"
    },
    {
        "Title": "Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases",
        "Summary": " clinical trial iit aimed evaluating safety tolerability pharmacokinetics pharmacodynamics efficacy patients active.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome, Autoimmune Diseases",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06549296"
    },
    {
        "Title": "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants with Systemic Lupus Erythematosus",
        "Summary": "Study evaluated safety preliminary efficacy ata3219 treatment participants lupus nephritis ln following lymphodepletion.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06429800"
    },
    {
        "Title": "GADD34 and Type I IFN Response Genes in SLE",
        "Summary": " gadd34 growth arrest dna damage regulatory subunit pp1 phosphat enzyme 1 phosphatase dephosphorylates eif2alpha eucaryotic initiation factor 2 alpha subunit representing negative feedback loop unfolded protein response",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03206359"
    },
    {
        "Title": "Epigenetics in Lupus Nephritis",
        "Summary": "Study identifies epigenetic changes detectable sera in patients suffering systemic lupus erythematosus. Study analyzes whether circulating dna fragments 1 different patients without lupu nephritis 2 present.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04648059"
    },
    {
        "Title": "Cyclosporine A or Intravenous Cyclophosphamide for Lupus Nephritis: The Cyclofa-Lune Study",
        "Summary": " cyclosporine suggested efficient safe treatment alternative. intravenous cyclophosphamide considered standard care treatment for proliferative lupus nephritis however use limited potentially severe toxic effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czech Republic",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00976300"
    },
    {
        "Title": "Association Between Long-term Hydroxychloroquine Treatment and Outcome of a History of Symptoms Suggestive of COVID-19 Infection During the Epidemic Period in France in Patients With Autoimmune Disease",
        "Summary": "The study aims to determine potential influence active hydroxychloroquine intake has on patients. Patients were asked to answer a standardized questionnaire phone call.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "SARS-CoV-2, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sjogren's Syndrome, Psoriatic Arthritis",
        "Phases": "N/A",
        "IDestudio": "NCT04345159"
    },
    {
        "Title": "Lupus Genetics Studies",
        "Summary": "Lupus erythematosus is a rare form of lupus. There are one living members diagnosed with the disease in the United States.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00071175"
    },
    {
        "Title": "Systemic Lupus Erythematosus and Chlordecone Impregnation in Martinique",
        "Summary": "Chlordecone could explained estrogenic hormonal properties systemic lupus erythematosus sle autoimmune disease whose sensitivity estrogen well known reflected 1 clear predominance women 2 predominance woman childbearing age 3 risk exacerbation event pregnancy",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Renal Disease",
        "Phases": "N/A",
        "IDestudio": "NCT06365359"
    },
    {
        "Title": "The Role of Some Hematological Parameters in Juvenile Systemic Lupue Erythematosus",
        "Summary": " juvenile systemic lupus erythematosus autoimmune disorder multisystem involvement leading inflammatory damage joints kidney central nervous system hematopoietic system although prevalence rate rises.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06227559"
    },
    {
        "Title": "Health-related Quality of Life Measure in Pediatric Lupus",
        "Summary": "Study uses pediatric systemic lupus erythematosus sle purpose prospective study primarily determine validity reliability new quality life hrqol measure. examine psychometric properties brief quality life qol.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Quality of Life",
        "Phases": "N/A",
        "IDestudio": "NCT00280137"
    },
    {
        "Title": "COVID-19 Vaccination in Rheumatic Disease Patients",
        "Summary": "Research done study immune responses vaccination patients rheumatic diseases. research done to test immune responses of patients with rheumatoid diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT04839315"
    },
    {
        "Title": "Evaluate Efficacy, Safety and Tolerability, PK and PD of Emapalumab in Children and Adults With MAS in Still's or SLE",
        "Summary": "Emapalumab is being tested for use in the treatment of systemic lupus erythematous. The study will assess safety tolerability efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Japan, Germany, France, Spain, Netherlands, Canada, China, Italy, United States, Poland, Sweden, United Kingdom",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Macrophage Activation Syndrome, Secondary Hemophagocytic Lymphohistiocytosis, Still Disease, Systemic Lupus Erythematosus, SJIA, AOSD, MAS",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05001737"
    },
    {
        "Title": "Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations",
        "Summary": " azathioprine still considered treatment choice manifestations systemic lupus erythematosus sle estimated efficacy 45 several studies demonstrated efficacy. hydroxychloroquine prednisolone relapsing flares included patients stratified according flare",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01112215"
    },
    {
        "Title": "Anti-infection of Low-does IL-2 in SLE",
        "Summary": "An objective clinical study evaluate potential effect patients may have on their quality of life. The study was conducted by the University of California, San Francisco.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02932137"
    },
    {
        "Title": "Web-based Genetic Research on Lupus",
        "Summary": "New lupus research study first understand genetic associations found people dna disease. Second apply understanding drug development efforts investigator partners pfizer.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02530944"
    },
    {
        "Title": "A Study Evaluating the Effects of GLPG3970 Given as Oral Treatment for 12 Weeks in Adults With Systemic Lupus Erythematosus",
        "Summary": " glpg3970 subjects active systemic lupus erythematosus sle evaluate effect disease biomarkers determine pharmacokinetics pk profile safety tolerability pharmacodynamics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Spain, Ukraine, Poland, Moldova, Republic of",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04700267"
    },
    {
        "Title": "A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.",
        "Summary": " purpose study determine whether effective treatment skin joint serological manifestations systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02185040"
    },
    {
        "Title": "A Phase 2a of RSLV-132 in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study evaluates impact of 13 intravenous infusions on systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02660944"
    },
    {
        "Title": "A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Baricitinib is a treatment for systemic lupus erythematosus sle completed final treatment visit study nct03616912.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Switzerland, Australia, United States, Serbia, Greece, Spain, Russian Federation, China, Italy, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Philippines, South Africa, France, India, Netherlands, Taiwan, Czechia, Japan, Argentina, Germany, Brazil, Israel, Croatia, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03843125"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus",
        "Summary": "Dapirolizumab pegol dzp treatment standard care soc medication achieve clinically relevant long term improvement moderate severe disease activity. purpose study evaluate ability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Australia, United States, Serbia, Greece, Spain, Korea, Republic of, Denmark, Italy, Poland, Belgium, Romania, Bulgaria, Philippines, France, Canada, Peru, Taiwan, Czechia, Argentina, Germany, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04294667"
    },
    {
        "Title": "Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis",
        "Summary": " lupus vasculitis autoimmune conditions life threatening order treat conditions toxic therapies cyclophosphamide steroids often required standard treatments associated significant side effects. proportion patient respond conventional therapies newer safer therapies sought rituximab.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, ANCA Associated Vasculitis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00293072"
    },
    {
        "Title": "Prediction of Lupus Renal Flares Study",
        "Summary": "Next 6 months patients systemic lupus erythematosus outpatient clinic included prospective biomarker study regardless disease activity. urinary cells analyzed flow cytometry 6 months sample collection clinical conducted.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05362812"
    },
    {
        "Title": "Observational Multicenter Case-control Study to Assess Nailfold Capillary Abnormalities in Systemic Lupus Erythematosus",
        "Summary": "Study investigate role nailfold capillaroscopy assessment patients systemic lupus erythematosus sle primary endpoint compare frequency major capllaroscopic abnormalities patients sle healthy controls secondary endpoints. Patients active sle active sle healthy",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02801812"
    },
    {
        "Title": "Anti-CD19 CAR-NK Cells in Refractory/Relapsed Systemic Lupus Erythematosus",
        "Summary": "Study aims to investigate safety efficacy of cells used to treat systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06421701"
    },
    {
        "Title": "Autoimmunity in Sisters of Lupus Patients",
        "Summary": "Study enrolled 400 unaffected sisters. Young women diagnosed with cancer followed annual health questionnaire csq blood sample.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01076101"
    },
    {
        "Title": "A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus",
        "Summary": "Study finds baricitinib is effective safe study drug for systemic lupus erythematosus slei.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Austria, Germany, Switzerland, Taiwan, Brazil, Greece, Israel, Australia, Croatia, Netherlands, Hungary, Mexico, China, Russian Federation, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03616912"
    },
    {
        "Title": "A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321",
        "Summary": " purpose study evaluate safety subjects to see if they are at risk of suicide. Study found no evidence of suicide risk among subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Philippines, Taiwan, Brazil, India, Colombia, Chile, Hong Kong, Mexico, Peru, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01305746"
    },
    {
        "Title": "Study of Systemic Lupus Erythematosus",
        "Summary": "Patients evaluated medical history physical examination blood urine tests procedures may include 1 electrocardiogram 2 urine collection 3 imaging studies chest joint magnetic resonance imaging mri scans bone scans bone densitometry 4 questionnaire degree disease activity survey risk factors disease",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00001372"
    },
    {
        "Title": "Safety and Efficacy of Telitacicept in the Treatment of Systemic Lupus Erythematosus (SLE)",
        "Summary": " systemic lupus erythematosus sle highly specific autoimmune disease involves multiple systems due abnormal immune activation classical diffuse connective tissue disease autoimmune inflammation prominent manifestation b cells.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06458972"
    },
    {
        "Title": "Systemic Lupus Erythematosus in Gullah Health",
        "Summary": " systemic lupus erythematosus sle autoimmune disease characterized production autoantibodies multiple organ involvement diverse clinical symptoms immunologic manifestations african americans disproportionately higher risk developing sle develop sle earlier age increased morbidity mortality compared euro",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00756769"
    },
    {
        "Title": "A Study of NKX019, a CD19 CAR NK Cell Therapy, in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Primary objective safety tolerability nkx019 administered lymphodepletion ld secondary objectives assess clinical activity. Subjects systemic lupus erythematosus sle without active lupUS nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06518668"
    },
    {
        "Title": "A Study of Imvotamab in Severe Systemic Lupus Erythematosus",
        "Summary": "Study to determine safety tolerability imvotamab patients severe systemic lupus erythematosus failed prior therapies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of, Poland, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06041568"
    },
    {
        "Title": "The Role of ITGAM in Systemic Lupus Erythematosus",
        "Summary": "Study examine role itgam molecule in human development. Study looked at subjects with known genetic variation in itgam gene.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01230112"
    },
    {
        "Title": "Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus",
        "Summary": "Study evaluate safety efficacy human umbilical cord derived mesenchymal stem cells transplantation systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT03219801"
    },
    {
        "Title": "WEUKBRE5716: Steroid-related Damage in Systemic Lupus Erythematosus (Hopkins)",
        "Summary": "Study designed assess association steroid exposure five potentially adverse events within cohort individuals systemic lupus erythematosus sle study objectives quantify fraction risk new diabetes ii hypertension ii cataracts iv osteoporosis v avascular necrosis",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01616472"
    },
    {
        "Title": "Screening Biomarkers for Severe Lupus Based on Multi-omics Studies",
        "Summary": " order achieve accurate diagnosis treatment disease performed rna sequencing atac assay transposase accessible chromatin chromatin open sequencing lupus patients early stage comparing normal controls. rheumatic immune diseases rheumatoid arthritis treatment dozens genes independently",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05539001"
    },
    {
        "Title": "A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluate efficacy safety treatment. active treatment active treatment. outcome study evaluate effectiveness of treatment. outcomes.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06535412"
    },
    {
        "Title": "A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice",
        "Summary": " anifrolumab study treatment effectiveness real world aster study collect real world data obtain good understanding sustained clinical effect patient quality life outcomes among diagnosed sle patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy, Sweden, United Arab Emirates",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05637112"
    },
    {
        "Title": "Catalytic Antibodies and Lupus in Martinique",
        "Summary": " martinique island french area high prevalence incidence systemic lupus erythematosus sle respectively 100000 100000 many cases disease concerns afro caribbean women whose excessively high also organic damages frequent disease fatal studies shown cyt",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01157468"
    },
    {
        "Title": "A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation",
        "Summary": " purpose study evaluate tablet formulation versus capsule formulation. Also evaluate effect meal increased gastric ph tablet formulation.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03254784"
    },
    {
        "Title": "Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity",
        "Summary": "Case control study aims to determine whether spontaneous coronary artery dissection scad associated autoimmune diseases update incidence scad cohort.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sj\u00f6gren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud",
        "Phases": "N/A",
        "IDestudio": "NCT03941184"
    },
    {
        "Title": "The Therapeutic Value and Mechanism of Recombinant Human Interleukin-2 on Children With Rheumatic Diseases",
        "Summary": "Study aims explore therapeutic value mechanism for children with rheumatic diseases. Study aims to identify potential treatments for systemic lupus erythematosus, primary sj\u00f6gren syndrome and juvenile idiopathic arthritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04397107"
    },
    {
        "Title": "A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus",
        "Summary": " deucravacitinib compared placebo active moderate severe systemic lupus erythematosus sle population. purpose study evaluate effectiveness safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Thailand, Greece, Spain, Poland, United Kingdom, Puerto Rico, Turkey, Bulgaria, India, Portugal, Peru, Taiwan, Czechia, Japan, Argentina, Brazil, Chile, Hungary, Mexico, Singapore",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05620407"
    },
    {
        "Title": "Haematological Indices in Systemic Lupus Erythematosus",
        "Summary": "Study investigates value several hematological indices. Red blood cell distribution width mean platelet volume mpv ratio neutrophil c3 ratio biomarkers activity systemic lupus erythematosis patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatic Diseases, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04110184"
    },
    {
        "Title": "A Study of Belimumab in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Two different doses belimumab administered to patients with systemic lupus erythematosus sle disease. Study evaluated efficacy safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Costa Rica, Sweden, United States, Spain, Italy, Poland, United Kingdom, Puerto Rico, Belgium, Romania, France, Netherlands, Canada, Germany, Czech Republic, Slovakia, Israel, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00410384"
    },
    {
        "Title": "Libman-Sacks Endocarditis as a Cause of Neuropsychiatric Systemic Lupus Erythematosus",
        "Summary": "Study determine whether endocarditis inflammation heart valves cause neuropsychiatric manifestations. stroke transient ischemic attacks cognitive dysfunction seizures acute confusional state psychosis patients systemic lupus erythematosus hypothesis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00858884"
    },
    {
        "Title": "Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus",
        "Summary": "Study evaluates safety tolerability pharmacokinetics pk pharmacodynamics pd efficacy kp104 participants systemic lupus erythematosus sle microangiopathy tma study consists 2 parts.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05504187"
    },
    {
        "Title": "A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study drug ly3471851 safe effective adults systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, Ukraine, Russian Federation, Korea, Republic of, Poland, Puerto Rico, Romania, India, Canada, Taiwan, Czechia, Japan, Argentina, Germany, Israel, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04433585"
    },
    {
        "Title": "Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases",
        "Summary": "Study assess effect mindfulness meditation program administered via smartphone application on rheumatic disease patients. Study assess effect on quality of life for patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03937856"
    },
    {
        "Title": "A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Main purpose study evaluate safety tolerability study drug known ly3471851. Study last 79 days participant.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03556007"
    },
    {
        "Title": "A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Repeat Doses of GSK2586184 and the Effect of Food and Gender",
        "Summary": "Study investigate safety tolerability pharmacokinetics pharmacodynamics single repeat doses 800 mg gsk2586184 healthy subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01687309"
    },
    {
        "Title": "Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients",
        "Summary": "Primary objective assess tolerability safety. Secondary objectives assess male female lupus patients pharmacokinetics. Following parameters safety estrogens.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02321709"
    },
    {
        "Title": "Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease",
        "Summary": " systemic lupus erythematosus relatively common autoimmune disease affects mainly disease result accelerated atherosclerosis major cause mortality morbidity research shown patients sle abnormalities myocardial perfusion even coronary stenoses coronary angiography.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00188188"
    },
    {
        "Title": "An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus",
        "Summary": "Study investigate assess effects participants systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Romania, Argentina, Germany, Taiwan, Brazil, Spain, Israel, Australia, Russian Federation, Colombia, Hungary, Canada, Korea, Republic of, Mexico, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03252587"
    },
    {
        "Title": "Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan",
        "Summary": "Ankylosing spondylitis rheumatoid arthritis ra systemic lupus erythematosus sle common rheumatic diseases dealt rheumatologists taiwan previous studies 3 diseases broad impacts quality life",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Ankylosing Spondylitis",
        "Phases": "N/A",
        "IDestudio": "NCT00747578"
    },
    {
        "Title": "Effect of Hormone Replacement Therapy on Lupus Activity",
        "Summary": "Menopausal symptoms depression assessed utilizing greene climacteric scale questionnaire. Bone mineral density lumbar spine hip performed dual energy absorptiometry. Blood urine samples measure biochemical markers.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00392093"
    },
    {
        "Title": "Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE)",
        "Summary": "Primary objective study confirm clinical efficacy epratuzumab treatment subjects systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Germany, South Africa, France, Brazil, Spain, Ukraine, India, Russian Federation, Hungary, Mexico, Canada, Italy, Poland, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01261793"
    },
    {
        "Title": "Objective Measurement With TCM Pattern for AIDDES",
        "Summary": "Explore association tcm pattern tcm tongue diagnosis autoimmune disease dry eye syndrome. explore association t cm pattern t cm tongue diagnosis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "RECRUITING",
        "Conditions": "Sj\u00f6gren's Syndrome, Systemic Lupus Erythematosus, Dry Eye Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT04747288"
    },
    {
        "Title": "BLYS and IFN in SLE",
        "Summary": " protocol tests whether changes blys ifn detected normal immune response vaccine. vaccine whether response differs lupus healthy controls.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00611611"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE",
        "Summary": "Belimumab administered subcutaneous sc rituximab administered intravenous iv infusions total duration study 104 weeks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Germany, France, Brazil, Spain, Netherlands, Russian Federation, Mexico, Canada, Korea, Republic of, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03312907"
    },
    {
        "Title": "A First Time in Human Study to Evaluate the Safety and Tolerability of GSK3996401 Following Dosing With GSK4347859 in Healthy Participants",
        "Summary": "First time human ftih study means first time gsk4347859 given humans study designed investigate safety tolerability concentration gsk3996401 activated form. Part 1 consists 2 planned cohorts 4 treatment periods expected 8 dose levels part 2 investigate",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06188507"
    },
    {
        "Title": "Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation",
        "Summary": "Main objective study generate diagnosis tools. Identification molecular causes pids variability disease outcome transcriptional level using combination omics signatures.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Autoimmune Lymphoproliferative Syndrome, Autoimmune Cytopenia, Autoimmune Diseases, Autoimmune Anemia, Autoimmune Thrombocytopenia, Autoimmune Hepatitis, Autoimmune Diabetes, Autoimmune Rheumatologic Disease, Systemic Lupus Erythematosus, Juvenile Idiopathic Arthritis, Hemophagocytic Lymphohistiocytoses, EBV Lymphoproliferation, RAS-Associated Autoimmune Leucoproliferative Disease, Primary Immunodeficiency, APECED, IPEX, BENTA, Enteropathy, Autoimmune, Combined Immunodeficiency, IBD",
        "Phases": "N/A",
        "IDestudio": "NCT04902807"
    },
    {
        "Title": "Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study evaluated safety tolerability, immunogenicity, pharmacokinetics, pharmacodynamics. Subjects were subjects in the study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00657007"
    },
    {
        "Title": "Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases",
        "Summary": " open clinical study evaluate efficacy safety chimeric antigen receptor cell immunotherapy targeting bcma cd19 sequentially treatment refractory autoimmune disease sjogren syndrome systemic lupus erythematosus autoimmune disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Lupus Erythematosus Acute, Sjogren's Syndrome",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06428188"
    },
    {
        "Title": "Nelfinavir in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune disease body immune system attacks different parts body. inflammation leads tissue damage different organ systems organ system may involved including skin joints kidneys nervous system heart lungs blood exact cause sle known patients",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02066311"
    },
    {
        "Title": "Effect of Curcumin on Systemic Lupus Erythematosus",
        "Summary": " curcumin found effects found improve disease activity lupus patients addition subjects rheumatoid arthritis well osteoarthritis also found benefit disease activity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03953261"
    },
    {
        "Title": "Dose-escalation Trial of Anti-C5aR Antibody in Healthy Subjects",
        "Summary": " trial conducted europe aim trial develop complement system targeted monoclonal antibody mab used treatment subjects chronic autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "COMPLETED",
        "Conditions": "Inflammation, Systemic Lupus Erythematosus, Rheumatoid Arthritis, Healthy",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02151409"
    },
    {
        "Title": "Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease",
        "Summary": " hydroxychloroquine hcq systemic lupus erythematosus sle medication effective reducing lupUS disease activity keeping patients stable reduced symptoms despite track record safety regard infection compared traditional immunosuppressive agents risk h",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05799378"
    },
    {
        "Title": "PRV-3279-2a Trial in Systemic Lupus",
        "Summary": "Study designed assess safety potential efficacy. flare prevention systemic lupus erythematosus sle patients. amelioration induced corticosteroid treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong, China, Puerto Rico, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05087628"
    },
    {
        "Title": "Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)",
        "Summary": " dipyridamole medication extensively used combination aspirin stroke prevention promising new treatment for lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01781611"
    },
    {
        "Title": "Hydroxychloroquine in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle disease immune system causing inflammation joints skin organ system many areas better approaches sle could improve outcomes one example relates hydroxychloroquine hcq key drug reduce risk serious disease flares increasing",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03802188"
    },
    {
        "Title": "A Study of GSK4527363 in Healthy Participants, Systemic Lupus Erythematosus (SLE) Participants and Healthy Chinese and Japanese Participants",
        "Summary": "Study assess safety tolerability pharmacokinetics pharmacodynamics immunogenicity gsk4527363 healthy participants part participants active sle part b healthy participants chinese japanese descent part c",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06576271"
    },
    {
        "Title": "A Clinical Study of CD19 Universal CAR-\u03b3\u03b4T Cells in Active Systemic Lupus Erythematosus",
        "Summary": "Cells active severe systemic lupus erythematosus. purpose study explore safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06106893"
    },
    {
        "Title": "Genetic Study of Lupus Patients and Their Families",
        "Summary": "The study aims to identify genetic factors associated with systemic lupus erythematosus sleus. The study also aims to collect information from families affected by lupUS.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00235378"
    },
    {
        "Title": "Aerobic Exercise on Improving Sleep in Systemic Lupus Erythematosus.",
        "Summary": "Exercise training improving sleep patients systemic lupus erythematosus. purpose study determine effectiveness.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, Sleep Disorders",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02037971"
    },
    {
        "Title": "Efficacy of Fish Oil in Lupus Patients",
        "Summary": "Dietary supplementation fish oil improve disease activity, according to study. Study looked at patients with systemic lupus erythematosus and other autoimmune diseases.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00828178"
    },
    {
        "Title": "Ascension\u00ae Post- Approval Study; PyroCarbon Metacarpophalangeal Total Joint Prosthesis",
        "Summary": "Mcp. study consecutive enrollment study patients treated mcp. patients. Patients treated for mcp treated as part of mcp study. study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus Erythematosus, Osteoarthritis, Post-traumatic Arthritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02408471"
    },
    {
        "Title": "Autologous Stem Cell Transplantation for Refractory Systemic Lupus Erythematosus (ASSIST)",
        "Summary": " immunoablative chemotherapy followed autologous hematopoietic stem cell transplantation asct recently emerged promising experimental therapy severely affected patients providing potential achieve remission. glucocorticoids immunosuppressants amelior",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00750971"
    },
    {
        "Title": "The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)",
        "Summary": "Study includes two visits screening visit women meet criteria offered participate sign informed consent form icf initial patient data input done retrospectively case report forms crf filled patient visit conducted accordance routine practice healthcare professionals hcps recommendations individual basis experienced rhe",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Russian Federation",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06056778"
    },
    {
        "Title": "Comparison Between Early-onset and Late-onset Patients With Systemic Lupus Erythematosus.",
        "Summary": "Study aims compare clinical features hematological indices disease activity patients systemic lupus erythematosus evaluate relationship.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06294483"
    },
    {
        "Title": "Lupus Atherosclerosis Prevention Study",
        "Summary": " cardiovascular disease specifically atherosclerosis major cause mortality. systemic lupus erythematosus sle developed countries. coronary artery disease stroke contribute morbidity surviving patients. traditional cardiovascular risk factors prothrombotic factors playing important roles",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00120887"
    },
    {
        "Title": "Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases",
        "Summary": " evaluate safety utaa09 injection treatment autoimmune disease aid evaluate pharmacokinetic pk profile. evaluate pharmacodynamic pd characteristics. evaluate initial efficacy. evaluate immunogenicity.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Systemic Sclerosis, Sjogren's Syndrome, Rheumatoid Arthritis, Immune Thrombocytopenia, Primary Biliary Cholangitis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06417398"
    },
    {
        "Title": "The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria",
        "Summary": "Lupus erythematosus sle although immunosuppressive therapy often effective treatment acute lupus nephritis significant proportion patients show persistent proteinuria resolution acute nephritic process develop progressive renal failure preliminary evidence calcitri",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus, Nephritis, Proteinuria",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00508898"
    },
    {
        "Title": "Memantine in Systemic Lupus Erythematosus",
        "Summary": " npsle syndromes recently developed cognitive dysfunction appears prevalent novel mechanism subset sle patients cognitive dysfunction antibodies nr2 glutamate receptor propose double trial determine whether sle patients without nr1 glutamate receptor antibody significant improvement.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00181298"
    },
    {
        "Title": "Anti-CD20 Antibodies for Treatment of SLE-PAH",
        "Summary": "Rituximab is being investigated as a treatment for autoantibody response disease. The trial is the first of its kind in the world.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Pulmonary Arterial Hypertension",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05828147"
    },
    {
        "Title": "Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Single Doses and Multiple Doses of BIIB059 (Litifilimab) in Healthy Volunteers and Participants With Systemic Lupus Erythematosus",
        "Summary": " primary objective parts 1 2 evaluate safety tolerability either intravenous iv doses single subcutaneous sc dose biib059 litifilimab healthy volunteers hv single iv dose participants systemic lupus erythematosus sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Healthy Volunteers",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02106897"
    },
    {
        "Title": "Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)",
        "Summary": " aim proposal test antibody restore normal threshold tolerance patients. compare polyreactivity autoreactivity immature central tolerance na\u00efve b cells peripheral tolerance peripheral blood along study bliss believe study treatment reconstitution time.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03975361"
    },
    {
        "Title": "Serologic Profile of SARS CoV2 in COVID-19 Patients With Systemic Diseases",
        "Summary": " observational study aiming assess serological profile patients. systemic diseases systemic lupus erythematosus sjogren syndrome sarcoidosis inflammatory myopathies beh\u00e7et disease rheumatoid arthritis spondylo",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Tunisia",
        "OverallStatus": "UNKNOWN",
        "Conditions": "SARS-CoV Infection, Systemic Disease, Systemic Lupus Erythematosus, Sjogren's Syndrome, Sarcoidosis, Inflammatory Myopathy, Beh\u00e7et Disease, Rheumatoid Arthritis, Spondyloarthritis",
        "Phases": "N/A",
        "IDestudio": "NCT04530461"
    },
    {
        "Title": "Single Dose Study to Investigate the Pharmacokinetics (PK) and Safety of Belimumab 200 Milligrams (mg) Intravenous and 200 mg Subcutaneous Via Auto-injector in Chinese Healthy Subjects",
        "Summary": "Belimumab 200 mg total study duration approximately 13 weeks. randomized parallel group single dose study healthy chinese subjects purpose study characterize pharmacokinetic profile safety profile.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04136145"
    },
    {
        "Title": "Cardiology Prevention in Systemic Lupus Erythematosus (SLE)",
        "Summary": " preventive cardiology program compared usual care slowing progression carotid imt plaque 2 effect. propose feasibility study aggressive cv risk factor management directed. hypothesize lupus patients randomized for less cardiovascular progression.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00610805"
    },
    {
        "Title": "A Study of CD19 Targeted CAR T Cell Therapy in Patients With Severe, Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": ". phase study obecabtagene autoleucel autologous cells engineered chimeric antigen receptor car targeting cd19 establish tolerability safety. preliminary efficacy pharmacokinetics patients severe refractory sle",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom, Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06333483"
    },
    {
        "Title": "Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer",
        "Summary": " nivolumab may help body immune system attack cancer. may interfere ability tumor cells grow spread. phase ib trial studies side effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease, Malignant Solid Neoplasm, Multiple Sclerosis, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Sjogren Syndrome, Systemic Lupus Erythematosus, Systemic Scleroderma, Ulcerative Colitis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03816345"
    },
    {
        "Title": "Anifrolumab PK Study for Systemic Lupus Erythematosus (SLE)",
        "Summary": "Anifrolumab is a drug used to treat systemic lupus erythematosus. The drug has been approved in China.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05001698"
    },
    {
        "Title": "Evaluating HIV-1 Neutralization Antibody Breadth in Response to HIV gp120 Protein Vaccine in HIV-uninfected Adults With Quiescent Systemic Lupus Erythematosus",
        "Summary": " purpose study evaluate breadth potency neutralizing antibody nab responses. examine safety tolerability hiv gp120 protein vaccine adults diagnosed systemic lupus erythematosus sle stable disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "HIV Infections, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03618056"
    },
    {
        "Title": "Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis",
        "Summary": "Study aims defining role circulating microparticles in two rare diseases. Study aims to develop new therapeutic strategies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Systemic Scleroderma",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03575156"
    },
    {
        "Title": "A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)",
        "Summary": "Ocrelizumab added soc corticosteroid plus one two immunosuppressant regimens compared placebo added soc patients class iii iv lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00626197"
    },
    {
        "Title": "The Systemic Lupus Erythematosus (SLE) Activity Gene Expression (SAGE) Study",
        "Summary": "New blood test would allow treating physicians to accurately predict lupus flares. Test would allow physicians to start therapy early and achieve remission quickly. New test would identify individuals less severe flares thus require less aggressive treatments.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00671047"
    },
    {
        "Title": "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis",
        "Summary": " clinical research study learn addition abatacept safe improves effectiveness treatment patients active lupus nephritis also taking mycophenolate mofetil mmf corticosteroids.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Turkey, Argentina, South Africa, Taiwan, France, Brazil, Australia, India, Russian Federation, Hong Kong, Canada, China, Korea, Republic of, United States, Mexico, Poland, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00430677"
    },
    {
        "Title": "Feasibility and Safety of Acupuncture for Systemic Lupus",
        "Summary": "Pilot study to evaluate whether acupuncture safe acceptable people systemic lupus erythematosus sle sle patients assigned randomly receive either 10 sessions acupuncture or control intervention.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00493753"
    },
    {
        "Title": "Effect of Telitacicept on Transitional Regulatory B Cells in Patients With Systemic Lupus Erythematosus",
        "Summary": " telitacicept treatment changes transitional regulatory b lymphocyte t1 t2b cell subsets plasma blasts expression levels cytokines april baff sle sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Telitacicept, Systemic Lupus Erythematosus, Therapy",
        "Phases": "N/A",
        "IDestudio": "NCT06137053"
    },
    {
        "Title": "Autophagy in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus systemic autoimmune disease characterized wide range clinical manifestations. Skin mucosal lesions severe injuries central nervous system kidneys organs presence high titres autoantibodies nuclear components.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03583853"
    },
    {
        "Title": "A Continuation Trial for Subjects With Lupus That Completed Protocol HGS1006-C1056 or HGS1006-C1057",
        "Summary": " continuation study provide continuing treatment subjects for patients. Patients in the study will continue to receive treatment for the rest of their lives.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Sweden, Spain, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, United Kingdom, Puerto Rico, Belgium, Romania, Philippines, France, India, Netherlands, Canada, Peru, Taiwan, Czechia, Argentina, Germany, Slovakia, Brazil, Israel, Chile, Colombia, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00712933"
    },
    {
        "Title": "CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Blisibimod is a subcutaneous injection used to treat lupus erythematosus sle disease. The study was designed to evaluate the efficacy and safety of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Philippines, Brazil, Belarus, India, Georgia, Russian Federation, Colombia, Hong Kong, Korea, Republic of, Mexico, Singapore, Taiwan, Malaysia, Sri Lanka, Guatemala, Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01395745"
    },
    {
        "Title": "Laser Puncture and Program of Lifestyle Modification in Lupus Females",
        "Summary": " serum lipid profile significantly dysregulated female systemic lupus erythematosus patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05381545"
    },
    {
        "Title": "A Model About the Response of Belimumab in SLE",
        "Summary": " prospective cohort study aims to determine predictive model response to belimumab week 48. The study is the first of its kind in the U.S.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04893161"
    },
    {
        "Title": "Safety and Tolerability Study Of PF-06835375 In Subjects With Seropositive Systemic Lupus Erythematosus Or Rheumatoid Arthritis",
        "Summary": " phase 1 single multiple dose escalation study evaluate safety tolerability pharmacokinetics pharmacodynamics subjects seropositive sle ra design sponsor open placebo controlled study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Rheumatoid Arthritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03334851"
    },
    {
        "Title": "Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care",
        "Summary": "Study conducted assess safety tolerability immunogenicity repeat doses bos161721 20 milligrams mg 60 mg 120 mg administered subcutaneously adult participants moderately severely active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Bulgaria, Argentina, Philippines, Ukraine, Georgia, Colombia, Hungary, Mexico, Peru, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT03371251"
    },
    {
        "Title": "Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)",
        "Summary": " clinical trial evaluate causality relationship non vagus nerve stimulation waveform parameters therapeutic effect thus unlocking pathway optimize parameters maximize benefits therapy minimize unwanted side effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Autoimmune Disorder, Vagus Nerve Autonomic Disorder",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05704153"
    },
    {
        "Title": "Sequential Belimumab and T-cell Based Therapy in SLE",
        "Summary": "Sle produced specific type white blood cells called b cells belimumab monoclonal antibody b cells blocking action blys protein prolongs longevity enhances functions b cells found elevated patients sle approved fda treat patients sle study aims study effects",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Singapore",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04447053"
    },
    {
        "Title": "Study of Daxdilimab (HZN-7734) for the Treatment of Systemic Lupus Erythematosus in an Open-label Extension Study",
        "Summary": " daxdilimab participants systemic lupus erythematosus completing treatment period recast sle clinical study. phase 2 extension study evaluate safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Taiwan, Greece, Spain, India, Mexico, Poland, United States, Serbia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05430854"
    },
    {
        "Title": "Randomized Study of Oral Contraceptives or Hormone Replacement Therapy in Women With Systemic Lupus Erythematosus",
        "Summary": "Oral contraceptives containing synthetic estrogens progestins disease activity premenopausal women inactive stable moderate systemic lupus erythematosus sle ii determine effect hormone replacement therapy conjugated estrogen progestin. objectives determine",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00006133"
    },
    {
        "Title": "Long-term Immunogenicity of a HPV Vaccine in SLE",
        "Summary": "Study found immunogenicity quadrivalent hpv vaccine patients were more likely to get the vaccine than healthy controls.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02477254"
    },
    {
        "Title": "Stress, Inflammation and Immune Response Pilot Study- Aim 3",
        "Summary": "The study will investigate effects stress glucose intake on the immune system. It will also test whether meditation alters neutrophil function.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Inflammation",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT04857151"
    },
    {
        "Title": "A Study to Evaluate the Tolerability, Safety and Effectiveness of Edratide in the Treatment of Lupus",
        "Summary": "It is thought edratide may able reduce symptoms of Parkinson's disease. It is also thought that it may be able to reduce symptoms in some other patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00203151"
    },
    {
        "Title": "Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases",
        "Summary": "Fluorine f 18 clofarabine is used to diagnose autoimmune inflammatory diseases. The tracer is injected into the body to measure the amount of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Autoimmune Disease, Crohn Disease, Inflammatory Disorder, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Takayasu Arteritis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT02925351"
    },
    {
        "Title": "Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease",
        "Summary": "Primary objective study assess dose response dose frequency epratuzumab patients. Secondary objective study assessed dose response and dose frequency of the drug in patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Brazil, Spain, Ukraine, India, Lithuania, Hungary, Hong Kong, Poland, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00624351"
    },
    {
        "Title": "Effects of Telehealth Initiative on Lupus Patients",
        "Summary": " sle mostly seen young women causes significant deformity patients sle disease activity body damage due disease treatment comorbidities drugs affect body image negatively sle causes changes body skin rashes uneven pigmentation vitiligo scars tooth loss alopecia",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05329831"
    },
    {
        "Title": "Safety of Administering Isoniazid to SLE Patients to Prevent TB",
        "Summary": "Systemic lupus erythematosus sle prototypical systemic autoimmune disease characterized heterogeneity multisystem involvement production multiple autoantibodies clinical features vary mild skin joint involvement severe conditions. Patients are immunocompromised due",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "RECRUITING",
        "Conditions": "Tuberculosis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT06618573"
    },
    {
        "Title": "Myeloid Derived Suppressor Cells in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle chronic invalidating chronic condition potential articular cutaneous renal neurologic involvement pathophysiology complex involves genetic environmental hormonal factors leading tolerance rupture among regulatory cells myeloid derived suppressor cells",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05424627"
    },
    {
        "Title": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With Autoimmune Disease (Ntrust-1)",
        "Summary": "Nkx019 allogeneic car nk cells targeting participants active lupus nephritis ln. phase 1 study determine safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Glomerulonephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06557265"
    },
    {
        "Title": "Atacicept Demonstrating Dose RESponSe",
        "Summary": "Systemic lupus erythematosis sle autoimmune disease meaning body immune system attacks organs tissues within immune system plasma cells make proteins called antibodies autoimmune disease bind one tissues thus referred autoantibodies atacicept blocks 2 factors",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01440231"
    },
    {
        "Title": "Epidemiology of Lupus Nephritis in Nephrology Unit in Assiut University Hospital",
        "Summary": "Study epidemiology lupus nephritis patients admitted nephrology unit inward outpatient clinic assiut nephrolog unit.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05120882"
    },
    {
        "Title": "A Study to Estimate the Relative Bioavailability, Tolerability and Safety of a Single Dose of Belimumab Self-Administered Subcutaneously (SC) by Healthy Subjects",
        "Summary": "Belimumab 200 mg belimumab sc single milliliter ml injection liquid formulation. 200 day 0 via assigned injection device subjects continue followed 70 days administration.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01894360"
    },
    {
        "Title": "A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Lupus Nephritis Previously Enrolled in Study U2970g",
        "Summary": "Rituximab administered scheduled basis approximately every 6 months subjects complete week 52 visit study u2970g eligible study long inclusion exclusion criteria met. phase ii multicenter extension study evaluate safety rituxin administered on a scheduled basis",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00404157"
    },
    {
        "Title": "Safety and Efficacy of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Proliferative Lupus Nephritis",
        "Summary": "Study evaluated efficacy safety intravenous treatment regimen two doses anifrolumab versus placebo adult subjects active proliferative lupus nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Argentina, Germany, Taiwan, France, Spain, Australia, Russian Federation, Hungary, Mexico, Korea, Republic of, Italy, Peru, United States, Poland, United Kingdom, Serbia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02547922"
    },
    {
        "Title": "NOX-E36 First-in-Human (FIH) Study",
        "Summary": "First time administered man principal aim study obtain safety tolerability data administered single intravenous iv subcutaneous sc doses. healthy male female subjects information together. pharmacokinetic pharmacodynamic data help establish doses dosage regimen route administration suitable multiple dose administration",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Chronic Inflammatory Diseases, Type 2 Diabetes Mellitus, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00976729"
    },
    {
        "Title": "Phase III Randomized, Double-Blind, Placebo-Controlled Study of Dehydroepiandrosterone in Women With Active Systemic Lupus Erythematosus",
        "Summary": " objectives evaluate safety efficacy synthetic dehydroepiandrosterone gl701 women active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00004662"
    },
    {
        "Title": "At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions",
        "Summary": "Mobile health platform helps patients contribute to medical research. Mobile health platform makes it easy for patients to participate in clinical trials.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis",
        "Phases": "N/A",
        "IDestudio": "NCT01931644"
    },
    {
        "Title": "Multicenter Trial Evaluating the Immunogenicity of HPV Vaccination in Girls on Immunosuppressive Therapy.",
        "Summary": "The primavera phase iia clinical trial objective assess immunologic response hpv vaccine population immunocompromised girls received immunosuppressive treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Transplantation, Systemic Lupus Erythematosus, Systemic Immune Disease",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01687192"
    },
    {
        "Title": "A Study to Characterize the Pharmacokinetics, Pharmacodynamics, and Safety of Anifrolumab in Adult Type I Interferon Test High Systemic Lupus Erythematosus Subject With Active Skin Manifestations",
        "Summary": " anifrolumab given via subcutaneous sc route administration adult systemic lupus erythematosus sle subjects type interferon ifn test high result active skin manifestations receiving standard care soc treatment addition efficacy anif",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hungary, Korea, Republic of, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02962960"
    },
    {
        "Title": "A Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": "Two different doses belimumab administered to patients with systemic lupus erythematosus sle disease. Study evaluated efficacy safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Argentina, Philippines, Brazil, Australia, India, Russian Federation, Colombia, Chile, Hong Kong, Korea, Republic of, Peru, Taiwan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00424476"
    },
    {
        "Title": "The Effect of BMS-986165 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients",
        "Summary": " purpose study investigate effect of combination oral contraceptive on healthy female patients. purpose study is to investigate effect on effect of oral contraceptive combination on healthy women.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Arthritic Psoriasis, Psoriasis, Inflammatory Bowel Diseases",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03262727"
    },
    {
        "Title": "Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine",
        "Summary": "Systemic lupus erythematosus sle chronic inflammatory disease often debilitating potentially consequences cause sle unknown current therapies lack specificity carry significant previously discovered depletion glutathione lymphocytes patients sle associated metabolic change elevation mitochondrial transmembrane",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00775476"
    },
    {
        "Title": "Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases",
        "Summary": " evaluate safety efficacy of cells subjects autoimmune diseases. evaluate safety effectiveness of cells subject to immune-boosting therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06316076"
    },
    {
        "Title": "Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study evaluates effect ramipril endothelial function on patients with systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT03979976"
    },
    {
        "Title": "Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus",
        "Summary": "Epratuzumab treatment subjects systemic lupus erythematosus sleus. primary objective study assess safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, Ukraine, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, United Kingdom, Belgium, Romania, Bulgaria, South Africa, France, Lithuania, Canada, Taiwan, Czechia, Germany, Estonia, Brazil, Israel, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01408576"
    },
    {
        "Title": "Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study designs patients purpose study study designed purposefully study population equivalent placebo group typical trials sle. hypothesis reason repeated disappointing outcomes clinical trials testing targeted immune biologics lupus may heterogeneity disease exacerbated variable effects immune homeostasis background medications must continued",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00987831"
    },
    {
        "Title": "Systemic Lupus Erythematosus and Accelerated Aging",
        "Summary": "Study aims evaluating phenomena immune system aging patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05698173"
    },
    {
        "Title": "Nivolumab in Patients With Advanced Non-Small Cell Lung Cancer and Pre-existing Autoimmune Disease",
        "Summary": "Nivolumab given days 1 15 cycle subjects permitted to continue treatment beyond initial recist. Patients screened within 28 days prior start dosing eligible.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Autoimmune Diseases, Non-small Cell Lung Cancer, Rheumatoid Arthritis, Psoriasis, Giant Cell Arteritis, Polymyalgia Rheumatica, Systemic Lupus Erythematosus, Crohn Disease, Multiple Sclerosis, Ulcerative Colitis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03656627"
    },
    {
        "Title": "A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult Subjects",
        "Summary": "The study is a randomized clinical study aimed evaluating safety tqb3702 tablets following single multiple doses administered healthy subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06448273"
    },
    {
        "Title": "PRediction Of Flares In Lupus With autoantibodiEs and Chemokines",
        "Summary": "Lupus erythematosus sle chronic autoimmune disease wide range clinical manifestations affecting several organs. Management lupus patients improved last years accurate models predicting disease progression lacking. Study design prospective observational single centre cohort study conducted.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04951427"
    },
    {
        "Title": "Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients",
        "Summary": "Study evaluated effect supervised physical exercise on patients with systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01712529"
    },
    {
        "Title": "Membrane Polyunsaturated Fatty Acid Content in Fibromyalgia and Systemic Lupus Erythematosus (SLE)",
        "Summary": "Polyunsaturated fatty acids \u03c93 pufas essential nutrients studies indicate incidence major depression md inversely related consumption fish rich concentration \u03c92 pufa plasma red blood cell rbc membranes several studies. \u03c96 \u03c9",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Israel",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Fibromyalgia, Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01460680"
    },
    {
        "Title": "Neuropsycatric Disorders Among Children With Systemic Lupus Erythematosus in Sohag University Hospital",
        "Summary": "Systemic lupus erythematosus sle chronic autoimmune disease involving multiple organs characterized production autoantibodies development tissue injury etiology sle partially known involving multiple genetic environmental factors many 50 patients sle neurological involvement course disease approximately 40",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06449794"
    },
    {
        "Title": "A Study of LY2127399 in Participants With Systemic Lupus Erythematosus",
        "Summary": " purpose sle study evaluate efficacy safety tolerability. two different doses ly2127399 administered participants active sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, United States, Thailand, Macedonia, The Former Yugoslav Republic of, Belarus, Ukraine, Korea, Republic of, Italy, Poland, Puerto Rico, Bulgaria, Philippines, Canada, Peru, Japan, Argentina, Germany, Croatia, Chile, Colombia, Singapore, Egypt, Guatemala",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01196091"
    },
    {
        "Title": "Study of Neonatal IgG Fc Receptor Expression in Natural Killer T Cells Expressing an Invariant T Receptor : Implication in the Pathophysiology of Systemic Lupus",
        "Summary": "Study evaluates variation expression neonatal fc receptor fcrn natural killer cells expressing invariant receptor inkt monocytes along surface expression fc gamma type ii receptor rii riii active newly diagnosed lupus patients compared inactive lup",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, Physiopathology",
        "Phases": "N/A",
        "IDestudio": "NCT05859191"
    },
    {
        "Title": "Balancing Lupus Experiences With Stress Strategies",
        "Summary": " linking psychosocial stress intervention clinical measures stress african american lupus patients assess utility method reducing perceived stress. providing necessary preliminary steps toward future investigations potential mechanisms.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT01351662"
    },
    {
        "Title": "Laser Acupuncture in Egyptian Systemic Lupus Females With Insulin Resistance",
        "Summary": " glucose hemosatasis oxidative stress abnormalities blood pressures high inflammatory status high presented lupus patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, PreDiabetes",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05632029"
    },
    {
        "Title": "Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level",
        "Summary": " statin used restricted groups rheumatologists due awareness side effects myositis hepatitis frequently found sle patients groups atherosclerosis patients reporting data autoimmune diseases occur statin use. early statin therapy sle patients high cholesterol level Atherosclerosis",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus, High LDL Cholesterol Level",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00866229"
    },
    {
        "Title": "A Single Ascending Dose Study in Healthy Participants and Multiple Dose Study of JNJ-55920839 in Participants With Mild to Moderate Systemic Lupus Erythematosus",
        "Summary": "Study assess safety tolerability following single ascending intravenous iv dose administration. Participants mild moderate systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Romania, Taiwan, Spain, Poland, United States, Moldova, Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Healthy",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02609789"
    },
    {
        "Title": "A Continuation Trial for Subjects With Systemic Lupus Erythematosus That Have Completed Protocol LBSL02",
        "Summary": " continuation study evaluate safety efficacy subjects sle disease. completed study lbsl02 benefitted treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00583362"
    },
    {
        "Title": "A Long-Term Study of the Safety and Tolerability of Repeated Administration of CEP-33457 in Participants With Systemic Lupus Erythematosus",
        "Summary": "The study evaluated long term safety tolerability of systemic lupus erythematosus sle. Participants participated in previous cephalon sponsored clinical study completed least visit 8 week 24 study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Germany, France, Spain, Ukraine, Hungary, Portugal, Poland, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01240694"
    },
    {
        "Title": "Duke Autoimmunity in Pregnancy Registry",
        "Summary": " autoimmune diseases lupus rheumatoid arthritis scleroderma sjogren syndrome wish become already pregnant follow women throughout pregnancy better understand autoimmune disease affects pregnancy vice versa.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Pregnancy, Systemic Lupus Erythematosus, Cutaneous Lupus, Rheumatoid Arthritis, Sjogren's Syndrome, Scleroderma",
        "Phases": "N/A",
        "IDestudio": "NCT00513591"
    },
    {
        "Title": "Velcade for Proliferative Lupus Nephritis",
        "Summary": " velcade induce remission class lupus nephritis refractory standard medications. primary objective test safety efficacy velcade.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis, Proteinuria, Hematuria",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01169857"
    },
    {
        "Title": "Comparison Between Tacrolimus (TAC) and Mycophenolate Mofetil (MMF) for Induction of Remission in Lupus Nephritis",
        "Summary": "Tacrolimus mycophenolate mofetil mmf induces complete remission in lupus nephritis patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01580865"
    },
    {
        "Title": "Lupus Flares and Histological Renal Activity at the End of the Treatment (LuFla)",
        "Summary": "Almost 30 percent patients total remission treatment relapse first 5 years factors associated renal relapses completly known investigators think histological control study performed patient complete remission.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Argentina",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT02313974"
    },
    {
        "Title": "Concentration-controlled Therapy of Mycophenolate Mofetil (MMF) in Proliferative Lupus Nephritis",
        "Summary": "Mycophenolic acid levels post dose monitored monthly 6 months. evaluate therapeutic response mmf treatment patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01042457"
    },
    {
        "Title": "The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus Nephritis",
        "Summary": "Study investigated effect mycophenolate mofetil cyclosphosphosphamide lymphocyte subsets patients proliferative lupus nephritis patients class ln randomized received 1 prednisolone plus ctx 6 months followed az",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02954939"
    },
    {
        "Title": "Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Ixazomib in Lupus Nephritis (LN)",
        "Summary": "ixazomib administered multiple oral doses escalating dose levels participants lupus nephritis. purpose study characterize safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, France, Spain, Russian Federation, Italy, United States, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02176486"
    },
    {
        "Title": "Safety and Efficacy on Deoxyspergualin (NKT-01) in Patients With Lupus Nephritis",
        "Summary": " aim open study determine efficient safe dose dosing schedule. induction response treatment lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czech Republic, Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00709722"
    },
    {
        "Title": "The Efficacy and Safety of Telitacicept and Belimumab in Active Lupus Nephritis in the Real World: a Prospective Cohort Study",
        "Summary": " lupus nephritis autoimmune disease inflammatory kidney damage caused deposition immune complexes kidney mainly characterized clinical manifestations albuminuria hematuria tubular urine pyuria creatinine elevation present many drugs glucocorticoid immunosuppress",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis, Belimumab, Telitacicept",
        "Phases": "N/A",
        "IDestudio": "NCT05588830"
    },
    {
        "Title": "T Regulatory Cells IN LUPUS NEPHRITIS",
        "Summary": "Study role regulatory cells pathogenesis lupus nephritis determine factors associated levels regs compare functional capacity regs ln normal individuals.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06428539"
    },
    {
        "Title": "Association Between Neuropathy and Some Autoantibodies in Systemic Lupus Erythematosus (SLE) Patients",
        "Summary": "Lupus nephritis peripheral neuropathy is a form of lupus. The disease is caused by a build-up of fluid on the optic nerve.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06610422"
    },
    {
        "Title": "Cardio Renal Effects of SGLT2 Inhibitors Among Lupus Nephritis Patients",
        "Summary": "Study aims assess sodium glucose linked transoprter inhibitors sgt2i role regression ongoing kidney cardiac diseases among lupus nephritis patient either diabetic different immunosuppressive therapy. dapagliflozin 10 mg 25",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "SLE, Lupus Nephritis, SGLT2 Inhibitors",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05748925"
    },
    {
        "Title": "International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus may change future due availability of new biological treatments. New biological treatments especially monoclonal antibodies patients active disease. One main causes treatment failure sle lack treatment adherence since drugs work.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01509989"
    },
    {
        "Title": "ELEVATE - (Empower Lupus Erythematosus Patients Via Allowing RemoTe Evaluation)",
        "Summary": " explore potential use of a personalized guided care monitoring module for patients with systemic lupus erythematosus sle using consented patient health information.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05347992"
    },
    {
        "Title": "Safety of Tofacitinib, an Oral Janus Kinase Inhibitor, in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus lupus autoimmune disease often involves many systems organs body symptoms include fever joint pains rashes serious Lupus can also damage organs like kidneys lungs brain drugs used in the study tofacit",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02535689"
    },
    {
        "Title": "Safety and Efficacy of Adipose Derived Stem Cells in Refractory Rheumatoid Arthritis, Systemic Lupus Erythematosus or Sharp's Syndrome",
        "Summary": "Study subjects significant refractory rheumatoid arthritis ra relapsing systemic lupus erythematosus sle sharp syndrome ss study enroll minimum 20 subjects ra 20 subjects sle 20 patients ss 6 week data serum tumor nec",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Rheumatoid Arthritis, Sharp's Syndrome",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02741362"
    },
    {
        "Title": "Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.",
        "Summary": "Study evaluate safety activity combination rituximab associated autoimmune diseases. Currently fda approved rheumatoid arthritis ra pemphigus vulgaris.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06581562"
    },
    {
        "Title": "ACTHar in the Treatment of Lupus Nephritis",
        "Summary": "Systemic lupus erythematosus sle disease immune system attacks healthy cells tissues causing inflammation damage organs. 50 sle patients experience inflammation kidneys. Two dosing arms acthar gel treating proliferative lupsus nephritis",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02226341"
    },
    {
        "Title": "Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis",
        "Summary": "Study evaluated abatacept treatment lupus nephritis. Used background cellcept mycophenolate prednisone corticosteroids.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, Russian Federation, Hong Kong, China, Italy, Korea, Republic of, Puerto Rico, Romania, Turkey, India, Canada, Peru, Taiwan, Czechia, Japan, Argentina, Brazil, Israel, Chile, Colombia, Mexico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01714817"
    },
    {
        "Title": "A Prospective Observational Registry of Patients Treated With LUPKYNIS\u00ae (Voclosporin) in the US",
        "Summary": " registry observational study designed assess utilization effectiveness lupkynis adult patients lupus nephritis ln united states us.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05337124"
    },
    {
        "Title": "A Phase II Study to Evaluate the Efficacy and Safety of SHR-1314 in Lupus Nephritis",
        "Summary": "Lupus nephritis is a chronic disease that affects more than 100,000 people in the U.S.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04924296"
    },
    {
        "Title": "Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis",
        "Summary": "Mescaline sodium tablets were tested on adult patients with lupus nephritis. Participants followed 60 180 270 540 days for treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05933213"
    },
    {
        "Title": "A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants",
        "Summary": " phase ii randomized study designed evaluate safety efficacy pharmacokinetics pk obinutuzumab adolescent participants ap aged 12 less 18 proliferative lupus nephritis ln. Also evaluate open label safety pk Obinut",
        "StudyType": "INTERVENTIONAL",
        "Countries": "South Africa, France, Brazil, Spain, Russian Federation, Mexico, Canada, Italy, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05039619"
    },
    {
        "Title": "Comparing the Efficacy of Tacrolimus and Mycophenolate Mofetil for the Initial Therapy of Active Lupus Nephritis",
        "Summary": " purpose study comparing efficacy tacrolimus mycophenolate mofetil initial therapy active lupus glomerulonephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT00371319"
    },
    {
        "Title": "Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis",
        "Summary": "Lupus eryhematosus sle may patients ameliorated medications suppress immune system nevertheless remains subset sle patients current strategies insufficient control disease. Investigators infuse expanded autologous msc patients lupus nephritis purpose",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00659217"
    },
    {
        "Title": "Study to Assess the Efficacy and Safety of FK506 Combined With Mycophenolate Mofetil (MMF) in Lupus Nephritis (III/IV/V)",
        "Summary": "Open prospective study assess efficacy safety. tacrolimus fk506 combined mmf treatment class. iv iv v iv v viii lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00298506"
    },
    {
        "Title": "Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease",
        "Summary": "In 1993 2006 987 patients older 20 years underwent native kidney biopsy renal division hospital 404 patients. 433 patients used recorded beginning 2003 2007 observation period patient defined start immediately registered measurement serum creatinine satisfying criteria designated index date lasted",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Diabetic Nephropathies, Lupus Nephritis, Rapidly Progressive Glomerulonephritis, Chronic Kidney Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT03201406"
    },
    {
        "Title": "Steroids in the Maintenance of Remission of Proliferative Lupus Nephritis",
        "Summary": " debate whether steroids prednisolone help suppress relapses systemic lupus erythematosus sle patients remission lupu nephritis prednisorone reduces relapses beneficial effects may be associated with the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00539799"
    },
    {
        "Title": "Comparison of the Efficacy of Two Rituximab Treatment Regimens in Patients With Lupus Nephropathy",
        "Summary": "Lupus nephropathy resistant conventional treatments. Two rituximab treatment regimens were compared.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01765842"
    },
    {
        "Title": "Trial of Belimumab Combined With Multi-target Induction Therapy in Lupus Nephritis",
        "Summary": "Belimumab combined therapy treatment severe lupus nephritis. Patients enrolled received pulse methylprednisolone dose followed intravenous belimumab dose 10mg per kilogram.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Remission, Safety Issues",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05863936"
    },
    {
        "Title": "Urinary G3BP as a Novel Biomarker in Lupus Nephritis",
        "Summary": "Lupus erythematosus without lupus nephritis glomerulonephritis kidney diseases find relation urinary binding protein levels lupUS neph arthritis correlate. urinary binding Protein levels sle disease activity activity.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06520670"
    },
    {
        "Title": "Aurinia Renal Response in Active Lupus With Voclosporin",
        "Summary": "Voclosporin compared placebo achieving renal response 52 weeks therapy subjects active lupus nephritis. purpose study assess efficacy voclosporins.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Costa Rica, United States, Serbia, Thailand, Belarus, Spain, Ukraine, Russian Federation, North Macedonia, Korea, Republic of, Poland, Puerto Rico, Turkey, Bulgaria, Philippines, South Africa, Dominican Republic, Netherlands, Canada, Peru, Taiwan, Japan, Argentina, Brazil, Vietnam, Croatia, Chile, Colombia, Mexico, Malaysia, Guatemala",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03021499"
    },
    {
        "Title": "JBT-101 in Systemic Lupus Erythematosus (SLE)",
        "Summary": "One hundred adults active joint disease least moderate pain enrolled. Participants receive 2 doses mouth three groups varying doses placebo 84 days continue followed by additional 28 days participant visits assess endpoints.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, SLE, Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03093402"
    },
    {
        "Title": "CLUE Study: Connective Tissue Disease Leg Ulcer Etiology Study",
        "Summary": "Explore hypothesis leg ulcers associated hypercoagulable states clue study evaluate patients connective tissue disease associated leg ulcer. identify risk factors especially hyper coagulability immunologic characteristics characterize pathogenesis predict response therapy assess impact lower extrem",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Connective Tissue Diseases, Blood Coagulation Disorders, Leg Ulcers, Rheumatoid Arthritis, Systemic Lupus Erythematosus, Systemic Scleroderma, Mixed Connective Tissue Disease",
        "Phases": "N/A",
        "IDestudio": "NCT00522002"
    },
    {
        "Title": "Mycophenolate Mofetil in Systemic Lupus Erythematosus (MISSILE)",
        "Summary": "Systemic lupus erythematosus sle independent risk factor atherosclerosis endothelial dysfunction earliest marker atheros sclerosis measured flow mediated dilation fmd brachial artery purpose study measure fmd mild.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, Atherosclerosis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01101802"
    },
    {
        "Title": "On Open-Label Study in Participants With Systemic Lupus Erythematosus",
        "Summary": " ly2127399 eligible sle participants completed core studies. purpose sle study evaluate safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Connective Tissue Disease, Autoimmune Disease",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01488708"
    },
    {
        "Title": "A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)",
        "Summary": "Obinutuzumab plus mycophenolate mofetil mmf acid mpa placebo plus participants proliferative ln. phase ii study compare efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, France, Costa Rica, Brazil, Spain, Israel, Colombia, Mexico, Italy, Peru, United States, Panama",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02550652"
    },
    {
        "Title": "The Effect of Curcumin on the Clinical Outcome of Pediatric Patients with Active Lupus Nephritis",
        "Summary": "Lupus nephritis sever common complication childhood onset systemic lupus erythematous aggressive inflammatory process triggered deposition. Children treated standard regimen consists immunomodulator mycophenolate mofetil strong steroid also hydro",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, SLE Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05714670"
    },
    {
        "Title": "Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis",
        "Summary": " antibodies directed receptor agonist antibodies previously studied human diseases preeclampsia transplantation scleroderma act binding at1 receptor effects blocked use angiotensin receptor blockers arb randomized open clinical trial investigators.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Atherosclerosis, Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03526042"
    },
    {
        "Title": "Dose Finding, Efficacy and Safety of BI 655064 in Patients With Active Lupus Nephritis",
        "Summary": "Overall purpose study assess efficacy three different doses bi 655064 placebo therapy standard care soc treatment active lupus nephritis order characterize relationship within therapeutic range select target dose phase ii development.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Thailand, Serbia, Greece, Spain, Hong Kong, Korea, Republic of, Italy, Poland, United Kingdom, Philippines, France, Canada, Portugal, Czechia, Japan, Germany, Mexico, Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02770170"
    },
    {
        "Title": "Long-Term Study of Multi-target Therapy as Maintenance Treatment for Lupus Nephritis",
        "Summary": " randomized prospective study compare efficacy safety therapy continuous induction maintenance treatment versus aza therapy. randomized prospectivestudy compare efficacy. safety therapy. continuous induction Maintenance treatment vs. aza Therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01056237"
    },
    {
        "Title": "Wellness & Workforce Solution for Lupus/Lupus Nephritis",
        "Summary": "Health360x aims to improve persistent disparities observed among women color lupus. Researchers test hypothesis culturally congruent coaching delivered via technology application.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06217107"
    },
    {
        "Title": "A Study of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis.",
        "Summary": "2 arm study compare efficacy safety cellcept plus corticosteroids versus cyclophosphamide. induction phase followed azathioprine maintenance phase maintaining remission renal function patients lupus nephritis patients randomized receive cellcept 1g bid",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00425438"
    },
    {
        "Title": "Safety and Efficacy Study of LymphoStat-B (Belimumab) in Subjects With Systemic Lupus Erythematosus (SLE)",
        "Summary": " purpose study evaluate safety efficacy. 3 different doses belimumab administered addition standard therapy patients active sle disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00071487"
    },
    {
        "Title": "Assessment of Safety and Efficacy of SGLT2is Among LN Patients",
        "Summary": "The study aims to assess safety efficacy of sglt2is among ln patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06113900"
    },
    {
        "Title": "Allogeneic Amniotic Mesenchymal Stem Cell Therapy for Lupus Nephritis",
        "Summary": "Study would evaluate safety efficacy of human amniotic mesenchymal stem cell treatment for lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Mesenchymal Stem Cells",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04318600"
    },
    {
        "Title": "The Iguratimod Effect on Lupus Nephritis (IGeLU)",
        "Summary": "Study randomized open trial patients active diffused lupus nephritis assess efficacy safety. Subjects randomly receive iguratimod cyclophosphamide followed azathioprine combined steroids.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02936375"
    },
    {
        "Title": "A Study of ANX009 in Adult Participants With Lupus Nephritis",
        "Summary": "Main purpose study to determine safety tolerability repeat doses. Participants lupus nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Philippines, Taiwan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05780515"
    },
    {
        "Title": "Efficacy and Safety of Tacrolimus Versus Mycophenolate in Lupus Nephritis",
        "Summary": "Corticosteroids combined with tac corticosteroid combined mmf. prospective randomized controlled international asian multicenter comparison.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02630628"
    },
    {
        "Title": "A Phase 1 Study of ADI-001 in Lupus Nephritis",
        "Summary": " phase 1 multicenter open label dose finding dose expansion study. patients lupus nephritis study consist different periods including screening lymphodepletion treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Autoimmune Diseases",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06375993"
    },
    {
        "Title": "RY_SW01 Cell Injection Therapy in Active Lupus Nephritis",
        "Summary": " cell injection preclinical research results shown injection significantly improved urine biochemical indicators tissue damage two lupus nephritis animal models msc administration occurrence rejection excellent safety mechanism action cell injection relatively clear demonstrating favorable therapeutic effects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06058078"
    },
    {
        "Title": "Lupus Nephritis Biomarker Study: Baseline Characteristics of Patients",
        "Summary": "The study followed lupus nephritis patients for 12 months. The aim was to establish baseline biomarker characteristics and determine variability.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT01470183"
    },
    {
        "Title": "Tacrolimus Versus Cyclophosphamide as Treatment for Lupus Nephritis",
        "Summary": "Tacrolimus may suitable substitute treatment cyc methods forty patients diffuse proliferative membranous recruited trial 45 lower ccr 10 increased serum creatinine nephritic proteinuria investigators compared efficacy adverse effects tac prednisone 12",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "SLE, Lupus Nephritis, Renal Insufficiency, End-stage Renal Disease",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01207297"
    },
    {
        "Title": "KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis",
        "Summary": "Glomerulonephritis generates enormous individual social economic burden however therapeutic options largely based on clinical pathological parameters. Human renal biopsies could provide strong foundation future precision medicine.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy, Focal Segmental Glomerulosclerosis, Lupus Nephritis, Crescentic Glomerulonephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03929887"
    },
    {
        "Title": "Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease",
        "Summary": " clinical study safety effectiveness chimeric antigen receptor cells treatment refractory lupus nephritis disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, IgG4-related Disease",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06497361"
    },
    {
        "Title": "A Study of QLG1074 Combined With Background Therapy in Subjects With Active Lupus Nephritis",
        "Summary": " ql1074 compared placebo achieving renal response 52 weeks therapy subjects active lupus nephritis. purpose study assess efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06406205"
    },
    {
        "Title": "Efficacy and Safety of Enteric-coated Mycophenolate Sodium in Combination With Two Corticosteroid Regimens for the Treatment of Lupus Nephritis Flare",
        "Summary": "Study investigate efficacy safety mycophenolate sodium combination. Two different corticosteroid cs regimes induction remission lupus nephritis flare patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, France, Greece, Spain, Colombia, Hungary, Italy, Taiwan, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00423098"
    },
    {
        "Title": "Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis",
        "Summary": "Study investigate mycophenic acid mpa pharmacokinetics pharmacogenomics impact clinical outcomes lupus nephritis patients active inactive recruited mpa levels checked 1 2 4 8 10 12 hrs mmf administration enzymatic assay upon",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT02453997"
    },
    {
        "Title": "Urinary T Cell Biomarker for Prediction in Lupus Nephritis",
        "Summary": "Researchers hypothesize amount urine time diagnosis predicts outcome patients active lupus nephritis. urine analysed flow cytometry every 60 days.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom, Germany",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04320797"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV Lupus Nephritis",
        "Summary": "Rituximab combination mycophenolate mofetil mmf compared placebo combination mmf subjects diagnosed international society pathology society 2003 class iv iv lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00282347"
    },
    {
        "Title": "A Study to Evaluate the Safety and Efficacy of Tacrolimus for Lupus Nephritis Under Actual Use Situations",
        "Summary": " evaluate safety efficacy tacrolimus lupus nephritis. evaluating safety efficacy. evaluating efficacy.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT01410747"
    },
    {
        "Title": "Functional MRI in Lupus Nephritis",
        "Summary": "Primary objectives study follows develop optimize renal functional magnetic resonance imaging mri protocol. Secondary objectives follow to explore whether renal functional mri techniques discriminate renal inflammatory activity damage.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Healthy, Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT01731054"
    },
    {
        "Title": "A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Nephritis",
        "Summary": "Study aims evaluate safety clinical effect daily oral treatment laquinimod capsules active lupus nephritis participants. Study assess laquininod doses milligrams mg 1 combination standard care treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France, Russian Federation, Canada, United States, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01085097"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients",
        "Summary": "Study evaluate efficacy safety tacrolimus steroid observing remission rate 24 weeks lupus nephritis patients steroid monotherapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01316133"
    },
    {
        "Title": "the Association Between Metabolic Syndrome and Its Components With Lupus Nephritis in Systemic Lupus Erythematosus Patients",
        "Summary": " systemic lupus erythematosus sle heterogeneous autoimmune disease involve many different organs display variable clinical course prevalence sle varies across gender geographic regions sle demonstrates striking female predominance peak incidence disease reproductive years adults female male ratio clinical features",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05964751"
    },
    {
        "Title": "Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis",
        "Summary": " patients sle admitted internal medicine department august 2019 january 2021 eligible targeted included study diagnosis sle according 1997 american college romatology revised criteria hochberg 1997 sle patients lupus nephritis take kidney biopsy standard care management",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03958851"
    },
    {
        "Title": "Efficacy of Lower Dose Prednisolone in the Induction of Remission of Lupus Nephritis",
        "Summary": "Rheumatology outpatient inpatient department bsmmu july 2018 september 2019 subjects enrolled informed consent. Patients received pulse methylprednisolone 500 daily 3 doses experimental group received oral prednisol one control group received",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bangladesh",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04146220"
    },
    {
        "Title": "Comparison of Low Dose Versus High Dose Cyclophosphamide as Induction Therapy in the Treatment of Lupus Nephritis",
        "Summary": "Study conducted find whether low dose high dose cyclophosphamide therapy effective treatment proliferative lupus. Also compare side effects risks infection.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "India",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02645565"
    },
    {
        "Title": "KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
        "Summary": "Study subjects refractory to lupus nephritis treated with chimeric antigen receptor cell therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05938725"
    },
    {
        "Title": "Detection of Annexin A2 in Systemic Lupus Erythematosus",
        "Summary": "Autoantibodies involved organ dysfunction sle patients moreover tlr expression sle significantly higher significantly correlated disease activity annexin a2 anxa2 member annexins superfamily exists monomer heterotetramer implicated several biological processes notably binds antibodies medi",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03031925"
    },
    {
        "Title": "Exploring Biomarkers for Therapeutic Response of Lupus Nephritis Based on Multi Omics Analysis",
        "Summary": "The study aims to find biomarkers that predict patients response to immunosuppressants. The aim is to collect 100 lupus nephritis patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06167174"
    },
    {
        "Title": "A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Lupus Nephritis (ZL-1103-013)",
        "Summary": " evaluate efficacy safety efgartigimod iv chinese patients active lupus nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05810948"
    },
    {
        "Title": "Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells",
        "Summary": "Mesenchymal stem cells mscs obtained bone marrow treatment adults active proliferative lupus nephritis objective study evaluate efficacy. purpose study evaluate safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03673748"
    },
    {
        "Title": "Lupus Nephritis: Role of Environmental and Occupational Exposures",
        "Summary": "Lupus erythematosus sle renal disease silica dust smoking. purpose study examine hormonal environmental risk factors possible interactions involved etiology. 100 patients renal biopsy documented proliferative membraneous nephritis compare exposures.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT00342329"
    },
    {
        "Title": "Multicenter Registry of Pediatric Lupus Nephritis in China",
        "Summary": "Study designed evaluate efficacy safety current treatment option outcome pediatric lupus nephritis patients china investigators perform prospective registration study among at least 35 pediatric nephrology medical centers china.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Children, Steroid, Immunosuppressive Treatment",
        "Phases": "N/A",
        "IDestudio": "NCT03791827"
    },
    {
        "Title": "Refractory ANCA Associated Vasculitis and Lupus Nephritis Treated With BCMA-targeting CAR-T Cells",
        "Summary": " lupus nephritis ln vasculitis severe autoimmune diseases may lead death patients particularly refractory conventional therapeutic agents. autoantibodies may exert important pathological roles pathogenesis. plasmablasts plasma cells bcma molecule",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, ANCA Associated Vasculitis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06277427"
    },
    {
        "Title": "Prospective, Randomized, Multicenter, Control Study to Assess the Efficacy and Safety of Tacrolimus in Induction and Maintenance Phase Treatment in Lupus Nephritis",
        "Summary": "rolimus vs. intravenous cyclophosphamide pulses treatment induction therapy ln iii iv v compare efficacy safety tacrolims vs azathioprine maintenance therapy. purpose study compare efficacy. safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Kidney Diseases, Lupus Nephritis, Tacrolimus, Induction Phase, Maintenance Phase",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00615173"
    },
    {
        "Title": "High Quality Evidence of Chinese Lupus Nephritis (HELP)",
        "Summary": "Hospitals developing ln database china patients every year baseline information entered registration system. investigators registering ln patients recruited hospitals developing lN database ch China patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03001973"
    },
    {
        "Title": "Human Umbilical Cord Mesenchymal Stem Cells Treatment for Lupus Nephritis (LN)",
        "Summary": "Lupus nephritis ln one serious complications main cause death patients systemic lupus erythematosus sle investigators investigated usefulness confirmed efficacy safety mesenchymal stem cells msc treatment ln animal models vitro experiments",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03580291"
    },
    {
        "Title": "Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis",
        "Summary": "Lupus nephritis patients for the first time received treatment for mycophenolate sodium.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Taiwan",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04645589"
    },
    {
        "Title": "Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus Nephritis",
        "Summary": " secukinumab versus placebo patients active lupus nephritis class iii iv without class v features also receiving background standard care therapy. pivotal randomized trial evaluating week 52 efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland, Australia, Norway, Sweden, United States, Thailand, Greece, Spain, Russian Federation, China, Denmark, Italy, Korea, Republic of, Romania, Turkey, Philippines, France, India, Canada, Portugal, Peru, Taiwan, Czechia, Japan, Argentina, Germany, Slovakia, Brazil, Vietnam, Croatia, Chile, Colombia, Mexico, Guatemala",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04181762"
    },
    {
        "Title": "KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis",
        "Summary": "Study subjects refractory to lupus nephritis treated with chimeric antigen receptor cell therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06342960"
    },
    {
        "Title": "Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)",
        "Summary": "Daxdilimab is being trialled as a treatment for lupus nephritis ln. The trial is a multicenter randomized trial.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Philippines, Taiwan, Brazil, Spain, Israel, Croatia, Thailand, Poland, United States, Malaysia, Serbia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05540665"
    },
    {
        "Title": "Etanercept for the Treatment of Lupus Nephritis",
        "Summary": "Lupus erythematosus is chronic multisystem autoimmune disease body immune system attacks normal tissues abnormal autoimmune response result damage many parts body including skin joints lungs heart brain intestines kidneys. kidney problems occur lupus patients",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00447265"
    },
    {
        "Title": "The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis",
        "Summary": "Lupus nephritis combination mycophenolate mofetil mmf corticosteroids study sponsored merck serono international operational oversight provided zymogenetics. purpose study learn whether atacicept treatment leads improvement",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czech Republic, United States, Singapore, Taiwan, Malaysia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00573157"
    },
    {
        "Title": "A Pharmacoeconomic Study Comparing the Use of Mycophenolate Mofetil or Cyclophosphamide as Induction Therapy in Lupus Nephritis Patients in Egypt",
        "Summary": "Mycophenolate mofetil cyclophosphamide induction therapy third party payer perspective ln patients egyptian context.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05195086"
    },
    {
        "Title": "The Expression Profile of New Complement Components in Childhood Lupus Nephritis",
        "Summary": " aim study evaluate whether c4d better biomarker. examine whether plasma levels correlate treatment response c4D kidney deposition systemic lupus.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05082363"
    },
    {
        "Title": "Study of Ravulizumab in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)",
        "Summary": "Ravulizumab administered intravenous iv infusion compared placebo compared placebo demonstrate efficacy terminal complement inhibition participants ln ln cohort igan igan cohort.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Germany, Taiwan, France, Spain, Australia, Netherlands, Canada, Italy, Korea, Republic of, United States, Poland, Singapore, Sweden, United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Immunoglobulin A Nephropathy",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04564339"
    },
    {
        "Title": "Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis.",
        "Summary": " purpose study determine whether mycophenolate mofetil superior azathioprine prevent flares lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00204022"
    },
    {
        "Title": "Clinical Trial Treatment in Lupus Nephritis",
        "Summary": "Lupus nephritis early recent years alternative regimens appeared induction maintenance similar results least offered classic pattern possibly fewer side effects especially long term association prednison mycophenolate created large expectations effect part therapeutic arsenal.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01299922"
    },
    {
        "Title": "Efficacy and Safety of Belimumab in Patients With Active Lupus Nephritis",
        "Summary": "Belimumab is being tested in adult patients with lupus nephritis. The study will evaluate the drug's efficacy and safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Spain, Russian Federation, Hong Kong, China, Korea, Republic of, United Kingdom, Belgium, Philippines, France, Netherlands, Canada, Taiwan, Czechia, Argentina, Germany, Brazil, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01639339"
    },
    {
        "Title": "An Efficacy and Safety Study of CNTO 136 in Patients With Active Lupus Nephritis",
        "Summary": "Cnto 136 administered intravenously patients active international society pathology society class iv iv lupus nephritis ln. purpose study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Netherlands, Mexico, Poland, United States, Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01273389"
    },
    {
        "Title": "BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis",
        "Summary": "Study investigate whether experimental drug bg9588 used treat lupus nephritis effectively less toxicity standard treatments including cyclophosphamide cytoxan azothioprine imuran prednisone body immune system naturally produces antibodies fight foreign",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Glomerulonephritis, Membranoproliferative, Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00001789"
    },
    {
        "Title": "Per-protocol Repeat Kidney Biopsy in Incident Cases of Lupus Nephritis",
        "Summary": "Lupus nephritis ln one severe complications systemic lupus erythematosus sle among people living sle develop ln course disease complication one factors contribute deterioration renal function centres perform kidney biopsies completion treatment episode",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Sweden",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04449991"
    },
    {
        "Title": "Renal Arterial Resistive Index as a Noninvasive Biomarker of Disease Activity in Lupus Nephritis Patients",
        "Summary": " systemic lupus erthymatosous sle achronic inflammatory multi system auto immue disease characterized pathogenic auto anti bodies production nuclear structures bolouri et sle affecting mainly woemn childbearing age.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06631404"
    },
    {
        "Title": "Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis",
        "Summary": " aim study evaluate efficacy therapeutic regimen decreases glucocorticoid exposure. patients proliferative lupus nephritis remission induction. evaluating histological clinical remission.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05207358"
    },
    {
        "Title": "Safety, Pharmacokinetics and Preliminary Efficacy Study of CFZ533 in Patients With Lupus Nephritis.",
        "Summary": "Study evaluate safety tolerability pharmacokinetics pharmacodynamics preliminary therapeutic efficacy. multiple doses cfz533 monoclonal antibody patients moderately active lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Tunisia, Turkey, Germany, Argentina, Russian Federation, Hungary, Hong Kong, China, Korea, Republic of, Taiwan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03610516"
    },
    {
        "Title": "Rituximab and Belimumab for Lupus Nephritis",
        "Summary": " experimental study researchers try find treatment lupus nephritis. combination rituximab cyclophosphamide ctx combination r ituximAB ctx followed treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02260934"
    },
    {
        "Title": "Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus",
        "Summary": " aim research project better understand origin clinical significance. two genetic signatures ifn signature plasma cell signature patient subgroups. clinical characteristics aim correlate genetic signatures cell activation profiles production specific cytokines. different populations whole blood cultures circulating cells.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Belgium",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05443516"
    },
    {
        "Title": "Assess the Efficacy and Safety of Multi-target Therapy in Lupus Nephritis",
        "Summary": "Lupus nephritis is a type of lupus. It is a chronic, progressive disease of the kidney.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00876616"
    },
    {
        "Title": "Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)",
        "Summary": "Central goal data repository collect data large population subjects variety renal disease states cohorts include subjects diabetes transplant related renal conditions. repository capacity store biospecimens electronic data.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Kidney Diseases, Kidney Failure, Chronic, Diabetic Nephropathy, Lupus Nephritis, Glomerulonephritis, IGA",
        "Phases": "N/A",
        "IDestudio": "NCT01802034"
    },
    {
        "Title": "A Study to Compare the Efficacy and Safety of Tacrolimus Capsules With Leflunomide Tablets in Lupus Nephritis Patients",
        "Summary": "Tacrolimus capsules and leflunomide tablets are used to treat lupus nephritis. Study compared efficacy and safety of the drugs.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01342016"
    },
    {
        "Title": "Sirolimus in Treatment of Proteinuric Flares of Lupus Nephritis",
        "Summary": "Sirolimus is an immunosuppressive medication used to treat lupus nephritis. The study is designed to assess safety tolerability of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis, Immunosuppression, Effect of Drug",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT04892212"
    },
    {
        "Title": "A Pilot Study for the Efficacy and Safety of Tacrolimus in the Treatment of Refractory Lupus Nephritis",
        "Summary": " purpose protocol determine whether tacrolimus prednisolone effective safe treatment refractory diffuse proliferative lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00569101"
    },
    {
        "Title": "Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis",
        "Summary": "Tacrolimus may effective treatment primary glomerulonephritis investigators plan study efficacy safety. Patients however respond conventional immunosuppressive therapy high risk progressing renal failure.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01206569"
    },
    {
        "Title": "The Mechanisms and Significances of Synergistic Effects of Mycophenolic Acid and LPS on IL-1\u03b2 Secretion by Mononuclear",
        "Summary": ". determine mechanisms significances synergistic effects mycophenolic acid lps secretion mononuclear.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT02435368"
    },
    {
        "Title": "BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis",
        "Summary": " biib023 compared placebo study population. primary objective study assess efficacy. secondary objectives study assess safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Thailand, Spain, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, Belgium, Philippines, France, Portugal, Peru, Argentina, Germany, Brazil, Colombia, Hungary, Mexico, Malaysia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01499355"
    },
    {
        "Title": "VIBRANT: VIB4920 for Active Lupus Nephritis",
        "Summary": "Vib4920 combined mycophenolate mofetil mmf prednisone achieving renal response participants active lupus nephritis ln. placebo controlled clinical trial.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05201469"
    },
    {
        "Title": "Lupus Landmark Study: A Prospective Registry and Biorepository",
        "Summary": "Lupus erythematosus sle including lupus nephritis ln. purpose registry biorepository provide mechanism store clinical data linked biospecimens molecular data support conduct future research systemic lupUS ery",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Neuropsychiatric Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05934149"
    },
    {
        "Title": "A Study of Nipocalimab in Adult Participants With Active Lupus Nephritis",
        "Summary": "Nipocalimab is a drug used to treat lupus nephritis. The study was designed to evaluate the efficacy of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04883619"
    },
    {
        "Title": "Mycophenolate Mofetil Versus Azathioprine for Maintenance Therapy of Lupus Nephritis",
        "Summary": "Study designed compare safety efficacy of mycocep capsules and mofetil. Study was conducted to assess the safety and efficacy of the capsules.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02949349"
    },
    {
        "Title": "Mesenchymal Stem Cell Transfusion for the Treatment of Refractory Lupus Nephritis",
        "Summary": "Lupus erythematosus lupus nephritis is a common serious complication. Clinical remission necessarily reflects improvement kidney tissues. 20 patients achieve complete response addition attainment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06485648"
    },
    {
        "Title": "A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Immune Nephritis",
        "Summary": "Study shows chimeric antigen receptor cells therapy can help patients with refractory immune nephritis. Patients treated with the therapy are less likely to suffer from the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Immune Nephritis, Autoimmune Diseases, Lupus Nephritis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT05085418"
    },
    {
        "Title": "Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies",
        "Summary": " phase ii trial assessing safety preliminary efficacy daily subcutaneous infusion administered 16 weeks 6 month safety follow patients glomerulopathies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "IgA Nephropathy, Lupus Nephritis, Membranous Nephropathy, C3 Glomerulonephritis, Dense Deposit Disease",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03453619"
    },
    {
        "Title": "To Compare the Efficacy and Safety of FK506 vs IVC in the Treatment of Class III-IV LN",
        "Summary": "Fk506 is an intravenous cyclophosphamide pulses treatment class. Fk506 has been shown to be effective in reducing blood concentration. It has also been found to be safe.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00302549"
    },
    {
        "Title": "Pentoxifylline in Lupus Nephritis",
        "Summary": "National guidelines recommend use induction therapy corticosteroids immunosuppressive agents followed prolonged maintenance therapy patients continue active nephritis ongoing protein urine proteinuria long recognized level chronicity proteinuria patients lupus neph arthritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03859570"
    },
    {
        "Title": "BAFF Levels and Lupus Nephritis (LN)",
        "Summary": "B baff plays pathogenic role sle part b cell autoantibody production baff role maintenance memory b cells promotes plasma cell survival treatment strategies involving baff blockade studied patients sle inducing overall improvement disease activity mainly musculoskeletal mucocut",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04369495"
    },
    {
        "Title": "RING - Rituximab for Lupus Nephritis With Remission as a Goal",
        "Summary": "Rituximab rtx efficacious achieve complete renal response cr lupus nephritis ln patients persistent proteinuria despite least 6 months standard care.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01673295"
    },
    {
        "Title": "Urine Exosomes to Identify Biomarkers for LN",
        "Summary": "Urine exosomes extracted from patients lupus nephritis healthy controls and systemic lupUS erythematosus without lupi. urine exosome extracted from\u00a0 patients\u00a0lupus\u00a0neph",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04894695"
    },
    {
        "Title": "The Relation Between Serum Zinc and Lupus Nephritis",
        "Summary": " serum zinc urea serum creatinine hemoglobin estimated glomerular filtration rate egfr. goal observational study investigate relation serum zinc lupus nephritis to hypozincemia.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06564181"
    },
    {
        "Title": "The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study",
        "Summary": "Study goal determine safety efficacy mmfbsa treatment proliferative ln subjects 8 18 years. Study placebo controlled clinical trial treatment arms 1 mmf dosed per area mmfBSa body surface area per dose every 12 hours 2 mm",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05538208"
    },
    {
        "Title": "CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus",
        "Summary": "Cnct19 is a single dose clinical study evaluating safety and preliminary efficacy. Patients were treated for systemic lupus erythematosus, nephritis, and thrombocytopenia.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT05930314"
    },
    {
        "Title": "A Study of Zetomipzomib (KZR-616) in Patients with Active Lupus Nephritis (PALIZADE)",
        "Summary": " zetomipzomib 30 mg 60 mg compared placebo achieving renal response 52 weeks treatment patients active lupus nephritis ln. purpose study assess efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Serbia, Greece, Spain, China, Korea, Republic of, United Kingdom, Puerto Rico, Philippines, South Africa, India, Portugal, Peru, Taiwan, Argentina, Brazil, Croatia, Colombia, Malaysia, Guatemala",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05781750"
    },
    {
        "Title": "Detection of Anti-glomerular Basement Membrane Antibodies (Anti-GBM): a Promising Biomarker for Lupus Nephritis (LN)?",
        "Summary": "Glomerulonephritis diseases often associated with lupus erythematosus sle severe impact prognosis complication real challenge clinicians predictable relapses biomarker use therefore essential conventional biomarkers proteinuria poor sensivity low specificity predict",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03664908"
    },
    {
        "Title": "A Study to Evaluate the Efficacy and Safety of Mizoribine in the Treatment of Lupus Nephritis",
        "Summary": "Lupus nephritis mzr standard therapy ctx analyzing overall remission rate treatment. demonstrate treatment effect lupusNephritismzr.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02256150"
    },
    {
        "Title": "Fibrinogen to Albumin Ratio (FAR) as a Predictive Biomarker for Lupus Nephritis (LN)",
        "Summary": " fibrinogen albumin ratio predictive biomarker lupus nephritis ln.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06288308"
    },
    {
        "Title": "Fixed-dose Versus Concentration-controlled Mycophenolate Mofetil for the Treatment of Active Lupus Nephritis",
        "Summary": "A. randomized study versus mycophenolate mofetil treatment active lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03920059"
    },
    {
        "Title": "A Study of Mycophenolate Mofetil (CellCept) in Management of Patients With Lupus Nephritis.",
        "Summary": "2 arm study assessed efficacy mycophenolate mofetil mmf cellcept compared cyclophosphamide inducing response patients lupus nephritis long term efficacy mmf compared azathioprine maintaining remission renal function.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Argentina, Germany, Czech Republic, France, Brazil, Greece, Spain, Australia, Hungary, Mexico, Canada, China, Italy, United States, Portugal, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00377637"
    },
    {
        "Title": "Universal CAR-T Cell Therapy for Refractory Lupus Nephritis",
        "Summary": " trial aims assess efficacy safety combination therapy using universal cells targeting bcma cd19 refractory lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06681337"
    },
    {
        "Title": "Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721",
        "Summary": "Oms721 narsoplimab was used to evaluate safety tolerability. The study also evaluate pharmacokinetics and pharmacodynamics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong, United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "IgAN, Lupus Nephritis, MN, C3 Glomerulopathy",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02682407"
    },
    {
        "Title": "Open-label Extension Study of Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Lupus Nephritis",
        "Summary": " secukinumab subjects completed core study treatment study cain457q12301 nct04181762 obtain data efficacy safety tolerability secuk inunab patients active lupus nephritis ln. purpose extension",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Philippines, Slovakia, Brazil, Spain, Vietnam, Australia, Colombia, Korea, Republic of, Portugal, Guatemala, Thailand",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05232864"
    },
    {
        "Title": "Aurinia Renal Assessments 2: Aurinia Renal Response in Lupus With Voclosporin",
        "Summary": "Study subjects lupus nephritis ln. purpose study assess safety tolerability voclosporin compared placebo. additional 24 months following completion of treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT03597464"
    },
    {
        "Title": "Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Phase Treatment in Lupus Nephritis",
        "Summary": "rolimus capsules advagraf induction therapy lupus nephritis ln vii. pilot study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01288664"
    },
    {
        "Title": "Phase 2 Study of Human Umbilical Cord Derived Mesenchymal Stem Cell for the Treatment of Lupus Nephritis",
        "Summary": "Lupus nephritis combined partial complete remission terms stabilization improvement renal function. efficacy measure treatment proliferative lupus Nephritis remission.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01539902"
    },
    {
        "Title": "An Open-label Study of Povetacicept (ALPN-303) in Autoimmune Kidney Diseases",
        "Summary": "Povetacicept is an immunoglobulin-like substance. It is used to treat kidney disease, nephritis, cytoplasmic antibody anca associated vasculitis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of, Australia, Puerto Rico, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Immunoglobulin A Nephropathy, Membranous Nephropathy, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05732402"
    },
    {
        "Title": "Dynamic Imaging of Variation in Lupus Nephritis",
        "Summary": " renal biopsy findings determine whether dwi bold t1rho may provide set tools assess renal function pathology ln. use variety renal imaging modalities including diffusion weighted imaging dwi blood oxygen level dependent bold imaging.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03180021"
    },
    {
        "Title": "Daratumumab to Treat Active Lupus Nephritis",
        "Summary": " daratumumab inducing complete partial remission patients active lupus nephritis. purpose research study safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04868838"
    },
    {
        "Title": "BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis",
        "Summary": "Primary objective study evaluate safety tolerability biib023 participants lupus nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Thailand, Spain, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, Belgium, Philippines, France, Peru, Argentina, Brazil, Colombia, Hungary, Mexico, Malaysia",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01930890"
    },
    {
        "Title": "TF, TFPI and Plasmin as Novel Bio-markers in Early Diagnosis of Lupus Nephritis",
        "Summary": "Urine plasmin performed best among four proteins discriminating active ln inactive disease even better traditional markers anti ds dna complement c3 furthermore combination urine plasmine tfpi showed higher specificity negative predictive values.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04218890"
    },
    {
        "Title": "An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis",
        "Summary": "The trial is designed to evaluate long term efficacy and safety of different doses of bi 655064 versus placebo therapy. The trial is being conducted by the University of California, San Francisco.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Germany, Philippines, Greece, Australia, Hong Kong, Canada, Korea, Republic of, Mexico, United States, Poland, Portugal, Malaysia, United Kingdom, Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03385564"
    },
    {
        "Title": "Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis",
        "Summary": "Study evaluate safety tolerability pk pd clinical activity itolizumab eq001 subjects systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "India, Poland, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04128579"
    },
    {
        "Title": "FKC288 in Participants With Autoimmune Kidney Diseases",
        "Summary": "Study exploratory clinical trial expected enroll 6 12 participants. Use boin bayesian optimal interval design dose escalation four predetermined dose groups alternative dose dose group plans.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, ANCA-associated Vasculitis, Membranous Nephropathy - PLA2R Induced, IgG4-Related Diseases",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06285279"
    },
    {
        "Title": "Open Label Pilot Trial of Rituximab in Lupus Membranous Nephritis",
        "Summary": "Rituximab is a treatment for\u00a0membranous lupus nephritis. The study was conducted to assess the efficacy and safety of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00908986"
    },
    {
        "Title": "Induction Therapy for Lupus Nephritis With no Added Oral Steroids: A Trial Comparing Oral Corticosteroids Plus Mycophenolate Mofetil (MMF) Versus Obinutuzumab and MMF",
        "Summary": "Study aims to demonstrate regimen free additional oral corticosteroids obinutuzumab. Study aims to compare efficacy treatments arms terms partial plus complete renal response week 52 proteinuria week 52 extrarenal flares response defined 4 points reduction",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04702256"
    },
    {
        "Title": "The Efficacy of Enteric-coated Mycophenolate Sodium (EC-MPS) (Myfortic) in The Treatment of Relapse or Resistant Proliferative Lupus Nephritis",
        "Summary": " investigate efficacy safety mycophenolate sodium myfortic compared intravenous cyclophosphamide treatment active nephritis. complete partial renal remission assessed renal function urinary sediment proteinuria patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01015456"
    },
    {
        "Title": "Pre-emptive Treatments in Lupus Nephritis Patients With Serological Reactivation",
        "Summary": "Asymptomatic serological reactivation asr lupus nephritis ln patients remained undefined project aims investigate impact treatment disease relapse ln Patients experienced asr. optimal management.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04870359"
    },
    {
        "Title": "MMF Versus CYC in the Induction Therapy of Pediatric Active Proliferative LN",
        "Summary": " prospective randomized multicenter study compare effectiveness mycophenolate mofetil versus cyclophosphamide induction therapy pediatric patients active proliferative lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Mycophenolate Mofetil, Cyclophosphamide, Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05495893"
    },
    {
        "Title": "Zanubrutinib in Participants With Active Proliferative Lupus Nephritis",
        "Summary": " zanubrutinib added standard care measured complete renal response participants active proliferative lupus nephritis. primary objective study evaluate efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04643470"
    },
    {
        "Title": "Evaluate the Safety of CS20AT04 Inj. in Subjects With Lupus Nephritis",
        "Summary": "Allogenic bone mesenchymal stem cells cs20at04 subjects lupus nephritis. evaluating dlt iv injection according to patients. purpose conducting phase 1 trial evaluate safety tolerability",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03174587"
    },
    {
        "Title": "Low-dose Combination of Mycophenolate Mofetil (MMF) and Tacrolimus (Tac) for Refractory Lupus Nephritis",
        "Summary": "Trial combination two drugs treatment refractory lupus nephritis. Trial was first of its kind in the U.S.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01203709"
    },
    {
        "Title": "To Compare the Efficacy and Safety of Tripterygium (TW) Versus AZA in the Maintenance Therapy for Lupus Nephritis",
        "Summary": "Study compared aza maintenance therapy lupus nephritis investigate safety tolerability. purpose study access efficacy tw compared to aza Maintenance therapy. investigate safety toleranceability tw versus aza. maintenance therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00881309"
    },
    {
        "Title": "SGLT2 Inhibitors Between Reno Protective Effects and Impact on Bone and Mineral Disease Among Lupus Nephritis Patients",
        "Summary": "100 patients randomized two groups receive sglt2i add drug replace another drug according patient clinical situation. dapagliflozin 10 mg used daily without food control group maintained medication.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "SGLT2 INHIBITORS, Lupus Nephritis, BMD",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT05704088"
    },
    {
        "Title": "Autologous Hematopoietic Stem Cell Transplantation for Refractory Lupus Nephritis",
        "Summary": "Study aimed evaluate long term efficacy remission survival safety. Autologous hematopoietic stem cell transplantation patients refractory lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03828071"
    },
    {
        "Title": "Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil",
        "Summary": " sponsor electively terminated study risk mitigation measures deemed necessary. unforeseen safety event could effectively implemented within protocol. maintaining study timelines within reasonable time frame.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01369628"
    },
    {
        "Title": "A Study to Evaluate Efficacy of CellCept (Mycophenolate Mofetil) in Patients With Lupus Nephritis",
        "Summary": "Lupus nephritis patients receive induction treatment cyclophosphamide monthly 6 months randomized maintenance phase study 6 months followed 6 months anticipated time study treatment 12 months.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Venezuela",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02081183"
    },
    {
        "Title": "Safety and Efficacy of PRG-1801 for Refractory Lupus Nephritis and IgG4-Related Disease",
        "Summary": " clinical study safety effectiveness bcma chimeric antigen receptor cells treatment refractory lupus nephritis disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis, IgG4-related Disease",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06497387"
    },
    {
        "Title": "Iguratimod as Treatment for Refractory Lupus Nephritis",
        "Summary": " iguratimod combined steroids is an immunosuppressive treatment for lupus nephritis. The study evaluated the safety and efficacy of the treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03054545"
    },
    {
        "Title": "Long-term Follow-up for Evaluating the Safety of CS20AT04 in Subject With Lupus Nephritis",
        "Summary": "Study participants received cs20at04 phase 1 clinical trial subjects participated voluntarily agree participate observation study. observation study planned evaluate safety efficacy.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Korea, Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04522505"
    },
    {
        "Title": "Serological and Urinary Biomarkers in Latin American Patients With Systemic Lupus Erythematosus: GLADEL 2.0 Cohort",
        "Summary": "Lupus nephritis is one main manifestationsin sle patients important impact morbidity mortality renal biopsy gold standard diagnosis. Multiple biomarkers studied different locations soluble markers blood urine biological fluids different nature autoantibodies genetic markers kidney damage",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Argentina",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT04534647"
    },
    {
        "Title": "Identifying New Therapeutic Targets for Lupus Treatment",
        "Summary": "Lupus nephritis ln occurs 30 cases 30 cases lupus associated end stage renal disease esrd 17 25 cases 10 years overall nearly 7. 45 patients suffer multiple relapses associated intermediate risk esrd esrd.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03921398"
    },
    {
        "Title": "Umbilical Cord Mesenchymal Stem Cell Transplantation for Lupus Nephritis",
        "Summary": " investigate safety efficacy umbilical cord mesenchymal stem cell transplantation patients systemic lupus erythematosus sle lupUS nephritis ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03458156"
    },
    {
        "Title": "Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis",
        "Summary": "Study evaluate efficacy safety orally administered tamibarotene patients lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01226147"
    },
    {
        "Title": "Pharmacokinetically-driven Dosing of Mycophenolate Mofetil for the Treatment of Pediatric Proliferative Lupus Nephritis",
        "Summary": "Current standard treatment proliferative lupus nephritis ln treatments precision dosing mmf mmFPk may offer beneficial modification current standard treatment mmkpk promises 30 higher ln response rates mmfbsa objective proposed randomized",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05101447"
    },
    {
        "Title": "A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis",
        "Summary": "Study evaluate efficacy safety pharmacokinetics obinutuzumab compared to placebo patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Germany, South Africa, France, Brazil, Spain, Israel, Russian Federation, Colombia, Mexico, Italy, Peru, United States, Poland, United Kingdom",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04221477"
    },
    {
        "Title": "An Investigational Study to Evaluate the Safety and Effectiveness of BMS-986165 With Background Treatment in Participants With Lupus Nephritis",
        "Summary": "Lupus nephritis ln. purpose study evaluate safety effectiveness compared placebo. regard measures kidney function participants lupusNephritisLn.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Belgium, Germany, Taiwan, Spain, Israel, Australia, Netherlands, Russian Federation, Mexico, Canada, China, Italy, United States, Korea, Republic of, United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03943147"
    },
    {
        "Title": "Phase 3 Study of Tacrolimus (FK506) for Lupus Nephritis: A Placebo Controlled, Double-Blind Multicenter, Comparative Study",
        "Summary": "Study consists of efficacy study steroid refractory lupus nephritis patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00429377"
    },
    {
        "Title": "Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases",
        "Summary": "Hydroxychloroquine thalidomide glucocorticoids considered gold standard technology qualitative quantitative analysis drugs blood comparison dosage saliva improvement simplification process biological agents focus understanding loss efficacy possible role antibodies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Juvenile SLE, Cutaneous Lupus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03122431"
    },
    {
        "Title": "Aurinia Early Urinary Protein Reduction Predicts Response",
        "Summary": "in mg twice daily bid combination standard care patients active lupus nephritis. exploratory study assessing ability biomarkers measured 8 weeks predict clinical response.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Malaysia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02949973"
    },
    {
        "Title": "Descartes-08 for Patients With Systemic Lupus Erythematosus",
        "Summary": "us lupus erythematosus slem. phase ii study evaluate safety tolerability manufacturing feasibility. car patients systematic lupUS ery thematosUS slemma. phase III study evaluate\u00a0 safety toler",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06038474"
    },
    {
        "Title": "GENetic & Immunologic Abnomalies in Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is a chronic autoimmune disease. The lupus mendelian genetics trex1 genes involved samhd1 frostbite. The acp5 gene is responsible for dysplasia syndrom",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01992666"
    },
    {
        "Title": "INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use",
        "Summary": "Study generate critical prospective evidence benefits adding anifrolumab standard care treatment sle routine clinical practice. Use standardized objectives criteria outcome measures across countries participating.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT06314282"
    },
    {
        "Title": "Targeted Therapy Using Intradermal Injection of Etanercept for Remission Induction in Discoid Lupus Erythematosus",
        "Summary": "Investigators also would like develop new tests measure skin inflammation scanning affected skin using optical coherence tomography oct thermography laser doppler imaging.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Discoid, Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Chronic Cutaneous",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02656082"
    },
    {
        "Title": "A Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "Main objective study evaluate safety efficacy elsubrutinib upadacitinib high dose low dose combinations vs placebo treatment. Participants moderately severely active.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, China, Italy, Korea, Republic of, Poland, United Kingdom, Puerto Rico, Bulgaria, France, Netherlands, Canada, Taiwan, Japan, Argentina, Germany, New Zealand, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03978520"
    },
    {
        "Title": "Comparison of Clinical and Serological Differences Among Juvenile, Adult, and Late-onset Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle heterogeneous autoimmune disease highly variable presentation course affect virtually every organ body many symptoms may observed skin musculoskeletal hematologic serological involvement commonly observed patients show predominately he",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT05724940"
    },
    {
        "Title": "A Study of CD19 Redirected Autologous T Cells for CD19 Positive Systemic Lupus Erythematosus (SLE)",
        "Summary": " autoimmune diseases involving multiple systems organs present variety autoantibodies conventional treatment options could barely cured. therapy therefore proposed recently used cancer treatment hailed promising remission rates.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03030976"
    },
    {
        "Title": "Efficacy and Safety of Artesunate Plus Standard of Care in Active Lupus Nephritis",
        "Summary": " randomized study study subjects class iv iv v lupus nephritis patients according 2003 classification ln active lesion needing corticosteroid combination immunosuppressant therapy subjects meet eligibility criteria.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03214731"
    },
    {
        "Title": "Efficiency of Use of Baracetinib in Treatment of Lupus Nephritis",
        "Summary": "Baricitinib oral selective janus kinase jak 1 jak2 inhibitor hypothesised might therapeutic benefit patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05432531"
    },
    {
        "Title": "Deployment o the Multidisciplinary Prospective Cohort Imminent",
        "Summary": " imids often affect young patients high impact morbidity mortality significant alteration quality life patients professional social emotional repercussions beyond burden imids share many common pathophysiological mechanisms treatments known targeted therapies despite progress field much remains done.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Chronic Inflammatory Disease, Angioedema, Severe Asthma, Lupus, Atopic Dermatitis, Psoriatic Arthritis, Multiple Sclerosis, Systemic Sclerosis, Beh\u00e7et Disease",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04334031"
    },
    {
        "Title": "Study to Evaluate the Safety, Tolerability and Short Term Efficacy of Extracorporeal Specific Immunoadsorption LupusorbTM Columns for the Treatment of Systemic Lupus Erythematosus (SLE) Patients",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune inflammatory disease primarily affecting women childbearing age associated severe morbidity mortality victims existing therapy however specific inevitable side effects may fatal therefore widely recognized need would highly advantageous.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Israel",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00608127"
    },
    {
        "Title": "A Study of Guselkumab in Participants With Active Lupus Nephritis",
        "Summary": " guselkumab participants active lupus nephritis ln. purpose study evaluate efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Argentina, Taiwan, Spain, Ukraine, Russian Federation, Mexico, Poland, United States, Thailand",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04376827"
    },
    {
        "Title": "A Study of Felzartamab in Participants With Lupus Nephritis",
        "Summary": "Felzartamab is being tested as a treatment for lupus nephritis ln. The trial will evaluate safety tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, Australia, Argentina, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06064929"
    },
    {
        "Title": "A Study of Telitacicept in Lupus Nephritis",
        "Summary": " purpose study evaluate safety efficacy telitacicept adult patients active lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05680480"
    },
    {
        "Title": "Safety and Efficacy Study of a Biologic to Treat Systemic Lupus Erythematosus",
        "Summary": "Study evaluating safety efficacy novel biologic treatment systemic lupus erythematosus male female adults patients qualify randomized either active placebo or active placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Spain, Russian Federation, Korea, Republic of, Italy, Poland, Puerto Rico, Romania, South Africa, France, Netherlands, Canada, Peru, Taiwan, Japan, Argentina, Germany, Lebanon, Brazil, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02265744"
    },
    {
        "Title": "A Pooled Analysis of the HGS1006-C1056 (BLISS-52) and HGS1006-C1057 (BLISS-76) Studies",
        "Summary": "Belimumab subgroup systemic lupus erythematosus sle patients higher disease activity positive low complement pooled analysis studies.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Discoid",
        "Phases": "N/A",
        "IDestudio": "NCT01858792"
    },
    {
        "Title": "LUMIER\u00b2 Study : LUpus Molecular Immunomonitoring to Evaluate the Risk of Relapse",
        "Summary": " blood transcriptomic signatures predict occurrence flares patients sle clinically quiescent inclusion systemic lupus erythematosus sle chronic disease evolving flares possible organ damage periods remission. current biological markers disease activity sufficient predict occurrence of flares. monitor",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02811094"
    },
    {
        "Title": "Prospective Study of TW in the Treatment of LN Type V With Gross Proteinuria",
        "Summary": "Study analyze clinical effects adverse reactions tripterygium glycosides tw ctx patients gross proteinuria. purpose study analyze clinical effect adverse reactions.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Proteinuria, CTX",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00935389"
    },
    {
        "Title": "A Study to Compare Mycophenolate Mofetil and Tacrolimus in the Treatment of Membranous Lupus Nephritis",
        "Summary": "Pilot study compared mycophenolate mofetil combination corticosteroid treatment with tacrolimus. Study duration was 24 months.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, Glomerulonephritis, Membranous",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00404794"
    },
    {
        "Title": "Prospective Study of Rapamycin for the Treatment of SLE",
        "Summary": " systemic lupus erythematosus sle autoimmune disease unknown origin involves multiple organs including joints skin kidneys central nervous system disease process caused dysfunction. Drugs currently used treatment sle partially effective carry significant risks.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00779194"
    },
    {
        "Title": "Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients",
        "Summary": "Study designed evaluate safety tolerability pharmacokinetics therapeutic efficacy treatment either vay736 ianalumab or iscalimab.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Japan, Argentina, Germany, France, Spain, Israel, Australia, Russian Federation, Hungary, China, Korea, Republic of, Poland, Taiwan, Thailand",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03656562"
    },
    {
        "Title": "Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effect of GSK2646264 in Cutaneous Lupus Erythematosus Subjects",
        "Summary": "Study designed examine safety tolerability pharmacokinetics pharmacodynamics clinical effect repeat dosing gsk2646264 patients subacute chronic cutaneous lupus erythematosus cle lesions acute cle like lesions induced photoprov",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT02927457"
    },
    {
        "Title": "Improving Quality of Life for African American Female Adolescents With Lupus",
        "Summary": "Lupus systemic lupus erythematosus sle cope disease. Study evaluate program designed help african american adolescents.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00068874"
    },
    {
        "Title": "A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus",
        "Summary": "Dapirolizumab pegol dzp versus placebo adult subjects moderately severely active systemic lupus erythematosus. purpose evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Bulgaria, Germany, Spain, Ukraine, Russian Federation, Colombia, Chile, Hungary, Mexico, Peru, United States, Poland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02804763"
    },
    {
        "Title": "Rheumatology-based Adaptive Intervention for Social Determinants and Health Equity",
        "Summary": " clinical trial identify patients inflammatory arthritis systemic rheumatic condition arthritis may respond simplest least expensive intervention address tailored list resources benefit resource specialist help address specific needs require navigator help coordinate services provided specialist medical mental health care needs main questions clinical trial aims",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Palindromic Arthritis, Juvenile Rheumatoid Arthritis, Ankylosing Spondylitis, Sacroiliitis, Psoriatic Arthritis, Mixed Connective Tissue Disease, Lupus, Enteropathic Arthropathies, Systemic Sclerosis, Sjogren's Syndrome, Sicca Syndrome, Inflammatory Arthritis, Undifferentiated Connective Tissue Diseases",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05715463"
    },
    {
        "Title": "3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erithematosus Study Protocol",
        "Summary": "3tr project funded innovative medicines initiative 2 joint undertaking grant agreement 831434 supported european union horizon 2020 research innovation programme eFPia transdisciplinary consortium primary aims identifying biosignatures predictors response therapy seven different autoimmune allergic inflammatory diseases",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05458622"
    },
    {
        "Title": "Pharmacokinetics Study of Ianalumab in Chinese Participants With Autoimmune Diseases",
        "Summary": "Chinese participants systemic lupus erythematosus sle sj\u00f6gren disease sjd collection intensive pk data chinese population designed ianalumab phase 3 studies. purpose pharmacokinetic pk study describe",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Sjogren Disease, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06411639"
    },
    {
        "Title": "JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)",
        "Summary": "Jy231 is an injection used to treat systemic lupus erythematosus sleus. The drug is currently being tested in the United States.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06675422"
    },
    {
        "Title": "Clarifying Misbeliefs About Hydroxychloroquine: Developing a Decision Aid for Patients With Lupus",
        "Summary": "Research study collect information lupus patients experience tool informs patients benefits harms medication hydroxychloroquine main question aims answer whether tool increase medication adherence.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT05922722"
    },
    {
        "Title": "Register of Patients With Anti-Phospholipids Syndrome (APS) and/or Systemic Lupus Erythematosus (SLE)",
        "Summary": " patients suffering aps without associated slews. purpose register collect medical information. patients suffering from aps with no slews without associatedslews.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Anti-Phospholipids Syndrome (APS), Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT02782039"
    },
    {
        "Title": "Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V",
        "Summary": "iptacopan lnp023 addition standard care treatment. overall purpose study evaluate efficacy safety tolerability. iptacOpan lNP023 is an addition to the standard of care treatment for cancer.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey, Germany, France, Brazil, Spain, Israel, India, Hungary, Hong Kong, China, Mexico, Portugal, United States, Singapore, Malaysia, Puerto Rico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05268289"
    },
    {
        "Title": "AURA-LV: Aurinia Urinary Protein Reduction Active - Lupus With Voclosporin (AURA-LV)",
        "Summary": "2 doses voclosporin compared placebo achieving complete remission. 24 weeks therapy subjects active lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Serbia, Belarus, Ecuador, Spain, Georgia, Russian Federation, Ukraine, China, Korea, Republic of, Poland, Sri Lanka, Bulgaria, Philippines, Taiwan, Bangladesh, Mexico, Singapore, Guatemala",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT02141672"
    },
    {
        "Title": "Study of ALXN2050 in Proliferative Lupus Nephritis (LN) or Immunoglobulin A Nephropathy (IgAN)",
        "Summary": " phase 2 randomized multicenter study alxn2050 120 180 milligrams mg addition background therapy consistent standard care adult participants 18 75 years age either ln igan study consist screening period blinded initial evaluation period blinded extended treatment period extension",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey, Argentina, Germany, Taiwan, Brazil, Spain, Israel, Australia, Mexico, China, Italy, Korea, Republic of, United States, Peru, Thailand, United Kingdom, Serbia",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Nephritis, Immunoglobulin A Nephropathy, IgAN, LN",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05097989"
    },
    {
        "Title": "An Investigation of AGS-009 in Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": " clinical trial conducted north america aim clinical trial investigate safety tolerability. pharmacokinetic signs bioactivity increasing single doses patients systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Inflammation, Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00960362"
    },
    {
        "Title": "An Exploratory Clinical Study of Anti-CD19 CAR NK Cells in the Treatment of Systemic Lupus Erythematosus",
        "Summary": "Single arm pilot study designed to determine safety effectiveness. single arm pilotStudy designed to determined safety effectiveness differentiation antigen 19 cd19 chimeric antigen receptor car natural killer nk cells.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06010472"
    },
    {
        "Title": "A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus Erythematosus",
        "Summary": ". purpose study assess safety drug levels participants cutaneous lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04493541"
    },
    {
        "Title": "CCCR Lupus Patient Navigator Program",
        "Summary": "Patient navigator services commonly provided include facilitation coordination care practical support including scheduling transportation referrals financial assistance programs appointment scheduling reminders education support effective patient navigators address health system patient barriers.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04461158"
    },
    {
        "Title": "Evaluation of MyoStrain\u2122 in Clinical Practice",
        "Summary": " evaluate myostrain cardiac mri pulse sequence clinical practice. evaluate mystrain cardiacMri pulse Sequence clinical practice in the U.S.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cardiac Failure, Coronary Artery Disease, Sarcoidosis, Amyloidosis, Lupus, Myocarditis, Drug Toxicity",
        "Phases": "N/A",
        "IDestudio": "NCT03825224"
    },
    {
        "Title": "Universal CAR-T Cells (BRL-301) in Refractory Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is one of the most lethal forms of Lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05988216"
    },
    {
        "Title": "A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus",
        "Summary": " multicenter randomized phase 1 clinical study evaluate safety tolerability pharmacokinetic profile. single multiple doses tj202 patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05140824"
    },
    {
        "Title": "COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders",
        "Summary": " randomized adaptive clinical trial comparing immune response different additional doses vaccine participants autoimmune disease requiring medications. negative serologic suboptimal responses defined roche result low immune response. 200 previous doses vaccine study focus 5 autoimmune diseases adults systemic lupus ",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05000216"
    },
    {
        "Title": "Patient-Centered Assessment of Symptoms and Outcomes",
        "Summary": "Researchers think therapy treat one type fatigue one condition able treat type fatigue conditions objective understand types fatigue. background cause fatigue well understood felt differently different people people think different types of fatigue different causes. eligibility adults 18 older felt fatigue month.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Fatigue, Cancer, CFS, ME/CFS, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Lupus, Systemic Lupus Erthematosus, Sjogrens",
        "Phases": "N/A",
        "IDestudio": "NCT03952624"
    },
    {
        "Title": "Efficacy of Fractional Er:YAG Laser in Lupus Erythematosus Scars",
        "Summary": " cutaneous lupus erythematosus cle chronic autoimmune connective tissue disease prevalence predominantly women mid adulthood. Many physicians afraid treating often stigmatizing scars considering huge psychological impact facial scaring quality life.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Cutaneous",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04707924"
    },
    {
        "Title": "Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Lupus",
        "Summary": "Lupus patients receive intravenous infusion cultured allogeneic adult umbilical cord derived mesenchymal stem cells treatment lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Antigua and Barbuda",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05018858"
    },
    {
        "Title": "A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)",
        "Summary": " deucravacitinib compared placebo participants active discoid subacute cutaneous lupus erythematosus. purpose study assess safety efficacy tolerability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, Argentina, Taiwan, France, Australia, Mexico, Poland, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Lupus Erythematosus, Discoid, Lupus Erythematosus, Subacute Cutaneous",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04857034"
    },
    {
        "Title": "Auto-immunity in Lupus Patients After Influenza Vaccine",
        "Summary": " annual influenza vaccination recommended patients systemic lupus erythematosus sle however concerns remain vaccination risk.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01072734"
    },
    {
        "Title": "A Study of KK4277 in Healthy Volunteers and Patients With Systemic Lupus Erythematosus and Cutaneous Lupus Erythematosus",
        "Summary": "Kk4277 healthy japanese adult males. part 1 evaluate safety tolerability single intravenous iv subcutaneous sc dose. part 2 evaluate safety toleranceability repeated iv sc administration. kk4 277 patients systemic lupus",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Korea, Republic of",
        "OverallStatus": "RECRUITING",
        "Conditions": "Healthy Volunteers, Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05411016"
    },
    {
        "Title": "Immune Cell Subsets in SLE Patients Treated with Telitacicept",
        "Summary": "Study participants met inclusion criteria treated tetanercept 160 mg week total 24 weeks clinical laboratory indicators collected treatment 4th week 12th week 24th week blood samples collected detection immune cell subsets.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT06677801"
    },
    {
        "Title": "Study to Assess Real-world Effectiveness of Belimumab for Treatment of Adults With LN",
        "Summary": "Study aims to provide first 5 years assessment renal function preservation. purpose study assess use effectiveness belimumab routine practice treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06527872"
    },
    {
        "Title": "A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State",
        "Summary": " systemic lupus erythematosus sle disease associated inflammation multiple organ systems study evaluate well elsubrutinib upadacitinib given alone combination works within body participants completed study study assess change disease symptoms.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan, Bulgaria, Argentina, Germany, Taiwan, Spain, Australia, New Zealand, Colombia, Hungary, China, Italy, Korea, Republic of, United States, Mexico, Poland, United Kingdom, Puerto Rico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04451772"
    },
    {
        "Title": "Efficacy of Seluang Fish Oil (Rasbora Argyrotaenia) and Synbiotics Supplementation on CD4+CD25+ Foxp3+ T-regulator Cells, IL17/IL-10 Ratio, and Disease Activity in Systemic Lupus Erythematosus Patients",
        "Summary": "Study aimed evaluate efficacy seluang fish oil rasbora argyrotaenia synbiotics containing lactobacillus helveticus r0052 60 bifidobacterium infantis r0033 20",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06659068"
    },
    {
        "Title": "Phase I Study in China - Tolerability of a Single Dose of Abatacept 30 mg/kg",
        "Summary": "Study to determine whether abatacept dose 30 via intravenous infusion safe well tolerated treatment lupus nephritis mainland chinese subjects.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00705367"
    },
    {
        "Title": "The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients",
        "Summary": "Periostin is a protein found in the urine of patients with lupus nephritis and other nephropathy.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis, IgA Nephropathy",
        "Phases": "N/A",
        "IDestudio": "NCT02493101"
    },
    {
        "Title": "Acthar for the Treatment of Systemic Lupus Erythematosus (SLE) in Patients With a History of Persistently Active Disease",
        "Summary": " phase 4 study performed examine effects acthar indicated use treatment. sle study enroll patients persistently active sle arthritic cutaneous involvement study involve two periods period provide safety efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01753401"
    },
    {
        "Title": "SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease",
        "Summary": "Lupus nephritis ln common manifestation patients systemic lupus erythematosus sle important cause acute kidney injury chronic kidney disease ckd although treatments active severe ln effective substantial proportion ln patients still develop",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis, Chronic Kidney Diseases",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06155604"
    },
    {
        "Title": "IMPT-514 in Systemic Lupus Erythematosus, Anca-associated Vasculitis, and Idiopathic Inflammatory Myopathy",
        "Summary": "B cell driven autoimmune diseases including active refractory systemic lupus erythematosus sle anca associated vasculitis aav idiopathic inflammatory myopathy iim.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), ANCA Associated Vasculitis (AAV), Idiopathic Inflammatory Myopathy (IIM)",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06462144"
    },
    {
        "Title": "Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases",
        "Summary": "2009 new pandemic strain influenza virus emerged raising major concerns public health patients immunosuppressive therapy indication immunization influenza virus h1n1 however concerns possibility reactivation autoimmune diseases determine adverse events insufficient immunogenicity patients lack studies evaluating efficacy",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Rheumatoid Arthritis, Spondyloarthritis, Systemic Lupus Erythematosus (SLE), Dermatomyositis (DM), DMixed Connective Tissue Disease, Systemic Vasculitis, Systemic Sclerosis (SSc), Sj\u00f6gren's Syndrome, Antiphospholipid Syndrome, Juvenile Idiopathic Arthritis, Juvenile SLE, Juvenile DM",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01151644"
    },
    {
        "Title": "Ultrasonic COmparison of Salivary Glands in Autoimmune Diseases (COUGAR)",
        "Summary": "Sj\u00f6gren disease compared patients connective diseases rheumatoid arthritis ra lupus scleroderma control patients patient dry syndrome without autoimmune disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Sjogren Syndrome, Dry Syndrome, Lupus, Scleroderma, Rheumatoid Arthritis",
        "Phases": "N/A",
        "IDestudio": "NCT06680310"
    },
    {
        "Title": "CYCLONES - CYClophosphamide LOw Dose and No Extra Steroid",
        "Summary": " glucocorticoids gc use increased survival patients systemic lupus erythematosus sle particularly cases nephritis significant improvement 80 introduction therapy combined immunosuppressants therapeutic scheme however results high incidence irreversible damage associated",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03492255"
    },
    {
        "Title": "Safety and Tolerability of MEDI-545 in Patients Who Have Systemic Lupus Erythematosus (SLE)",
        "Summary": "The study evaluated safety tolerability intravenously administered compared placebo dose escalation range. Adult patients receiving 20 less prednisone orally equivalent dose another oral corticosteroid.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00299819"
    },
    {
        "Title": "Long-Term Outcome of Children and Adolescents With Anti-Phospholipid Antibodies",
        "Summary": "Study looked at people with antibodies associated with blood clots. Study looked at changes in people with certain types of proteins blood called antibodies.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT00581763"
    },
    {
        "Title": "A Study to Evaluate the Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adults With Active Systemic Lupus Erythematosus",
        "Summary": "Primary objective study evaluate safety tolerability litifilimab participants active systemic lupus erythematosus sle secondary objectives study evaluate effect litifilsimab disease activity participants sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Serbia, Spain, China, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Bulgaria, Philippines, France, Taiwan, Czechia, Japan, Argentina, Brazil, Israel, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05352919"
    },
    {
        "Title": "Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus",
        "Summary": " lupus erythematosus sle sle. goal study evaluate safety efficacy of car cells treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Lupus Nephritis (LN)",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06585514"
    },
    {
        "Title": "A Study to Compare the Efficacy and Safety of Tacrolimus Capsules and Cyclophosphamide Injection in Treatment of Lupus Nephritis",
        "Summary": "Tacrolimus capsules induction remission patients lupus nephritis compare efficacy safety cyclophosphamide injections.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02457221"
    },
    {
        "Title": "Comparison between2 Drugs in Lupus Nephritis",
        "Summary": " aim work study effect side effects cyclophosphamide versus mycophenolate lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04424602"
    },
    {
        "Title": "Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle mixed connective tissue disease mctd autoimmune diseases immune system attacks parts body abnormal immune reaction causes inflammation damage various body parts affect joints skin kidneys heart lungs blood vessels brain sle mct",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Mixed Connective Tissue Disease (MCTD), Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT00582881"
    },
    {
        "Title": "Aerobic Exercise Versus Whole-Body Vibration on Fatigue, Functional Capacity, Quality of Life in Systemic Lupus",
        "Summary": "Study conducted investigate therapeutic efficacy aerobic exercise versus vibration fatigue functional capacity quality life patients systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic, Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05321108"
    },
    {
        "Title": "Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid",
        "Summary": "Primary objective study describe compare plasmatic concentrations among three distinct groups. 1 patients suffering bullous pemphigoide 2 patients suffering dermatological diseases 3 elderly control group.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Pemphigoid, Bullous, Pemphigus, Lupus Erythematosus, Cutaneous",
        "Phases": "N/A",
        "IDestudio": "NCT01559155"
    },
    {
        "Title": "SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus",
        "Summary": " randomized phase clinical study evaluate safety tolerability pharmacokinetics pharmacodynamics single dose healthy volunteers multiple doses sg301 sc injection participants systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06144710"
    },
    {
        "Title": "A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus",
        "Summary": "Study evaluated safety drug levels drug effects cells. Participants received multiple increasing doses via intravenous iv infusion subcutaneous sc injection.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Bulgaria, Germany, Argentina, Spain, Mexico, Poland, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06013995"
    },
    {
        "Title": "Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus",
        "Summary": "Study multicenter randomized multiple dose study approximately 24 subjects scle enrolled. cohort 1 consist 12 subjects 6 amg 557 6 placebo randomized receive amg. 557 210 mg matching placebo. cohort 2 consist 12 Subjects 6Amg 5",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, Australia, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus, Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01389895"
    },
    {
        "Title": "Anti-CD19-CD3E-CAR-T Cells in Relapsed/Refractory Autoimmune Disease",
        "Summary": "A U.S. trial evaluate safety efficacy cells in relapse refractory autoimmune diseases. The trial will also evaluate the safety and efficacy of using the cells to treat the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06373081"
    },
    {
        "Title": "Transcultural Validation in French of the Systemic Lupus Activity Questionnaire (SLAQ) and the Lupus Quality Of Life (LupusQoL) Questionnaire",
        "Summary": " evaluation lupus patients must include several approaches. particular disease activity quality life systemic lupUS activity questionnaire slaq validated. evaluate disease activity advantage inexpensive easy use large cohorts used several studies never validated french. evaluate quality life specific systemic l",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT02857452"
    },
    {
        "Title": "A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets",
        "Summary": "Study determine drug level profile different formulations of tablets. Study determine drug levels profile different tablets different formulations tablets.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04065932"
    },
    {
        "Title": "A Study of Clinical Characteristics ,Risk Factors and Outcome of Lupus Nephritis Among Children With Systemic Lupus Erthromatousus in Sohag Univeristy Hospital",
        "Summary": " systemic lupus erthrematosus inflamatory autoimmune condition characterized multisystem affection chronic course unpredictable flares despite potentially afffecting every oragan kidney.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06491602"
    },
    {
        "Title": "Pilot Study to Assess Flares Following Inactivated Influenza Vaccine in Children With Systemic Lupus Erythematosus (SLE)",
        "Summary": " open label pilot observational prospective study safety inactivated influenza vaccine iiv children systemic lupus erythematosus sle conducted influenza season study test conventional novel biomarkers assess disease flare vaccine response.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT02006784"
    },
    {
        "Title": "Acceptability and Persistence of the Use of a Patient-centred E-health Tool for Lupus Patients Followed in a Specialised Centre in France",
        "Summary": " clinical research requires consideration several aspects particular disease activity quality life health systems increasingly using patient reported outcome measures pro data measure different dimensions disease experience addition growing number tools patients indeed collection data via electronic system.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT03953690"
    },
    {
        "Title": "A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy",
        "Summary": " multicenter study autologous therapy targeting cd20 bcma treatment adult patients autoimmune diseases refractory to standard therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Immune-Mediated Necrotizing Myopathy, Neuromyelitis Optica Spectrum Disorders, Multiple Sclerosis-Relapsing-Remitting, Myasthenia Gravis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06249438"
    },
    {
        "Title": "Efficacy and Safety of Oral Alitretinoin (Toctino\u00ae) in the Treatment of Patients With Cutaneous Lupus Erythematosus",
        "Summary": "Oral alitretinoin is used in the treatment of lupus disease. The drug has been shown to have a positive effect on patients with the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Cutaneous",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01407679"
    },
    {
        "Title": "Metformin In Prevention of Lupus Nephritis",
        "Summary": "Lupus erythematosus sle largely effect prognosis sle patients previous data showed development ln common first year sle occupying 17 group established prediction model predict probability ln sle patients without renal involvement.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT04145687"
    },
    {
        "Title": "Efficacy of 595 nm Pulsed-dye Laser in Treatment of Discoid Lupus Erythematosus",
        "Summary": " forty dle lesions patients recruited study lesions one side body treatment group side served control patients continue systemic treatments pdl designed used adjunctive treatment treatments. pdl delivered treatment group every 4 weeks 4 consecutive months lesions control group received sham patients",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Discoid",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT03178188"
    },
    {
        "Title": "Efficacy and Safety of Fumaric Acid Esters (Fumaderm\u00ae) in the Treatment of Patients With Cutaneous Lupus Erythematosus",
        "Summary": "Fumaric acid esters have been used to treat cutaneous lupus erythematosus. The study evaluated the therapeutic effect of fumaric acids on the skin.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Cutaneous",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01352988"
    },
    {
        "Title": "A Study of LCAR-AIO in Subjects with Relapsed/Refractory Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is one of the most deadly diseases in the world. The disease is caused by a build-up of blood vessels in the body.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06653556"
    },
    {
        "Title": "Disease Progression and Activity in Patients With Systemic Lupus Erythematosus",
        "Summary": "Study continuing patients systemic lupus erythematosus sle control subjects enrolled in study. Study will examine associations sociodemographic factors disease damage work disability.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT00339261"
    },
    {
        "Title": "Omega-3 Replacement With Krill Oil in Disease Management of SLE",
        "Summary": " randomized controlled multicenter study sle patients given placebo 24 weeks randomized period followed open label extension ole treatment next 24 weeks patients maintained stable doses background medications except glucocorticoids decreases doses.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03626311"
    },
    {
        "Title": "Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)",
        "Summary": " purpose study determine rozibafusp alfa could useful therapeutic agent. current treatment landscape subjects subject to ongoing disease activity despite treatment standard care therapies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Greece, Spain, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, Bulgaria, France, Canada, Portugal, Czechia, Japan, Argentina, Germany, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04058028"
    },
    {
        "Title": "AZAHAR Study To Describe Anifrolumab in a Real-World Setting",
        "Summary": " azahar observational retrospective longitudinal study adults patients sle initiated treatment anifrolumab june 1 2023 may 31 2024 overall objective describe characteristics clinical outcomes.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT06626945"
    },
    {
        "Title": "Cutaneous Lupus Erythematosus and Elidel",
        "Summary": " trial evaluates therapeutic effect elidel pimecrolimus on chronic discoid lupus erythematosus dle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Discoid",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00222183"
    },
    {
        "Title": "Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)",
        "Summary": " aim proposal test antibody restore normal threshold tolerance patients. compare polyreactivity autoreactivity immature central tolerance na\u00efve b cells peripheral tolerance peripheral blood along study bliss believe study treatment reconstitution time.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Immune Thrombocytopenia (ITP), Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03975361"
    },
    {
        "Title": "Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases",
        "Summary": " investigator initiated trial assess efficacy safety relapse refractory autoimmune diseases china. Investigator initiated trial to assess efficacy and safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Systemic Vasculitis, Antiphospholipid Syndrome",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05859997"
    },
    {
        "Title": "Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis",
        "Summary": "The trial evaluate efficacy safety tolerability subcutaneous ianalumab given every 4 weeks and every 12 weeks. The study also compared placebo combination to a placebo.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Spain, Hong Kong, China, Italy, Korea, Republic of, United Kingdom, Romania, France, India, Lithuania, Canada, Taiwan, Czechia, Argentina, Germany, Estonia, Brazil, Vietnam, Chile, Colombia, Hungary, Mexico, Singapore, Malaysia, Guatemala",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05126277"
    },
    {
        "Title": "The Safety and Efficacy of Anti-CD19 CAR-T Cells in Patients With Relapsed/Refractory Autoimmune Diseases",
        "Summary": "A U.S. trial evaluate safety efficacy cells in relapse refractory autoimmune diseases. The trial will also evaluate the safety and efficacy of using the cells to treat the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Sjogren's Syndrome, Systemic Sclerosis, Inflammatory Myopathy, ANCA Associated Vasculitis, Antiphospholipid Syndrome",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06420154"
    },
    {
        "Title": "Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis",
        "Summary": "Antifrolumab is used to treat proliferative lupus nephritis. This study will evaluate the safety and efficacy of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States, Thailand, Russian Federation, China, Italy, Poland, Belgium, Turkey, Bulgaria, France, India, Netherlands, Peru, Taiwan, Japan, Argentina, Germany, Brazil, Vietnam, Colombia, Hungary, Mexico, Malaysia",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05138133"
    },
    {
        "Title": "Autologous Adoptive T Regulatory Cell Transfer in Autoimmune Diseases.",
        "Summary": "Researchers aim to develop effective safe treatment autoimmune diseases adoptive regulatory cells transfer. Study includes ten patients refractory lupus nephritis and ten patients type 1 diabetic patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Nephritis, Type 1 Diabetes Mellitus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05566977"
    },
    {
        "Title": "Acthar SLE (Systemic Lupus Erythematosus)",
        "Summary": "Two doses 40 u 80 u acthar sle patients immune mediated hematologic manifestations requiring steroid use minimum 2 weeks prior screening. randomized study exploring efficacy safety steroid sparing ability.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus (SLE), Repository Corticotropin Injection",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT02779153"
    },
    {
        "Title": "Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE",
        "Summary": "Study examines impact anifrolumab disease activity on lupus patients. Study also examines impact on immune phenotypes, neutralizing antibodies.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT04726553"
    },
    {
        "Title": "3TR (Taxonomy, Treatment, Targets and Remission) Systemic Lupus Erythematosus Study Protocol 2",
        "Summary": "3tr project funded innovative medicines initiative 2 joint undertaking grant agreement 831434 supported european union horizon 2020 research innovation programme eFPia transdisciplinary consortium primary aims identifying biosignatures predictors response therapy seven different autoimmune allergic inflammatory diseases",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (SLE)",
        "Phases": "N/A",
        "IDestudio": "NCT05747651"
    },
    {
        "Title": "A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CCX168 in Healthy Participants",
        "Summary": "Primary objective study evaluate safety tolerability single multiple oral doses ccx168 range dose levels healthy male female participants.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "COMPLETED",
        "Conditions": "Vasculitis, Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05984251"
    },
    {
        "Title": "Fibroblast Activating Protein Inhibitor PET Imaging in Lupus Nephritis",
        "Summary": " abnormal high expression fibroblast activating protein fap found inflammatory reactions benign fibrosis tissue autoimmune nephropathy lupus nephritis ln lead tubular atrophy excessive deposition extracellular matrix may accompanied abnormally increased expression",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05845151"
    },
    {
        "Title": "SSerum/Urinary Monocyte Chemoattractant Protein-1 Level as a Marker for Lupus Nephritis",
        "Summary": "Lupus erythematosus is a chronic inflammatory autoimmune disease affecting many organ systems. Patients develop renal disease esrd within 15 years of diagnosis.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT03164720"
    },
    {
        "Title": "Comparing the Therapeutic Efficacy of Pimecrolimus Cream With Betamethasone Cream for Discoid Lupus Erythematosus",
        "Summary": "Corticosteroids may induce side effects thinning skin scarring therefore alternative medication efficacy without sought pimecrolimus newer drug specially designed treat inflammatory diseases skin efficacy treating discoid lupus erythematosus studied",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Iran, Islamic Republic of",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00608673"
    },
    {
        "Title": "Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives",
        "Summary": "\"Biospecimens\" is a collection of annotated biospecimens associated medical data. The data is intended to help researchers discover develop new treatments, preventative methods, and develop treatments.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Age-Related Macular Degeneration, Allergies, Alpha-Gal Syndrome, Alzheimer Disease, Amyloidosis, Ankylosing Spondylitis, Arthritis, Alopecia Areata, Asthma, Atopic Dermatitis, Autism, Autoimmune Hepatitis, Behcet's Disease, Beta-Thalassemia, Cancer, Celiac Disease, Kidney Diseases, COPD, Crohn Disease, Cystic Fibrosis, Diabetes, Dravet Syndrome, DMD, Fibromyalgia, Graves Disease, Thyroid Diseases, Hepatitis, Hidradenitis Suppurativa, ITP, Leukemia, ALS, Lupus or SLE, Lymphoma, Multiple Sclerosis, Myasthenia Gravis, Heart Diseases, Parkinson Disease, Pemphigus Vulgaris, Cirrhosis, Psoriasis, Schizophrenia, Scleroderma, Sickle Cell Disease, Stroke, Ulcerative Colitis, Vasculitis, Vitiligo",
        "Phases": "N/A",
        "IDestudio": "NCT05635266"
    },
    {
        "Title": "Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus",
        "Summary": " clinical study test efficacy safety nicotinamide skin lesions refractory treatment hydroxychloroquine plus corticosteroids. patients cutaneous lupus erythematosus cle systemic lupUS ery thematos",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus Rash",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03260166"
    },
    {
        "Title": "Positron Emission Tomography (PET) to Locate Areas of White Blood Cell Activity",
        "Summary": "Study examine whether pet imaging reveal happening lymph nodes patients systemic lupus erythematosus. Study determine whether pet detect areas increased activity.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Systemic",
        "Phases": "N/A",
        "IDestudio": "NCT00029926"
    },
    {
        "Title": "Renal Assessment for Early Detection of Renal Impairment in Systemic Sclerosis and Systemic Lupus Erythematosus Patients",
        "Summary": " evaluate renal resistive index ssc sle patients early detection renal impairment. evaluate renal mri ssc Sle patients early discovery of renal impairment measure serum levels cd147 sscsle patients correlation.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Sclerosis and Systemic Lupus Erythematous",
        "Phases": "N/A",
        "IDestudio": "NCT06287125"
    },
    {
        "Title": "Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity",
        "Summary": " dietary supplementation methyl donors demonstrated increase dna methylation leucocytes. Limited dietary intake methyl donors associated dna hypomethylation considering sle disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Overweight and Obesity, Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05097365"
    },
    {
        "Title": "Creatine Supplementation in Pediatric Rheumatology",
        "Summary": " creatine supplementation may improve strength muscle mass bone mass muscle function healthy elderly people investigators speculate creatine supplementation could therapeutic effects pediatric rheumatic juvenile systemic lupus erythematosus juvenile dermatomyositis patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Juvenile Systemic Lupus Erythematosus, Juvenile Dermatomyositis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01217320"
    },
    {
        "Title": "AS-OCT Study of Cornea and Tear Film Parameters in Juvenile SLE Patients",
        "Summary": "Study assess tear film parameters tear meniscus height, area, depth and corneal pachymetry epithelial thickness.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Juvenile Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05015465"
    },
    {
        "Title": "Nurses' Health Study and Health Professionals Follow-Up Study (Dermatological Component)",
        "Summary": " dermatological diseases skin cancers inflammatory autoimmune dermatoses cohort female registered nurses male health professionals. determine relationships dietary factors subsequent risk.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Skin Cancer, Melanoma, Non-melanoma Skin Cancer, Psoriasis, Rosacea, Lupus Erythematosus, Atopic Dermatitis",
        "Phases": "N/A",
        "IDestudio": "NCT03253666"
    },
    {
        "Title": "Weaning of Immunosuppression in Nephritis of Lupus",
        "Summary": " hydroxychloroquine possibly associated low dose corticosteroids. 2 years patients stable remission proliferative lupus nephritis patients continuing treatment hydroxy chloroquine.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Nephritis of Lupus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01284725"
    },
    {
        "Title": "Study of Ruxolitinib Cream for the Treatment of Discoid Lupus Erythematosus",
        "Summary": " purpose study assess potential efficacy topical ruxolitinib treatment discoid lupus erythematosus dle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04908280"
    },
    {
        "Title": "ASA Patterns for Prevention of Preeclampsia in SLE Pregnancies",
        "Summary": "Preeclampsia serious maternal condition affecting 5 pregnancies general population 30 lupus pregnancies aspirin acetylsalicylic asa shown reduce risk. Half women high risk therefore recommended health professionals initiate aspirin early pregnancy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "COMPLETED",
        "Conditions": "Pre-Eclampsia, Pregnancy Complications, Systemic Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03749044"
    },
    {
        "Title": "To Assess Prevention of Bone Loss in Women With Lupus Receiving Treatment With Glucocorticoids",
        "Summary": "Women with systemic lupus erythematosus sle also receiving treatment glucocorticoids prednisone. purpose clinical trial study effects gl701 bone mineral density.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico, United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00053560"
    },
    {
        "Title": "Phase 2a Study Evaluating the Arsenic Trioxide (ATO) in Systemic Lupus (SLE) (Protocol LUPSENIC)",
        "Summary": "Primary objectives investigate safety tolerability ato iv infusions patients sle determine maximum tolerated dose ato secondary objectives evaluation clinical biological response sle ato time relapse case positive response determination efficacy pharmacokinetic study ato",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01738360"
    },
    {
        "Title": "Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)",
        "Summary": " cutaneous lupus erythematosus cle disease wide spectrum clinical manifestations variable prognosis aim study create standardized evaluation different subtypes disease order receive overview spectrum clinical laboratory features well therapeutic strategies patients cle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00420173"
    },
    {
        "Title": "A Pilot Trial of Topical Thalidomide for the Management of Chronic Discoid Lupus Erythematosus",
        "Summary": "Pilot trial to determine whether 20 percent thalidomide ointment safe effective treatment chronic discoid lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00001680"
    },
    {
        "Title": "Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions (2)",
        "Summary": " lupus erythematosus le autoimmune disorder includes broad spectrum clinical forms one forms discoid.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Denmark",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00625157"
    },
    {
        "Title": "Lupus and Observance",
        "Summary": "There were 76 cases of systemic lupus associated increased risk relapses hospitalizations and poor renal prognosis. Poor therapeutic observance described 3 cases.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus, Skin Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT03019926"
    },
    {
        "Title": "Headache in Juvenile Onset Systemic Lupus Erythematosus",
        "Summary": "Study compare individuals juvenile onset systemic lupus erythematosus without headache.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Turkey",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Headache, Juvenile Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06658457"
    },
    {
        "Title": "Treatment of Refractory Systemic Lupus Erythematosus by Allogeneic Mesenchymal Stem Cells Derived From the Umbilical Cord",
        "Summary": " systemic lupus erythematosus sle rare prevalence 000 persons heterogeneous disease ad affecting sexes races peak incidence prevalence among black people predilection women decade life sle characterized successive periods flares remission may vary duration quality prognosis severe",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus, Stem Cell Transplant",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT03562065"
    },
    {
        "Title": "Pilot Study Related to the Effect of Clopidogrel on Plasmatic Soluble CD40 Ligand During Systemic Lupus Erythematous",
        "Summary": "Systemic lupus erythematosus sle pathogenesis systemic autoimmune disease characterized multiorgan involvement platelets major source soluble cd40l scd40l propose study effect clopidogrel platelet inhibitor plasm",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematous",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02320357"
    },
    {
        "Title": "Rheumatology Diet Study",
        "Summary": "Study aims collect information rheumatology patients dietary habits autoimmune disease activity dietary changes disease symptom improvements perceptions dietary habits affects autoimmune disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Diet Habit, Rheumatologic Disease, Autoimmune Diseases, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Dermatomyositis/Polymyositis, Sjogren's Syndrome, Systemic Lupus Erythematous, Scleroderma, Fibromyalgia",
        "Phases": "N/A",
        "IDestudio": "NCT06339957"
    },
    {
        "Title": "Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)",
        "Summary": "The study aims to evaluate the efficacy of filgotinib lanraplenib in treating cutaneous lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03134222"
    },
    {
        "Title": "Transition to Adulthood Through Coaching and Empowerment in Rheumatology",
        "Summary": " tracer study aiming investigate feasibility transition coaching sessions. Patients moving paediatric adult rheumatology care.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Juvenile Idiopathic Arthritis, Juvenile Rheumatoid Arthritis, Juvenile Dermatomyositis, Juvenile Psoriatic Arthritis, Autoinflammatory Disease, Autoimmune Diseases, Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05545839"
    },
    {
        "Title": "Translation of a Diagnostic Test for Lupus Flare Prediction From Bench to Clinic",
        "Summary": "Study investigating development diagnostic test intended to predict flares. Patients systemic lupus erythematosus period participant donate blood samples.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "System; Lupus Erythematosus, Lupus Erythematosus, SLE, Lupus Flare",
        "Phases": "N/A",
        "IDestudio": "NCT04018222"
    },
    {
        "Title": "Delivery of Enhance Fitness Trial",
        "Summary": " arthritis common condition united states leading cause pain disability physical exercise recommended managing arthritis access exercise programs limited particularly rural areas. Investigators propose evaluate remote delivery exercise program called enhance fitness.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Arthritis, Rheumatoid Arthritis, Fibromyalgia, Gout, Osteoarthritis, Lupus or SLE",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05275348"
    },
    {
        "Title": "Long-term Immunogenicity of a Live Herpes Zoster Vaccine in Systemic Lupus Erythematosus (SLE) Patients",
        "Summary": "Zostavax stable systemic lupus erythematosus sle patients previous history hz varicella infection important research question whether immunogenicity hz vaccine sle patients is safe. Recent randomized controlled trial rct group",
        "StudyType": "OBSERVATIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04089930"
    },
    {
        "Title": "Study of Daxdilimab (HZN-7734) in Patients With Moderate-to-Severe Primary Discoid Lupus Erythematosus",
        "Summary": "Daxdilimab is being tested on patients with lupus erythematosus. The drug is being trialled in a phase 2 randomized study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Bulgaria, Argentina, Germany, France, Brazil, Greece, Canada, Denmark, Poland, United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05591222"
    },
    {
        "Title": "Prognosis Assessment of the Increase of GADD34 Gene Expression for Patient Suffering From Systemic Lupus Erythematosus",
        "Summary": "Gadd34 described potential key regulator cytokine production human elevated blood marker sle patients study aim prove gadd34 rna level mononuclear blood cells used to assess risk.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT02455089"
    },
    {
        "Title": "Prevalence and Clinical Severity of Cutaneous Lupus Erythematosus",
        "Summary": " cutaneous lupus erythematosus cle database established 2006 database. University pennsylvania university texas southwestern utsw.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Cutaneous Lupus Erythematosus (CLE)",
        "Phases": "N/A",
        "IDestudio": "NCT01510067"
    },
    {
        "Title": "A Study to Evaluate the Safety and Tolerability of Multiple Intravenous Doses of MEDI 545 in Patients With Systemic Lupus Erythematosus",
        "Summary": ". evaluate safety tolerability multiple iv doses medimunne antibody adult patients sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Chile, Brazil, Argentina, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT00482989"
    },
    {
        "Title": "A Study to Assess the Safety and Efficacy of Secukinumab in Alleviating Symptoms of Discoid Lupus Erythematosus",
        "Summary": " discoid lupus erythematosus chronic inflammatory skin condition may lead itch skin pain open sores scarring disfigurement hair loss studies shown may play major role inflammation pathogenesis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03866317"
    },
    {
        "Title": "The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology.",
        "Summary": "Migraine frequent debilitating neurologic disorder frequent women prevalent patients autoimmune inflammatory diseases multiple sclerosis ms rheumatoid arthritis ra crohn disease cd systemic lupus erythematosus sle endometriosis. Patients long standing",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Migraine Disorders, Pain, Autoimmune Diseases, Multiple Sclerosis, Endometriosis, Rheumatoid Arthritis, Crohn Disease, Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06426316"
    },
    {
        "Title": "Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus",
        "Summary": "Sar443122 cutaneous lupus erythematosus cle secondary objectives assess effect sar443122 physician global assessment disease activity physga disease activity assess effect.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Argentina, Spain, Ukraine, Australia, India, Russian Federation, Chile, Hungary, Canada, Italy, Mexico, United States, Poland, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04781816"
    },
    {
        "Title": "Combined Pneumococcal Conjugate and Polysaccharide Vaccination in Inflammatory Rheumatic Disease",
        "Summary": "Pneumococcal vaccination using conjugate vaccine combined schedules polysaccharide vaccine addition aim study clinical aspects vaccination regarding tolerability immunosuppressed patients ird impact existing rheumatic disease possible association onset new autoimmune diseases immunity following",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatoid Arthritis, Systemic Lupus, Sj\u00f6gren Syndrome, Systemic Vasculitis, Spondyloarthritis",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03762824"
    },
    {
        "Title": "Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis",
        "Summary": "Lupus erythematosus sle remains challenge particularly renal involvement lupus nephritis last 60 years corticosteroids backbone treatment. Rituximab associated significant toxicity although randomized placebo controlled trials ritux",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus, Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01773616"
    },
    {
        "Title": "MFERG Study of HCQ Retinopathy in Lupus Nephritis Patients: A Randomized Controlled Clinical Trial",
        "Summary": "Study assess multifocal erg mferg changes sle patients treated chloroquine renal patients comparison sle patients without kidney affection.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "mfERG in Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05111158"
    },
    {
        "Title": "The Effects of Mesenchymal Stem Cell Secretome in Lupus Patients",
        "Summary": "Research clinical trial administering mesenchymal stem cell secretome lupus patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT05921058"
    },
    {
        "Title": "Longitudinal Study of Quality of Life and Activity in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus complex disease whose evaluation everyday practice clinical research requires several aspects taken into account.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01904812"
    },
    {
        "Title": "Use of Baricitenib to Maintain of Remission",
        "Summary": " baricitinib selective janus kinase jak inhibitors 1 2 recognized potential therapeutic option systemic lupus sle also known baricit inib jak inhibitor demonstrated efficacy safety treatment dermatitis arthritis 1. Jak inhibitor studies conducted",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus or SLE, Nephritis",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05686746"
    },
    {
        "Title": "Autotaxin as Abiomarker in Systemic Lupus Erythematosus Patients",
        "Summary": " serum atx level sle patients comparison healthy subjects evaluation relation serum at x level disease activity different clinical manifestation sle patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT06063668"
    },
    {
        "Title": "Biocollection of Rare Pediatric-onset of Autoimmune and Autoinflammatory Diseases",
        "Summary": "Rare diseases defined affect one person around three million people france majority rare diseases caused genetics tend severe. autoimmune autoinflammatory diseases involve excess innate immune response precise mechanisms not fully understood.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus, Autoimmune Diseases, Autoinflammatory Disease, Genetic Disease",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06435468"
    },
    {
        "Title": "Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
        "Summary": "Study evaluated efficacy safety intravenous treatment regimen two doses anifrolumab versus placebo adult subjects moderately severely active systemic lupus erythematosus sleus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Romania, Argentina, Germany, Taiwan, Brazil, Ukraine, Israel, Australia, New Zealand, Chile, Colombia, Hungary, Italy, Korea, Republic of, United States, Peru, Poland, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Active Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02446912"
    },
    {
        "Title": "Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)",
        "Summary": " part investigate efficacy different sunscreens prevention skin lesions following standardized photoprovocation ultraviolet b light patients cle. part ii evaluate influence different sunscreen expression biomarkers skin patients cle healthy controls following uv irradiation.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01146444"
    },
    {
        "Title": "Expression of Fas Protein in Skin Biopsies of Participants With Scarring Alopecia",
        "Summary": " proteins involved genetic work may also better define disease well future treatment options. purpose research study see specific protein interested involved scarring hair loss.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Central Centrifugal Scarring Alopecia, Lichen Planopilaris, Discoid Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT00691769"
    },
    {
        "Title": "Sunscreen RV 2457C in Photoinduced CLE",
        "Summary": "Lupus erythematosus characterized large clinical spectrum sunligt well established factor induction exacerbation disease subsets. Antimalarial agents topical steroids main treatments chronic. Second line therapies include retinoids sulfones immunos",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus, Skin Lesion, Experimental Photoinduction, Protective Sunscreen",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00470912"
    },
    {
        "Title": "Efficacy and Safety of Delgocitinib Cream in Discoid Lupus Erythematosus.",
        "Summary": "The trial was designed to establish the efficacy and safety of delgocitinib cream. The trial included patients with discoid lupus erythematosus dle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France, Germany, Denmark, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03958955"
    },
    {
        "Title": "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ABT-199 in Female Patients With Systemic Lupus Erythematosus (SLE)",
        "Summary": ". assess safety tolerability pharmacokinetics female subjects systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Mexico, Germany, Puerto Rico, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01686555"
    },
    {
        "Title": "Study of the Role of Soluble Forms of RAGE (sRAGE/esRAGE) as Diagnostic and Prognostic Biomarkers of Systemic Lupus Erythematosus.",
        "Summary": "Rage regulates number crucial cell processes like inflammation tissue cellular homeostasis rage able bind advanced glycation end products ages pentosidine carboxymethyllysine cml h1 also ligands hmgb1 high mobility group",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02891213"
    },
    {
        "Title": "Tapinarof for Cutaneous Lupus Erythematosus",
        "Summary": "The cutaneous lupus trial is a prospective interventional clinical trial patients chronic subacute cutaneousLupus. The trial aims to identify topical ahr agonism leads improvement cutaneous Lupus lesions. The goal is",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06661213"
    },
    {
        "Title": "A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus",
        "Summary": "Study designed evaluate safety tolerability multiple intravenous administered doses. Patients cutaneous lupus erythematosus changes disease activity also evaluated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Moldova, Republic of, Canada, United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01470313"
    },
    {
        "Title": "IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus",
        "Summary": "Treatment intravenous immunoglobulin ivig can replace current systemic immunosuppressive therapy cutaneous lupus erythematosis cle patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT01841619"
    },
    {
        "Title": "Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus",
        "Summary": "Lupus disease immune system normally fights infection begins attack healthy cells body phenomenon called autoimmunity immune system attacks called autoantigen lupus affect many parts body often affects skin immune cells attacking autoantigens skin causing rash",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01498406"
    },
    {
        "Title": "Anifrolumab Asian PhIII Efficacy Study for Systemic Lupus Erythematosus (SLE)",
        "Summary": "Anifrolumab is an intravenous treatment regimen for systemic lupus erythematosus sleus. The study evaluated the efficacy and safety of the regimen.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Philippines, Hong Kong, Korea, Republic of, China, Taiwan, Thailand",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Active Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT04931563"
    },
    {
        "Title": "Description of Compliance With Hydroxychloroquine Treatment in Patients With Systemic Lupus Erythematosus",
        "Summary": " project focuses patients systemic lupus erythematosus taking plaquenil. Half patients chronic illness poorly compliant treatment lupUS one investigators want use already validated existing questionnaire.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06161363"
    },
    {
        "Title": "Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus",
        "Summary": "Anifrolumab is an intravenous treatment regimen for systemic lupus erythematosus sleus. The study was designed to evaluate efficacy and safety of the regimen.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Belgium, Japan, Bulgaria, Argentina, Germany, South Africa, France, Brazil, Spain, Lithuania, Russian Federation, Mexico, Canada, Korea, Republic of, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Active Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02446899"
    },
    {
        "Title": "Deep Phenotyping of Cutaneous Lupus Erythematosus",
        "Summary": "Cutaneous lupus erythematosus ( cle) is an autoimmune disease with a complex heterogeneous character. The main objective of this study is to characterize cle using a deep phenotyping approach.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "RECRUITING",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06411106"
    },
    {
        "Title": "Leflunomide Versus Azathioprine for Maintenance Therapy of Lupus Nephritis",
        "Summary": " leflunomide versus azathioprine maintenance therapy lupus nephritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Nephritis, Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01172002"
    },
    {
        "Title": "Efficacy and Safety of ASF-1096 Cream 0.5% in the Treatment of Discoid Lupus Erythematosus (DLE) Lesions",
        "Summary": " lupus erythematosus le autoimmune disorder includes broad spectrum clinical forms one forms discoid.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Sweden",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00625521"
    },
    {
        "Title": "Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus",
        "Summary": "Study evaluated efficacy of ruxolitinib cream on discoid lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06261021"
    },
    {
        "Title": "Efficacy of Topical Tacrolimus in Different Subtypes With Cutaneous Lupus Erythematosus (CLE)",
        "Summary": "Lupus erythematosus tacrolimus targets lymphocytes suppresses activation inhibiting expression cytokine genes. Treatment might result improvement skin lesions patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00317681"
    },
    {
        "Title": "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)",
        "Summary": "Edecesertib formerly participants cutaneous lupus erythematosus cle without systemic lupuses. Study evaluated safety tolerability edecesERTib.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT04809623"
    },
    {
        "Title": "Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "Main goal study determine bone marrow transplant bmt. less specific pool donors combination high dose cyclophosphamide induce remission refractory systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Lupus Erythematosus, Graft-versus-host Disease",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02080195"
    },
    {
        "Title": "Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)",
        "Summary": "Edecesertib is a drug used to treat cutaneous lupus erythematosus. The drug also has side effects. The study is part of a larger clinical study.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Czechia, Spain, Germany, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Cutaneous Lupus Erythematosus (CLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05629208"
    },
    {
        "Title": "Evaluation of Influenza A/H3N2 Vaccine in Patients With Rheumatologic Diseases",
        "Summary": " studies literature shown reduced effectiveness influenza h3n2 virus vaccine compared to h1n1 influenza b reduction efficacy may partly result from need to propagate. Vaccine factors may also contribute reduction efficacy h3N2 viruses include high level genetic",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus, Sjogren's Syndrome",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT03540823"
    },
    {
        "Title": "To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus",
        "Summary": "First study cutaneous lupus erythematosus subjects evaluate safety tolerability pharmacokinetics pharmacodynamics efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01300208"
    },
    {
        "Title": "Pilot Tape Harvesting Study",
        "Summary": "Main objectives study determine rna recovery tape harvesting allows identification disease gene signature interferon ifn signature lupus biomarkers may differentiate affected normal unaffected skin. determine atopic dermatitis ad gene signature differentially expressed epidermis active",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Atopic Dermatitis, Healthy, Discoid Lupus Erythematosus, Subacute Cutaneous Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT02125695"
    },
    {
        "Title": "Efficacy and Safety of Efavaleukin Alfa in Subjects With Active Systemic Lupus Erythematosus",
        "Summary": "Primary objective evaluate efficacy safety efavaleukin alfa subjects active systemic lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Switzerland, United States, Greece, Spain, Russian Federation, Hong Kong, Korea, Republic of, Italy, Poland, Turkey, Bulgaria, France, Canada, Taiwan, Japan, Chile, Colombia, Mexico",
        "OverallStatus": "TERMINATED",
        "Conditions": "Active Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT04680637"
    },
    {
        "Title": "A 2-stage, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus",
        "Summary": "Study aims evaluate efficacy safety subcutaneous sc anifrolumab versus placebo adult participants cutaneous lupus erythematosus cle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Austria, Australia, United States, Serbia, Thailand, Greece, Spain, China, Denmark, Italy, Korea, Republic of, Poland, United Kingdom, Belgium, Romania, Bulgaria, Philippines, South Africa, Turkey, France, Netherlands, Canada, Portugal, Taiwan, Japan, Argentina, Germany, Slovakia, Brazil, New Zealand, Chile, Colombia, Mexico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06015737"
    },
    {
        "Title": "Clinical Study on Targeted CD19 CAR-T Therapy for Autoimmune Diseases",
        "Summary": " open clinical pharmacological translational research study aiming evaluate safety tolerability. pharmacokinetics pharmacodynamics efficacy patients active.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "SLE (Systemic Lupus), Systemic Sclerosis, ANCA Associated Vasculitis, Idiopathic Inflammatory Myopathies, Sjogren's Syndrome, Autoimmune Diseases",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06548607"
    },
    {
        "Title": "Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus",
        "Summary": " studies shown significant differences severity outcome lupus patients colored skin compared caucasians many factors lead discrepancy genetics poverty education level well behavioral cultural factors cutaneous lupUS erythematosus cle disease flares remissions identifiable triggers one",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01629784"
    },
    {
        "Title": "Exploring Accessible Beauty for Individuals With Upper Extremity Deficits",
        "Summary": "Research aims to identify barriers faced individuals upper extremity disabilities. Study seeks provide insights recommendations improving accessibility beauty products ultimately promoting inclusivity.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Stroke, Ischemic, Stroke Hemorrhagic, Stroke (CVA) or TIA, Stroke, Acute, Traumatic Brain Injury, SCI - Spinal Cord Injury, Ehlers-Danlos Syndromes (EDS), Lupus Erythematosus, Guillain-Barre Syndrome, Multiple Sclerosis, Myasthenia Gravis, Amyotrophic Lateral Sclerosis, Graves Disease, Muscular Dystrophies",
        "Phases": "N/A",
        "IDestudio": "NCT05945784"
    },
    {
        "Title": "Dietary Phytoestrogens as Risk Factors for Systemic Lupus Erythematosus",
        "Summary": "Study aims determining dietary phytoestrogens risk factors. systemic lupus erythematosus sle dietary enquiry phy toestrogens measurements performed blood urine patients sle active phase disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Rheumatoid Arthritis, Autoimmune Thrombocytopenia",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03421184"
    },
    {
        "Title": "National Systemic Lupus Erythematosus Prospective Cohort, Saudi Arabia",
        "Summary": " sle disease saudi arabia yet well defined especially population high consanguinity high inbreeding coefficient prospective cohort study sle patients saudiArabia.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Saudi Arabia",
        "OverallStatus": "RECRUITING",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT04604990"
    },
    {
        "Title": "Low-dose UVA1 Radiation in Cutaneous Lupus Patients",
        "Summary": "Researchers conducting clinical trial determining effects uva1 phototherapy cutaneous lupus cle patients past research systemic lupUS sle subjects indicates treatment likely effective.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01776190"
    },
    {
        "Title": "A Study to Investigate BMS-986165 and Methotrexate in Healthy Male Patients",
        "Summary": " purpose study investigate effects blood levels methotrexate given single dose in healthy male patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus, Psoriatic Arthritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03402087"
    },
    {
        "Title": "Use of Social Media to Improve Medication Adherence in Adolescents and Young Adults With Systemic Lupus",
        "Summary": " goal study examine effect online educational program without social media. primary goal study determine whether medication adherence would improved adolescents. secondary goal determine whether secondary outcomes quality life stress improved model whether changes associated improvements medication management.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03218033"
    },
    {
        "Title": "The Living With a Long-Term Condition Study",
        "Summary": "New distress measure test valid reliable measure aim project provide initial validation illness related distress scale community sample recruited online platforms objective study gather initial validity reliability data scale.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Asthma, Atrial Fibrillation, Cancer, Cerebrovascular Disorders, Stroke, CKD, Copd, Fibromyalgia, Pain, Heart Diseases, Heart Disease Chronic, Dementia, Diabetes, Epilepsy, Heart Failure, High Blood Pressure, Hypertension, Hiv, AIDS, IBD, IBS, Liver Diseases, Long COVID, Lupus Erythematosus, Multiple Sclerosis, Obesity, Osteoarthritis, Arthritis, Rheumatoid Arthritis, Osteoporosis, Parkinson Disease, Sickle Cell Disease, Hepatitis, Endometriosis, PCOS, Neurological Disorder, POTS - Postural Orthostatic Tachycardia Syndrome, MND (Motor Neurone DIsease), Cystic Fibrosis, Migraine, Spondylitis, Celiac Disease, Hidradenitis Suppurativa, Eczema, ME/CFS",
        "Phases": "N/A",
        "IDestudio": "NCT06072287"
    },
    {
        "Title": "Evaluation of Plasma Vitamin C Levels in a Population of Chronic Rheumatism in Immuno-Rheumatology",
        "Summary": " hypovitaminosis c defined plasma vitamin c level less 23 deficiency would affect 5 10 general population industrialized countries. scurvy almost forgotten carential pathology caused deep vitamin c ascorbic acid deficiency priori exceptional industrialized countries according",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus or SLE, Spondyloarthritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05345899"
    },
    {
        "Title": "Safety Study of Clinical and Immune Effects of Phosphodiesterase 4 (PDE-4) Inhibitor in Cutaneous Lupus Patients",
        "Summary": "Study to determine clinical immunological effects phosphodiesterase type 4 inhibitor skin inflammation associated cutaneous lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00708916"
    },
    {
        "Title": "The Epidemiology, Management and Comorbidities in Alopecia Areata in Czech Republic",
        "Summary": "Study series consists three studies aim assess incidence prevalence risk factors comorbidities management patients alopecia areata czech republic based.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Czechia",
        "OverallStatus": "COMPLETED",
        "Conditions": "Alopecia Areata, Alopecia Totalis, Alopecia Universalis, Alopecia Areata (& Ophiasis), Alopecia Barbae, Alopecia Diffuse, Autoimmune Diseases, Autoimmune Hyperthyroidism, Autoimmune Hypothyroidism, Diabetes Mellitus, Type 1, Ulcerative Colitis, Inflammatory Bowel Diseases, Crohn Disease, Rheumatoid Arthritis, Down Syndrome, Atopic Dermatitis, Atopic Asthma, Atopic Rhinitis, Vitiligo, Psoriasis, Ankylosing Spondylitis, Multiple Sclerosis, Lupus Erythematosus, COVID-19 Pandemic, Vaccine Reaction, Infections, Anemia, Pernicious",
        "Phases": "N/A",
        "IDestudio": "NCT05098600"
    },
    {
        "Title": "Long Term Safety of Anifrolumab in Adult Subjects With Active Systemic Lupus Erythematosus",
        "Summary": " study characterise safety tolerability intravenous anifrolumab. purpose study characterises safety tolerable intravenous aetiology for intravenous intravenous \u00a0anifrolumsab. Purpose study characterised safety toler",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Australia, United States, Spain, Ukraine, Russian Federation, Korea, Republic of, Poland, United Kingdom, Romania, Bulgaria, South Africa, France, Lithuania, Canada, Peru, Taiwan, Japan, Argentina, Germany, Israel, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "COMPLETED",
        "Conditions": "Active Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT02794285"
    },
    {
        "Title": "Posterior Segment Evaluation of Patients With SLE Using OCT and OCTA",
        "Summary": "Study evaluate different structural retinal changes using oct patients and newly diagnosed patients. Patients treated compare parameters normal subjects. Results published in the Journal of Retina Research.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT04866615"
    },
    {
        "Title": "BElimumab corticoSteroids Sparing Treatment in Systemic Lupus Erythematosus",
        "Summary": "Belimumab human monoclonal antibody first immunotherapy used treatment systemic lupus erythematosus sle licensed 2011 france currently belimumab reimbursed treatment active sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT05624437"
    },
    {
        "Title": "Clinico-biological Collection to Investigate the Physiopathology of Systemic Autoimmune Diseases",
        "Summary": "Project aims to identify new biomarkers and identify new therapeutic strategies for autoimmune disease. Patients presenting systemic autoimmune disease are the focus of the project.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus, Scleroderma, Myositis, Vasculitis, Inflammatory Bowel Diseases",
        "Phases": "N/A",
        "IDestudio": "NCT05251415"
    },
    {
        "Title": "Cutaneous Lupus Registry",
        "Summary": " approximately million individuals united states systemic lupus erythematosus 85 individuals develop skin lesions point disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT01266915"
    },
    {
        "Title": "Yellow Fever Vaccine in Patients With Rheumatic Diseases",
        "Summary": "According to world health organization since december 2016 brazil showing significant increase cases yellow fever humans view vaccination suitable residents travelers risk area however immunosuppressed patients formal recommendation vaccinate live virus vaccine hand safety efficacy vaccine demonstrated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Brazil",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus, Rheumatoid Arthritis, Spondyloarthritis, Inflammatory Myopathy, Systemic Sclerosis, Mixed Connective Tissue Disease, Takayasu Arteritis, Granulomatosis With Polyangiitis, Sjogren's Syndrome, Juvenile Idiopathic Arthritis, Juvenile Dermatomyositis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03430388"
    },
    {
        "Title": "Photoprovocation Testing in Subjects With Cutaneous Lupus",
        "Summary": "Photosensitivity is a common condition in lupus patients. It is one of the main diagnostic criteria for the disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Photosensitivity Conditions",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT01516788"
    },
    {
        "Title": "Immune Adsorption Role in Treatment of Resistant Lupus",
        "Summary": "Lupus heterogeneous autoimmune disease autoantibodies formation lupus nephritis carries worst prognosis c1q deficiency correlates activity renal involvement may help evaluation therapies include plasma exchange immune adsorption recently.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04108611"
    },
    {
        "Title": "Topical Nicotinamide in Treatment of DLE",
        "Summary": "Lupus erythematosus cle lupus affecting skin autoimmune disease. Body immune system attacks healthy skin. Often appears ages 20 50 years affects women men may happen.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Discoid Lupus Erythematosus",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT05362188"
    },
    {
        "Title": "Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser",
        "Summary": "Cutaneous lupus erythematosus cle often presents disfiguring vascular lesions frequently difficult treat. purpose using 595 nm vbeam pulsed dye laser study help improve study patients skin disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00523588"
    },
    {
        "Title": "Evaluation of Lenalidomide (REVLIMID\u00ae) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)",
        "Summary": "Study conducted evaluate safety effectiveness lenalidomide. Subjects cutaneous lupus erythematosus cle study drug used indication treat 6 subjects 12 months.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus (CLE)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00633945"
    },
    {
        "Title": "Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE",
        "Summary": " systemic lupus erythematosus sle systemic autoimmune disease characterized various immunological abnormalities including dysregulated activation b lymphocytes overt production.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT03752983"
    },
    {
        "Title": "PatientSpot Formerly Known as ArthritisPower",
        "Summary": " patient power patient research network database registry collect prospective information demographics diagnoses medications willingness participate research participants rheumatoid arthritis ra spondyloarthritis spa musculoskeletal conditions chronic neurological conditions like migraine.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity",
        "Phases": "N/A",
        "IDestudio": "NCT03840928"
    },
    {
        "Title": "Immune Response to SARS-CoV-2 Vaccination in Systemic Lupus",
        "Summary": "Main objective study impact vaccination specific humoral cellular immune response evolution pathological immune system disease lupus population.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT04894253"
    },
    {
        "Title": "Serum Ceramides Level in Systemic Lupus Erythematosus (SLE) Patients as a Novel Marker for Renal Impairment",
        "Summary": "The study was conducted in patients with renal impairment. The aim was to determine whether the patient was at risk for renal impairment or not. The study followed three cycles of treatment.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT04256577"
    },
    {
        "Title": "Analysis of B Cells From Autoimmune Individuals",
        "Summary": "Study aims to find individual autoimmunity exhibit increased numbers. b cells express two types of antibodies instead of one type.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus, Rheumatoid Arthritis, Type 1 Diabetes",
        "Phases": "N/A",
        "IDestudio": "NCT02747277"
    },
    {
        "Title": "Volatile Organic Compounds (VOCs) as a Biomarker in Immune-mediated Pulmonary Arterial Hypertension (PAH)",
        "Summary": "Pulmonary arterial hypertension using profile volatile organic compounds hypothesis first investigators hypothesize time diagnosis voc profiles discriminate patients idiopathic pah ipah patients systemic sclerosis systemic lupus erythematosus ctd without p",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Netherlands",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Pulmonary Arterial Hypertension, Systemic Sclerosis, Systemic Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT03819777"
    },
    {
        "Title": "Psycho-social Consequences of Systemic Lupus Erythematosus",
        "Summary": " project allow us evaluate understand impact sle couple life relational affective components addition study describe representations sick people relatives lupus disease.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT03913754"
    },
    {
        "Title": "Monitoring of Inflammatory Conditions",
        "Summary": "One year treatment study currently underway determine optimal monitoring strategy still safe changes monitoring strategy must acceptable patients healthcare professionals hcp treat study aims measure often common inflammatory conditions immune suppressing medication attend monitoring blood tests.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Inflammatory Disease, Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, System; Lupus Erythematosus, Psoriatic Arthritis, Reactive Arthritis, Inflammatory Arthritis, Psoriasis",
        "Phases": "N/A",
        "IDestudio": "NCT05458531"
    },
    {
        "Title": "AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus",
        "Summary": "Lupus nephritis class iv without presence class v forms refractory systemic lupus erythematosus. Monotherapy combination depleting mab rituximab obinutuzumab cycloph",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV, Refractory Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06265220"
    },
    {
        "Title": "MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE",
        "Summary": " clinical trials sle arthritis forty patients sle moderate severe synovitis minimum 3 tender 3 swollen joints wrists hands. randomized new increased methotrexate therapy plus single injection depomedrol matched placebo baseline.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus Arthritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03355482"
    },
    {
        "Title": "Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone",
        "Summary": "Lupus nephritis accounts morbidity mortality patients sle glucocorticoids combined cyclophosphamide cyc effective treatment patients. leflunomide novel immunosuppressive agent currently used treatment rheumatoid pilot",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Nephritis, Lupus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00268567"
    },
    {
        "Title": "Preventive Approach to Congenital Heart Block With Hydroxychloroquine",
        "Summary": "Women antibodies proteins called face 2 chance child life threatening heart condition regardless whether active lupus remission vague symptoms heart problem referred congenital heart block serious third degree complete block represents damage thought caused autoantibodies heart beats abnormally slowly almost",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Congenital Heart Block, Neonatal Lupus, Autoantibody-Associated Heart Block",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01379573"
    },
    {
        "Title": "A Study of RD06-04 in Patients With Active Autoimmune Diseases",
        "Summary": " phase trial iit aimed evaluating safety tolerability pharmacokinetics pharmacodynamics efficacy patients autoimmune diseases mediated autoantibodies. Study population includes patients systemic lupus erythematosus sle systemic sclerosis ssc vasculitis a",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "SLE (Systemic Lupus), Sclerosis, ANCA Associated Vasculitis, IIM, SS, MS, NMO Spectrum Disorder, MG",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT06548620"
    },
    {
        "Title": "Tacrolimus Combined With Prednisone Treatment of Idiopathic Membranous Nephropathy and Nephrotic Syndrome",
        "Summary": " idiopathic membranous nephropathy imn one common forms nephrotic syndrome. adults usually treated corticosteroids combination cytotoxic drugs especially cyclophosphamide cyclosporine.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Idiopathic Membranous Nephropathy, Nephrotic Syndrome",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT00362531"
    },
    {
        "Title": "Application of MRI for Musculoskeletal Involvement in SLE",
        "Summary": "Articular involvement reach 95 within chronic multisystemic manifestations sle 1 originally pattern articular inflammation described emergence sensitive imaging techniques mri 2 3 show synovitis erosions hand carpus sle hand 18 carpus 97 healthy individuals bone",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Hand Rheumatism, Systemic Lupus Erythematosus Arthritis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04035265"
    },
    {
        "Title": "A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (AMETHYST)",
        "Summary": "Researchers learn study drug called litifilimab biib059 participants cutaneous lupus erythematosus cle. Study focus participants either active subacute cle chronic cle may also systemic lupsus sle. Study",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Switzerland, Sweden, United States, Serbia, Saudi Arabia, Spain, China, Italy, Korea, Republic of, Poland, United Kingdom, Puerto Rico, Bulgaria, Philippines, France, Canada, Portugal, Taiwan, Japan, Argentina, Germany, Slovakia, Brazil, Chile, Colombia, Hungary, Mexico",
        "OverallStatus": "RECRUITING",
        "Conditions": "Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05531565"
    },
    {
        "Title": "Safety and Efficacy of KRP203 in Subacute Cutaneous Lupus Erythematosus",
        "Summary": "Study assess safety efficacy krp203 clinically active subacute cutaneous lupus erythematosus patients demonstrated inadequate response standard treatment antimalarials.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Greece, Germany, Italy",
        "OverallStatus": "COMPLETED",
        "Conditions": "Subacute Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01294774"
    },
    {
        "Title": "Clinical Characteristic and MEFV Gene Mutations in Patient With Juvenile Onest Systemic Lupus Erythematosus",
        "Summary": "Study summarizes main clinical characteristics patients jsle admitted followed followed assiut university children hospital compare mefv gene mutations patients. Country considerably high carrier rate mefV gene variants.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT04645225"
    },
    {
        "Title": "Glycosylation Analysis of Lupus Anti-DNA Antibodies (GALA)",
        "Summary": " systemic lupus erythematosus sle severe autoimmune disease patients often develop numerous autoantibodies abs unfortunately none sle specific abs described far correlated enough disease activity used useful biomarker reliably help therapeutic decision abs effector functions including",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Lupus Erythematosus Disseminatus, Autoimmune Diseases, Chronic Disease",
        "Phases": "N/A",
        "IDestudio": "NCT05394922"
    },
    {
        "Title": "Myofascial Techniques and Proprioceptive Neuromuscular Facilitation in Patients With Systemic Lupus Erythematosus.",
        "Summary": "Systemic lupus erythematosus autoimmune disease musculoskeletal system affected 90 patients common manifestations myalgias arthralgias arthritis objective analyse efficacy intervention using myofascial techniques proprioceptive neur",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06383104"
    },
    {
        "Title": "Renal Survival in Patients with Lupus Nephritis",
        "Summary": "Lupus erythematous chronic multifactorial autoimmune disease affects many organs including kidney. Lupus nephritis 39 develop absence antinuclear antibodies circulating polyclonal autoantibodies.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis (LN)",
        "Phases": "N/A",
        "IDestudio": "NCT06588192"
    },
    {
        "Title": "A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus",
        "Summary": " phase 1b study administered subcutaneously patients moderate severe systemic lupus erythematosus sle.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "SLE, SLE (Systemic Lupus)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06613360"
    },
    {
        "Title": "Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders",
        "Summary": "Children treated glucocorticoids rheumatic disorders. Pilot phase randomized clinical trial denosumab. Primary outcomes include suppression bone turnover markers. Secondary outcomes include changes bone density measured.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Osteoporosis, Juvenile Rheumatoid Arthritis, Dermatomyositis, Polyarthritis, Systemic Lupus Erythematosis, Vasculitis, Glucocorticoid-induced Osteoporosis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02418273"
    },
    {
        "Title": "NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis",
        "Summary": "Study determine safety preliminary efficacy nk010 nk042 combination rituximab rtx treatment patients refractory systemic lupus erythematosus sle lupUS nephritis ln China.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Refractory Systemic Lupus Erythematosus, Refractory Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06676631"
    },
    {
        "Title": "IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study aims assess efficacy specifically achieving treatment endpoint lupus low disease activity state lldas 360 days improvement disease activity measured 360 days persistence duration im19 cells peripheral blood subjects also evaluated. Study plan includes five phases screening phase cell collection phase",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Refractory Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06513429"
    },
    {
        "Title": "SLE Vasculitis In Egyptian Patients",
        "Summary": " systemic lupus erythematosus sle complex heterogeneous autoimmune disease wide variety clinical serological manifestations may affect organ vasculitis prevalence sle reported 11 36.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Vasculitis Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04386889"
    },
    {
        "Title": "Pilot Trial of Mesenchymal Stem Cells for Systemic Lupus Erythematosus",
        "Summary": "Lupus erythematosus is a systemic lupus disease. Lupus is the most common form of cancer. The disease is often fatal.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT03171194"
    },
    {
        "Title": "Cutaneous Lupus Medication Experience Study",
        "Summary": " cutaneous lupus chronic relapsing skin disease many presentations effect physical appearance greatly affects patients quality life. 10 patients develop systemic Lupus topical therapies mainstay. Patients often find treatments messy inconvenient ineffective.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "ACTIVE_NOT_RECRUITING",
        "Conditions": "Cutaneous Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT02176148"
    },
    {
        "Title": "Long-Term Organ Damage: Anifrolumab Versus Real-World Standard of Care in Adult Patients With Active Systemic Lupus Erythematosus",
        "Summary": "Anifrolumab plus standard care tulip versus real world standard care organ damage. adult patients moderately severely active systemic lupus erythematosus sle patients initiated 300 mg anifrolomab indexed date initiating an",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "Long-Term Organ Damage in Adult Patients With Active Systemic Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06485674"
    },
    {
        "Title": "Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone",
        "Summary": "Study aims compare efficacy 532nm potassium titanyl phosphate ktp laser with topical corticosteroids alone. Study aims to compare efficacy of laser treatments for cutaneous lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Cutaneous Lupus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03639857"
    },
    {
        "Title": "MB-CART19.1 in Refractory SLE",
        "Summary": " phase multicentre interventional trial patients refractory to systemic lupus erythematosus. phase part maximum patients treated maximum 3 dose levels phase iia part maximum treated patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany",
        "OverallStatus": "RECRUITING",
        "Conditions": "SLE - Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06189157"
    },
    {
        "Title": "A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus",
        "Summary": " purpose study assess safe tolerable treating subjects discoid lupus erythematosus. pharmacokinetic pharmacodynamics also evaluated.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Discoid Lupus",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01466725"
    },
    {
        "Title": "Fitness Integrative Training for Pediatric Rheumatology Disorders",
        "Summary": "Study evaluates feasibility fitness integrative training program teens fit teens. 2 combined cognitive behavioral therapy neuromuscular exercise training program patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Juvenile Idiopathic Arthritis, Systemic Lupus Erythematosus of Childhood, Joint Hypermobility, Juvenile Dermatomyositis",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06556992"
    },
    {
        "Title": "Transforming Care for Individuals with Childhood-onset Systemic Lupus Erythematosus",
        "Summary": "Study aims investigate feasibility effectiveness cognitive behavioral coping skills program treatment education approach lupus teach youth csle integrated medical care teach program.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus of Childhood (Disorder)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06232304"
    },
    {
        "Title": "Mesenchymal Stem Cells Transplantation for Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study explore new approach treat patients medical condition known systemic lupus erythematosus sle resistant previous treatments. Using new population cells capability restore normal immune system longer attack.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Refractory Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT00698191"
    },
    {
        "Title": "IL-26 and Systemic Lupus Erythematosus",
        "Summary": "Lupus displays severe side effects limited efficacy underscoring need better dissection pathogenic mechanisms. Preliminary data il26 signaling could impaired systemic lupus moreover il 26 could marker disease activity potential therapeutic target.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Diagnosis of Lupus According to ACR criteriaAgreement for the Blood Sampling",
        "Phases": "N/A",
        "IDestudio": "NCT01889641"
    },
    {
        "Title": "Phenomics in Autoimmune and Inflammatory Diseases",
        "Summary": "iad heuristic help revise nosography understanding diseases. family systemic diseases iad form continuum pure inflammatory diseases pure autoimmune diseases encompassing large panel inflammatory diseases autoimmune components vice versa. cross phenotyping patients iad heuristics help revise",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Healthy Volunteer, Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes /TNF-receptor Associated Periodic Syndrome, Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative Rectocolitis, Type 1 Diabetes, Unclassified IAD Knee and/or Hip Arthritis, Muscular Dystrophy",
        "Phases": "N/A",
        "IDestudio": "NCT02466217"
    },
    {
        "Title": "Efficacy and Safety of Tacrolimus Sustained-release Capsules in Induction Treatment in Refractory Lupus Nephritis",
        "Summary": "Tacrolimus capsules are used to treat lupus nephritis ln. Pilot study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "COMPLETED",
        "Conditions": "Nephritis, Lupus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01328834"
    },
    {
        "Title": "Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus",
        "Summary": "Fluorinated steroids including dexamethasone improving heart function general health newborns chb. newborns born congenital heart block chb condition occurring babies neonatal lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Congenital Heart Block, Neonatal Lupus, Atrioventricular Nodal Dysfunction, Myocardial Injury",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00007358"
    },
    {
        "Title": "COVID-19 Booster and IIV Schedule in Immunocompromised Hosts",
        "Summary": "Researchers compare 1 seasonal inactivated influenza vaccine iiv recommended booster dose inducing peak protective humoral response compared strategy sequential administration booster dose followed seasonal iiv given one month later. Researchers compare 1 influenza vaccines administered day 0 booster interval 2 vaccine administered",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada",
        "OverallStatus": "RECRUITING",
        "Conditions": "COVID 19, Influenza, Rheumatoid Arthritis (RA), Systemic Lupus Erthematosus, Inflammatory Bowel Disease, Solid Organ Transplant Recipients, Immunocompromised Host, People Living With HIV",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06599658"
    },
    {
        "Title": "Urinary Congophilia As an Indicator of Activity of Lupus Nephritis",
        "Summary": "Lupus nephritis ln. evaluation impact sle urinary levels congophilia relationship renal histopathology activity.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Nephritis (LN)",
        "Phases": "N/A",
        "IDestudio": "NCT06654024"
    },
    {
        "Title": "Abatacept for SLE Arthritis (IM101-330)",
        "Summary": "Research trial patients diagnosed systemic lupus erythematosus sle swollen tender joints called inflammatory polyarthritis. Study subjects receive treatment either abatacept placebo week 16 weeks total 16 injections.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus Arthritis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02429934"
    },
    {
        "Title": "Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune inflammatory disease pathogenesis sle results interactions genes hormones environment however exact etiology unknown sle affect many organs systems including musculoskeletal hematological renal neuropsychiatric cardiovascular",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Turkey",
        "OverallStatus": "RECRUITING",
        "Conditions": "System; Lupus Erythematosus, Cognition Disorder, Autoimmune",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05984316"
    },
    {
        "Title": "Omalizumab for Lupus",
        "Summary": "Lupus autoimmune disease means body immune system mistakenly attacks healthy tissue resulting inflammation tissue damage sle involve almost organ symptoms range severity mild symptoms also vary. 15 study visits 38 weeks two visits overnight hospital stays rest outpatient visits visit participants monitored physical exam",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erthematosus, Sjogren's Syndrome",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01716312"
    },
    {
        "Title": "Long Non Coding RNA in Complications of Systemic Lupus",
        "Summary": "Systemic lupus erythematosus sle largely unknown. precise role rna setting complication complication systemic lupUS ery thematosUS sle largely known.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Complication in Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03185767"
    },
    {
        "Title": "Prospective Maternal Surveillance of SSA (Sj\u00f6gren Syndrome A) Positive Pregnancies Using a Hand-held Fetal Heart Rate Monitor",
        "Summary": "Pregnant women use doppler fetal heart rate monitor to detect abnormal heart rates rhythms. Mothers with ssa sj\u00f6gren syndrome b antibody positive use monitor.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Sjogren's Syndrome, Neonatal Systemic Lupus Erythematosus, Fetal Heart Block Complete",
        "Phases": "N/A",
        "IDestudio": "NCT02920346"
    },
    {
        "Title": "Neuromuscular Ultrasonography Utility for Detection of Peripheral Neuropathy in Systemic Lupus Erythematosus",
        "Summary": "Study aims evaluate rule nmus detection peripheral neuropathy sle patient correlate traditional neurophysiological studies clinical signs activity sle.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "Peripheral Neuropathy, System; Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04527172"
    },
    {
        "Title": "Fetal-Hope Study: Home Monitoring of Fetal Heart Rate in SSA+ Pregnant Women",
        "Summary": "Pregnant women positive could become standard practice. Anti antibodies frequently found pathologies sjogren syndrome sle worldwide approximately women reproductive age positive antibodies women pregnancy complicated cardiac abnormalities fetus particularly varying degrees atrioventricular block.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Pregnancy Related, Autoimmune Diseases, Neonatal Lupus, SLE, Sjogren's Syndrome, Fetal Heart Rate or Rhythm Abnormality Affecting Fetus",
        "Phases": "N/A",
        "IDestudio": "NCT05958446"
    },
    {
        "Title": "DR-0201 in Subjects With Autoimmune Diseases",
        "Summary": "Pk pd immunogenicity preliminary clinical response following iv administration subjects sle cle pss dcssc. dose study evaluate safety tolerability pk pD immunogenitability preliminary clinicalresponse following iv treatment subjects sle Cle pssd",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, South Africa, Bosnia and Herzegovina, Australia, New Zealand, Poland, Serbia",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "SLE, SLE (Systemic Lupus), CLE, Cutaneous Lupus, Sjogren's Syndrome, Primary Sj\u00f6gren Syndrome, Dermatomyositis, Polymyositis, Scleroderma, SSc, Diffuse Sclerosis, dcSSc, Diffuse Cutaneous Systemic Sclerosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06647069"
    },
    {
        "Title": "Atacicept in Subjects With Active Lupus Nephritis (COMPASS)",
        "Summary": "An objective study evaluate effect atacicept compared placebo changes renal response adult subjects ln.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain, Puerto Rico, United States",
        "OverallStatus": "SUSPENDED",
        "Conditions": "Lupus Nephritis (LN)",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05609812"
    },
    {
        "Title": "Discoid Lupus Erythematosus of the Scalp and a Trial of Biologic Therapy With Raptiva",
        "Summary": "Lupus condition chronic inflammation cause autoimmune disease autoimmune diseases illnesses occur body tissues attacked immune system immune system complex system within body designed fight infectious agents example bacteria foreign invaders.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Discoid Lupus Erthematosus of the Scalp",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00308204"
    },
    {
        "Title": "Circulating MicroRNAs in Understanding Pathogenesis of Systemic Lupus Erythematosis",
        "Summary": "Study aims to identify expression signature plasma of patients with systemic lupus erythematosis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosis",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02756546"
    },
    {
        "Title": "Interferon Pathway Activation in Monogenic and Nonmonogenic Forms of Pediatric SLE",
        "Summary": "Monogenic forms involve interferon type pathway pathway pathway renally active adult sle correlates extent renal damage pediatric sle particularly lupus nephritis activation pathway never studied known whether monogenic forms underlie pronounced Interferon activation.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Italy",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus of Childhood",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06586710"
    },
    {
        "Title": "Effect of Vitamin D Supplement on Disease Activity in SLE",
        "Summary": "Study effect of vitamin supplementation on disease activity levels. Study looked at the effects of vitamin B1 on the body's immune system. The study looked at effects on the immune system and the brain.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Vitamin D Deficiency, Hypocalcemia, Hyperparathyroidism, Systemic Lupus Erythematosus (Disorder)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05260255"
    },
    {
        "Title": "Voclosporin in Adolescents With Lupus Nephritis",
        "Summary": " voclosporin compared placebo achieving renal response following 24 weeks therapy. adolescents active lupus nephritis ln. purpose study assess efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Adolescent Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05288855"
    },
    {
        "Title": "IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy",
        "Summary": " treatment trial evaluates addition necrosis drug certolizumab usual treatment heparin agent aspirin pregnant women antiphospholipid syndrome aps repeatedly positive tests lupus anticoagulant lac determine regimen improve pregnancy outcomes",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "High Risk Pregnancy, Pregnancy Complications, Antiphospholipid Syndrome in Pregnancy, Lupus Anticoagulant Disorder",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03152058"
    },
    {
        "Title": "Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus",
        "Summary": " phase iib randomized multicenter study evaluate efficacy safety orelabrutinib adult subjects receiving standard care soc therapy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, SLE",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT05688696"
    },
    {
        "Title": "Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy",
        "Summary": "New immunosuppressive drug sirolimus reducing amount protein urine patients membranous nephropathy condition involves damage walls tiny blood vessel filters kidneys. Low blood protein levels high blood cholesterol patients may leg swelling impaired kidney function.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Membranous Glomerulonephritis, Lupus Membranous Nepropathy",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00050713"
    },
    {
        "Title": "Autologous Stem Cell Transplantation: International Lupus Trial",
        "Summary": "Study evaluated remission induction therapy refractory lupus erythematosus autologous hematopoietic stem cell transplantation.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT05063513"
    },
    {
        "Title": "Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients",
        "Summary": "Study aims to determine prevalence of diabetes mellitus sDM among systemic lupus erythematosus patients. Study also aims to identify associated risk factors.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "RECRUITING",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04024306"
    },
    {
        "Title": "Cardiovascular Protective Role of Laser Acupuncture in Systemic Lupus",
        "Summary": " systemic lupus erythematosus chronic multisystemic autoimmune disorder predominantly affecting women. cardiovascular disease due presence factors oxidative stress cytokines dyslipidemia diabetes hypertension.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Egypt",
        "OverallStatus": "COMPLETED",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04970199"
    },
    {
        "Title": "Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus",
        "Summary": "Cutaneous lupus frequent approximately 70 patients develop cutaneous involvement point course disease spite esthetic consequence acute phase main problem still related disfiguring incapacitating nature topical steroids antimalarial therapy continue conventional therapy unfortunately approximately 30 refractory",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01408199"
    },
    {
        "Title": "Leflunomide in Systemic Lupus Erythematosus",
        "Summary": " leflunomide sle patients active disease refractory cyclophosphamide. pilot study evaluate efficacy safety.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Hong Kong",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Eythematosus (SLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00637819"
    },
    {
        "Title": "Rare AutoImmune SElf-management Programme Development",
        "Summary": "Rare autoimmune rheumatic diseases. life organ threatening rairds impair quality life similar chronic diseases. heart failure aim study explore content structure support programme. people raird focus groups.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erthematosus, Systemic Vasculitis, Inflammatory Myositis, Systemic Sclerosis (SSc), ANCA Associated Vasculitis (AAV), Sjogren Syndrome",
        "Phases": "N/A",
        "IDestudio": "NCT06642870"
    },
    {
        "Title": "Efficacy and Safety of Tripterygium Wilfordii in Patients With Lupus Nephritis",
        "Summary": " glucocorticosteroid combined oral t2 extract tripterygium wilfordii hook f treatment patients lupus nephritis. randomized prospective clinical trial observation period 24 weeks. evaluation clinical efficacy safety profile.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Nephritis, Lupus",
        "Phases": [
            "PHASE2",
            "PHASE3"
        ],
        "IDestudio": "NCT01646736"
    },
    {
        "Title": "Five-Year Actively Controlled Clinical Trial in New Onset Juvenile Systemic Lupus Erythematosus Nephritis",
        "Summary": " project involving 185 partners 46 countries 46 countries 110 21 eu states 75 25 states randomised clinical trials. rct juvenile systemic lupus erythematosus jsle phase ii iv iv jsle proliferative nephritis",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Italy",
        "OverallStatus": "WITHDRAWN",
        "Conditions": "Systemic Lupus Erythematosus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT00336414"
    },
    {
        "Title": "FLARE Lupus Research Study Systemic Lupus Erythematosus",
        "Summary": "First phase pilot study assess changes quality life end mymee program patients. Second phase assess changes healthcare utilization cost one year period program end.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03426384"
    },
    {
        "Title": "Cyclophosphamide Versus Mycophenolate Mofetil in Lupus Nephritis",
        "Summary": "52 patients screened 49 patients meeting international society renal pathology society criteria enrolled study. 25 24 patients cyclophosphamide cyc mycophenolate mofetil mmf groups respectively forty two patients 21 group could complete study till end 6",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "COMPLETED",
        "Conditions": "To Compare the Effects of Mycophenolate Mofetil With Cyclophosphamide in Neplaese Lupus Nephritis Patients",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03200002"
    },
    {
        "Title": "Monitoring Lupus Nephritis Through Urinary Extracellular Vesicles",
        "Summary": "Lupus nephritis is a severe manifestation of systemic lupus erythematosus sle lead irreversible kidney damage detected managed promptly. Recent research suggested urinary extracellular vesicles are potential biomarkers.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Denmark",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT06642402"
    },
    {
        "Title": "Anemia in Systemic Lupus Erythematosus Specially Refractory Type",
        "Summary": " systemic lupus erythroematosis sle systemic autoimmune disease multisystemic involvement condition several phenotypes varying clinical presentations mild mucocutaneous manifestations multiorgan severe central nervous system involvement several immunopathogenic pathways play role",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Refractory Anemia in Systemic Lupus Erythematosis",
        "Phases": "N/A",
        "IDestudio": "NCT06210295"
    },
    {
        "Title": "Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus",
        "Summary": " multicenter study aims evaluate treatment adherence satisfaction patients cutaneous lupus influenced perception disease fear side effects cost medications. Relationship adherence measured vas 80 higher medical adherence inventory scale.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "RECRUITING",
        "Conditions": "Cutaneous Lupus",
        "Phases": "N/A",
        "IDestudio": "NCT06506214"
    },
    {
        "Title": "Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus sle occurs predominantly women driven type interferon dysregulation neutrophil hyperresponsiveness neutrophils females reduced mitochondrial bioenergetic capacity affects immunometabolism nicotinamide aden",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (Sle)",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT06032923"
    },
    {
        "Title": "Estimate of the Activity and the Forecast of the Lupus Disease of the Adult by a Transcriptomic Score (STUDY LU-PUCE)",
        "Summary": " lupus erythematosus systemic disease evaluation activity remains difficult heterogeneousness clinical biological symptoms aim study develop objective specific invasive methods evaluation activity forecast disease using analysis transcriptome circulating blood transcriptomic analysis realized parallel usual patients affected systemic",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Disease",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00920114"
    },
    {
        "Title": "Role of Estrogen in the Flarring up of Lupus Nepheritis",
        "Summary": "Lupus nepheritis is a rare form of lupus. It is caused by an over-reactive immune system. It can be fatal.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Activity of Lupus Nepheritis",
        "Phases": "N/A",
        "IDestudio": "NCT04468438"
    },
    {
        "Title": "Safety Study of AMG 557 in Subjects With Lupus Arthritis",
        "Summary": " multicenter randomized parallel multiple dose study enroll approximately 40 systemic lupus erythematosus subjects. Study will focus on subjects with active lupsus arthritis.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Germany, Taiwan, France, Australia, Denmark, United States, Malaysia, United Kingdom",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Arthritis, Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT01683695"
    },
    {
        "Title": "NCF Gene & TNFSF4 in SLE Patients",
        "Summary": "Investigators objective identify association snp polymorphisms tnfs4 ncf gene sle egyptian patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT05314881"
    },
    {
        "Title": "Rituximab Objective Outcome Measures Trial in SLE",
        "Summary": "Lupus erythematosus sle lupus sle autoimmune disease immune system attacks body tissues part body may affected commonly. Lupus usually treated steroids drugs suppress immune system although help many patients respond well enough also concern",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United Kingdom",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Systemic Lupus Erythematosus Arthritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03054259"
    },
    {
        "Title": "Bone Mineral Density in Patients with Childhood-onset Systemic Lupus Erythematous, in Relation to Disease Clinical Criteria",
        "Summary": " determine common clinical characteristics patients childhood systemic lupus erythematosus detect prevalence low bone mineral density.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Systemic Lupus Erthematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06586359"
    },
    {
        "Title": "Swiss Pediatric Inflammatory Brain Disease Registry (Swiss-Ped-IBrainD)",
        "Summary": "National patient registry collects information diagnosis symptoms treatment pediatric patients inflammatory brain disease switzerland first implemented 2020 pediatric clinic university hospital bern centers switzerland opened recruitment 2021.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "RECRUITING",
        "Conditions": "Optic Neuritis, Transverse Myelitis, Acute Disseminated Encephalomyelitis, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder, Anti-NMDAR Encephalitis, Anti-GAD65 Associated Autoimmune Encephalitis, Anti-AMPAR-1/2 Associated Autoimmune Encephalitis, Anti-Lgi-1 Associated Autoimmune Encephalitis, Anti-CASPR-2 Associated Autoimmune Encephalitis, Anti-GABAR-1/2 Associated Autoimmune Encephalitis, Onconeuronal Antibody (Hu, Ri, Yo, Amphiphysin, CRMP-5, Ma-1, Ma-2, SOX-1) Associated Autoimmune Encephalitis, Hashimoto Encephalitis, CNS Vasculitis, CNS Sarcoidosis, CNS Lupus, Rasmussen Encephalitis",
        "Phases": "N/A",
        "IDestudio": "NCT05017142"
    },
    {
        "Title": "A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (LTE AMETHYST)",
        "Summary": "Study researchers learn study drug called litifilimab biib059 participants cutaneous lupus erythematosus cle. Study focus participants either active subacute cle chronic cle may also systemic lupUS ery",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Bulgaria, Argentina, Germany, Switzerland, France, Slovakia, Brazil, Spain, Chile, Hungary, Canada, Italy, Korea, Republic of, United States, Sweden, United Kingdom",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT06044337"
    },
    {
        "Title": "Coping Skills Training (CST) for Children With Chronic Health Conditions",
        "Summary": "Children 8 12 years age parents participants study children hospital wisconsin dealing one three chronic health conditions rheumatologic conditions epilepsy spina bifida asthma. purpose study purpose study pilot adapted coping skills training cst intervention feasibility preliminary efficacy sample",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Rheumatologic Conditions (JRA,Lupus), Epilepsy, Spina Bifida, Asthma",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00359775"
    },
    {
        "Title": "Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases",
        "Summary": "Study investigates genetic architecture of inflammatory skin diseases. Study aims to identify responsible gene may targets for clinical intervention.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Switzerland",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue, Pyoderma Gangrenosum, Erosive Pustular Dermatosis of the Scalp, Sweet's Syndrome, Behcet's Disease, Bowel-associated Dermatosis-arthritis Syndrome, Pustular Psoriasis, Acute Generalized Exanthematous Pustulosis, Keratoderma Blenorrhagicum, Sneddon-Wilkinson Disease, IgA Pemphigus, Amicrobial Pustulosis of the Folds, Infantile Acropustulosis, Transient Neonatal Pustulosis, Neutrophilic Eccrine Hidradenitis, Rheumatoid Neutrophilic Dermatitis, Neutrophilic Urticaria, Still's Disease, Erythema Marginatum, Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes, Dermatitis Herpetiformis, Linear IgA Bullous Dermatosis, Bullous Systemic Lupus Erythematosus, Inflammatory Epidermolysis Bullosa Aquisita, Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis), Small Vessel Vasculitis Including Urticarial Vasculitis, Erythema Elevatum Diutinum, Medium Vessel Vasculitis",
        "Phases": "N/A",
        "IDestudio": "NCT01952275"
    },
    {
        "Title": "Individual Patient Expanded Access IND of Autologous HB-adMSCs for the Treatment of Systemic Lupus Erythematosus (SLE)",
        "Summary": "Study conducted according to international standards good clinical practice fda title 21 part 312 international conference harmonization guidelines applicable government regulations hope biosciences stem cell research foundation policies procedures.",
        "StudyType": "EXPANDED_ACCESS",
        "Countries": "United States",
        "OverallStatus": "NO_LONGER_AVAILABLE",
        "Conditions": "System; Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT04907175"
    },
    {
        "Title": "Open-label Trial of Acthar Gel in Subjects With Moderate to Severe Active Systemic Lupus Erythematosus",
        "Summary": " systemic lupus erythematosus serious potentially condition significant unmet medical need aim investigator initiated single center study evaluate efficacy safety daily subcutaneously sq injection acthar gel 10 days optional 5 day rescue period day 10 dose primary",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Erythematosus Systemic Exacerbation",
        "Phases": [
            "PHASE4"
        ],
        "IDestudio": "NCT01769937"
    },
    {
        "Title": "Gradual Withdrawal of Low-dose Glucocorticoid in Clinically Quiescent Systemic Lupus Erythematosus.",
        "Summary": "Study aims compare flare rate maintenance versus gradual withdrawal 5 prednisone systemic lupus erythematosus patients clinically quiescent disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus, SLE",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06234852"
    },
    {
        "Title": "A Study of Laquinimod in Participants With Systemic Lupus Erythematosus (SLE) Active Lupus Arthritis",
        "Summary": " laquinimod capsules milligrams mg 1 mg participants active lupus arthritis. Study aims evaluate safety clinical effect daily oral treatment.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Canada, United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Arthritis",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT01085084"
    },
    {
        "Title": "Magnetic Resonance Spectroscopy, Perfusion, and Diffusion Tensor Imaging in Neuropsychiatric Lupus",
        "Summary": "Study determine three functional magnetic resonance brain imaging techniques. Magnetic resonance spectroscopy mrs magnetic resonance perfusion diffusion tensor imaging dti detect brain alterations distinctive neuropsychiatric systemic lupus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Neuropsychiatric Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT00730002"
    },
    {
        "Title": "Genomic Effects of Glucocorticoids in Patients With Systemic Lupus Erythematosus",
        "Summary": "The immune system becomes overactive attacks healthy cells mistake many people use glucocorticoids gcs treat sle gcs calm overactive immune system changing body reads genes gcs side effects increase time researchers want learn gcs work may help",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematous (SLE)",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT04233164"
    },
    {
        "Title": "Disease and Biomarker Profiling of Chinese Lupus Nephritis",
        "Summary": "Study proposes take bothcandidate approach reported biomarkers unbiased proteomics profiling tools somascan measures protein analytes analyze 100 class v ln patients welldocumented clinical annotation treatment schedule disease follow serum plasma urr.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Characterize the Molecular Profile of Lupus Nephritis(LN) Patients to Understand Themechanism(s)Contributing to Patient Responsiveness to Soc, Integrated Analysis of LN Patient Molecular Profiling and Clinical Annotations to Understand LNdisease Heterogeneity for Disease Endotype, Validate the Association of the Candidate Biomarker Panel Proposed in Table 3-1 With LN Diseasemonitoring",
        "Phases": "N/A",
        "IDestudio": "NCT06210464"
    },
    {
        "Title": "Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease",
        "Summary": "Single arm study evaluate efficacy safety of cd19 targeted cells therapy. Patients refractory to autoimmune disease.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06056921"
    },
    {
        "Title": "An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).",
        "Summary": "565 participants participated in the study. The purpose of the study was to determine safety tolerability pharmacokinetics.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Spain",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus, SLE",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06335979"
    },
    {
        "Title": "Gut Microbiota Dysbiosis in Lupus Nephritis",
        "Summary": " evaluate dysbiosis intestinal microbiota adult patients lupus nephritis compared healthy controls.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Gut Microbiota Dysbiosis in Lupus Nepheritis",
        "Phases": "N/A",
        "IDestudio": "NCT06231303"
    },
    {
        "Title": "Anti-ficolin-3 Antibodies in Lupus Nephritis",
        "Summary": " systemic lupus erythematosus sle chronic autoimmune disease characterized production multiple autoantibodies accumulation immune complexes resulting systemic inflammatory response tissue damage. underlying mechanisms complex defects dying cells elimination likely contribute autoantigen overload development autoim",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Systemic Lupus Erythematosus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT03842787"
    },
    {
        "Title": "Fatigue in Systemic Lupus Erythematosus",
        "Summary": "Study will investigate effects biopsychosocial status quality life functional status hematological markers fatigue individuals.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Turkey",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Fatigue, Systemic Lupus Erthematosus",
        "Phases": "N/A",
        "IDestudio": "NCT06652256"
    },
    {
        "Title": "Effects of Nigella Sativa on T Cells and Cytokine Profile in Pediatric SLE Patients",
        "Summary": " clinical trial learn nigella sativa oil works improve sledai score sle pediatric student also learn treg helper cells cytokine patient main questions aims answer nigella sitiva oil lower sledai scored pediatric patient effects effects on treg cells",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Indonesia",
        "OverallStatus": "COMPLETED",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT06560775"
    },
    {
        "Title": "Autologous EBV-specific Cytotoxic T Cells for the Treatment of Systemic Lupus Erythematosus (SLE)",
        "Summary": "The pilot study was designed to evaluate the safety efficacy of adoptive transfers. The study also sought to determine whether the adoptive transfer was safe for patients.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Serologically Active Adult Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE1",
            "PHASE2"
        ],
        "IDestudio": "NCT02677688"
    },
    {
        "Title": "Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases",
        "Summary": " chronic inflammatory skin diseases constitute heterogeneous group pathologies affect skin also organs joints lungs muscles. prognosis factors help precisely guide treatment regimen intensification based on individual markers.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Atopic Dermatitis, Psoriasis, Hidradenitis Suppurativa, Lichen Planus, Cutaneous Lupus, Dermatomyositis, Cutaneaous Scleroderma, Neutrophilic Dermatosis, Cutaneous Granulomatosis, Active Leprosy",
        "Phases": "N/A",
        "IDestudio": "NCT06599411"
    },
    {
        "Title": "Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity",
        "Summary": "5 biomarker serum patients sle comparison healthy patients correlation disease activity. assessment cxcl5 biomarkers serum patients and healthy patients. assessment cxcl5.5.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": "N/A",
        "IDestudio": "NCT06610409"
    },
    {
        "Title": "Long-Term Voclosporin Treatment in Adolescent Subjects with Lupus Nephritis",
        "Summary": "Voclosporin is used to treat lupus nephritis in adolescents. The study will assess safety and tolerability of the drug.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "ENROLLING_BY_INVITATION",
        "Conditions": "Adolescent Lupus Nephritis",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT05962788"
    },
    {
        "Title": "A Study of TAK-007 in Adults With Refractory Lupus Nephritis (LN)",
        "Summary": "Main aim study learn well adults refractory lupus nephritis ln tolerate check side effects adverse events.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Refractory Lupus Nephritis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06377228"
    },
    {
        "Title": "Preventive IVIG Therapy for Congenital Heart Block",
        "Summary": " neonatal lupus nl name given group conditions affect babies mothers certain autoantibodies components body cells called nl appear temporary rash usually goes away time baby 6 months old rarely abnormal blood liver condition also improves time cause permanent often",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Congenital Heart Block, Neonatal Lupus, Autoantibody-associated Heart Block",
        "Phases": [
            "EARLY_PHASE1"
        ],
        "IDestudio": "NCT00460928"
    },
    {
        "Title": "Observational Study of the Performance of Cephen Reagents in the Context of Research Into Lupus Anticoagulants",
        "Summary": "The current la screening method hematology laboratory strasbourg university hospital includes pair. lupus anticoagulants antiphospholipid antibodies psa screening done demonstrating prolongation coagulation times corrected intake phosphol",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Lupus Anticoagulant",
        "Phases": "N/A",
        "IDestudio": "NCT05172778"
    },
    {
        "Title": "Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN)",
        "Summary": "Filgotinib lanraplenib previously adults lupus membranous nephropathy. primary objective study evaluate efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "COMPLETED",
        "Conditions": "Lupus Membranous Nephropathy",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT03285711"
    },
    {
        "Title": "Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires",
        "Summary": "Lupus erythematosus sle disease affects females nine times often males people sle often treated cyclophosphamide cyc cyc damage woman ovaries may cause infertility drug called gnrha sometimes given protect ovaries cyc",
        "StudyType": "OBSERVATIONAL",
        "Countries": "United States",
        "OverallStatus": "RECRUITING",
        "Conditions": "Systemic Lupus Erythematosus (Sle), Primary Ovarian Insufficiency (Poi)",
        "Phases": "N/A",
        "IDestudio": "NCT05567198"
    },
    {
        "Title": "A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G",
        "Summary": " phase 2 study evaluate safety pharmacodynamics pharmacokinetics clinical activity administered subcutaneously male female participants aged 18 years older. immunoglobulin nephropathy igan lupus nephritis ln complement component 3 glomer",
        "StudyType": "INTERVENTIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "IgA Nephropathy, Lupus Nephritis (LN), C3 (Complement Component 3) Glomerulopathy",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT06419205"
    },
    {
        "Title": "Role of Inflammation in Psychiatric Disorders in Patients With Cutaneous Lupus",
        "Summary": "Study determine role inflammation high prevalence psychiatric disorders lupus srl patients. inflammation lead decrease synthesis neurotransmitters via activation ido enzyme induce synthesis neurotoxic molecules kynurenin pathway leads development psychiatric disorders.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "France",
        "OverallStatus": "COMPLETED",
        "Conditions": "Skin Restricted Lupus, Psychiatric Disorders",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT03125083"
    },
    {
        "Title": "Efficacy of Intense Pulsed Light in the Treatment of Facial Telangiectasia in Systemic Lupus Erythematosus",
        "Summary": " clinical trial intends evaluate efficacy safety intense pulsed light ipl treatment facial telangiectasia patients systemic lupus erythematosus slem.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Facial Telangiectasia in Patients With Systemic Lupus Erythematosus",
        "Phases": [
            "NA"
        ],
        "IDestudio": "NCT04717583"
    },
    {
        "Title": "Safety of PiggyBac Transposon CAR T-cells Targeting CD-19 in Refractory Lupus.",
        "Summary": " lupus erythematosus sle patients responded standard immunosuppressive treatments. phase 1 clinical trial evaluate safety efficacy piggybac chimeric antigen receptor car targeting cd19.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Thailand",
        "OverallStatus": "RECRUITING",
        "Conditions": "SLE (Systemic Lupus)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06150651"
    },
    {
        "Title": "Prognostic Factors for Treatment Responses in Patients With Active Lupus Nephritis at Sohag University Hospital",
        "Summary": " systemic lupus erythematosus sle autoimmune disease may give rise to multiple organ involvement immune complex deposits lupUS nephritis ln one severe manifestations. immunosuppressive treatment major therapy active.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "Egypt",
        "OverallStatus": "UNKNOWN",
        "Conditions": "We Aim to Examine the Predictors of Sustained Complete Renal Remission in Patients With Lupus Nephritis at Sohag University Hospital",
        "Phases": "N/A",
        "IDestudio": "NCT04756492"
    },
    {
        "Title": "Multicenter Study Assessing the Efficacy & Safety of Hydroxychloroquine Sulfate in Patients With Systemic Lupus Erythematosus or Cutaneous Lupus Erythematosus With Active Lupus Erythematosus Specific Skin Lesion",
        "Summary": " hydroxychloroquine sulphate hcq patients cutaneous lupus erythematosus cle systemic lupsus sle active skin manifestation clasi. primary objective investigate efficacy skin manifestation 16 weeks treatment daily regimen hydroxy",
        "StudyType": "INTERVENTIONAL",
        "Countries": "Japan",
        "OverallStatus": "COMPLETED",
        "Conditions": "Cutaneous Lupus Erythematosus-Systemic Lupus Erythematosus",
        "Phases": [
            "PHASE3"
        ],
        "IDestudio": "NCT01551069"
    },
    {
        "Title": "The Safety and Efficacy of Etanercept (Enbrel\u00ae) for the Treatment of Discoid Lupus Erythematosus",
        "Summary": "20 week study assess safety efficacy etanercept treatment discoid lupus erythematosus.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "United States",
        "OverallStatus": "UNKNOWN",
        "Conditions": "Discoid Lupus Erythematosus (DLE)",
        "Phases": [
            "PHASE2"
        ],
        "IDestudio": "NCT00797784"
    },
    {
        "Title": "BCMA-CD19 cCAR T Cell Treatment of Relapsed/Refractory Systemic Lupus Erythematosus (SLE)",
        "Summary": "Ccar cells are used to treat relapsed and refractory cancer patients. The study is the first of its kind in the world.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "RECRUITING",
        "Conditions": "Relapsed/Refractory, Systemic Lupus Erythematosus (SLE)",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT05474885"
    },
    {
        "Title": "Belimumab In Prevention of LN",
        "Summary": "Lupus erythematosus chronic autoimmune disease involve multiple systems largely impair patients health kidney one commonly affected organs reported 70 sle patients developed lupus nephritis within past 10 years sle patients recorded retrospective study highest 17 5",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Whether Belimumab Could Reduce 2-year Risk of New-onset Lupus Nephritis",
        "Phases": "N/A",
        "IDestudio": "NCT05585671"
    },
    {
        "Title": "F01 in the Treatment of Moderate-to-severe Refractory Systemic Lupus Erythematosus",
        "Summary": "F01 patients refractory systemic lupus erythematosus. phase clinical study evaluate safety pharmacokinetic profile preliminary efficacy.",
        "StudyType": "INTERVENTIONAL",
        "Countries": "China",
        "OverallStatus": "NOT_YET_RECRUITING",
        "Conditions": "Lupus Erythematosis",
        "Phases": [
            "PHASE1"
        ],
        "IDestudio": "NCT06468683"
    },
    {
        "Title": "NFC Changes in SLE Patients and Its Correlation With Anti-U1RNPAntibodies and Disease Activity",
        "Summary": "1 detection different pattern nail fold capillary changes sle patient. 2 correlation nail fold capsillaries changes sle patients antibodies. 3 correlation nail Fold Capillaries Changes sle disease activity. 4 frequency nail foldCapillariesChanges sle patients.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "",
        "OverallStatus": "UNKNOWN",
        "Conditions": "System Lupus Erythematosus",
        "Phases": "N/A",
        "IDestudio": "NCT05106998"
    },
    {
        "Title": "Anti-nucleosome B Lymphocytes in Lupus",
        "Summary": " lupus disease characterized production pathogenic autoantibodies participate damages phenotype b cells producing pathogenicAutoantibody. Lupus project proposes detect antinucleosome b cells.",
        "StudyType": "OBSERVATIONAL",
        "Countries": "France",
        "OverallStatus": "TERMINATED",
        "Conditions": "Systemic Lupus Erythematosus With or Without Clinical Activity",
        "Phases": "N/A",
        "IDestudio": "NCT01889654"
    }
]